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3ABSTRACT
BACKGROUND: Neuroendocrine tumours (NETs) are fairly rare neoplasms that
present many clinical challenges. The complexity, heterogeneity, and rarity of NETs
have contributed to their limited therapeutic options. To improve the outcome from
NETs, a better understanding of their biology is needed. Several receptor targets exist,
against whom agents such as antibodies or tyrosine kinase inhibitors are being
developed and tested in clinical trials. Several of these agents have been used in
combination with chemotherapy or radiation with promising results. These receptors
include the tyrosine kinases EGFR and C-KIT, and the somatostatin receptor SSTR2.
However, their role in neuroendocrine tumour growth remains unclear.
METHODS: We investigated the anti-proliferative effect of EGFR inhibitor gefitinib,
as single agent or in combination with widely used chemotherapeutic agents. The
chemotherapeutic agents were also examined for their effect on EGFR activity.
Cisplatin and radiation were studied for their effect in EGFR activity and localisation in
combination with gefitinib and the anti-EGFR antibody cetuximab by immunoblotting
and immunofluorescence, while the comet assay for quantitation of DNA damage was
used to examine modulation of DNA repair by radiotherapy. The cytotoxic efficacy of
agents against SSTR2 was also examined, while the expression of C-KIT was analysed
in 95 NET patients by immunohistochemistry.
RESULTS: Gefitinib demonstrated anti-proliferative effect associated with induction
of apoptosis but no cell cycle arrest. Cisplatin induced a transient activation of EGFR
and nuclear translocation, which was mediated through the Ras/MAPK and PI-3K/Akt
signalling cascades. Cisplatin and radiation-induced EGFR translocation was blocked
by gefitinib and cetuximab, and this was associated with a delay in the repair of
radiation-induced DNA strand breaks. Nuclear translocation was mediated by nuclear
pore complex importins and exportins, and utilized the EGFR nuclear localisation
sequence. C-KIT was identified in a number of NET patients. The drugs against SSTR2
had no effect on the growth of cells.
CONCLUSIONS: Targeting EGFR in combination with radiation may provide
therapeutic potential in neuroendocrine tumours patients.
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CHAPTER 1
GENERAL   INTRODUCTION
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1.1 Cancer
Cancer is a disease involving dynamic changes in the human genome. The molecular
basis of cancer involves mutations which produce oncogenes with dominant gain of
function and tumour suppressor genes with recessive loss of function. Mutations vary
from specific point mutations to alterations in whole chromosomes; these differences
can affect the genes governing the normal regulatory mechanisms of cell growth and
proliferation (Vogelstein & Kinzler, 1993). Uncontrolled cell proliferation or inefficient
mechanisms of programmed cell death can result in tumour growth. There are well over
200 different forms of tumour subtypes arising in different organs.
As summarised by Hanahan & Weinberg, (2000), the vast majority of malignant
tumours can be identified by six fundamental changes; self-sufficient growth signals,
insensitivity to anti-growth signals, evading programmed cell death (apoptosis),
limitless replicating potential (immortality), sustained angiogenesis and tissue invasion
and metastasis. These characteristics can be acquired during the course of tumour
development through a series of genetic changes culminating in the uncontrolled and
eventual malignant transformation of a clonal cell population. This multi-step process
initiating from a normal cell population, develops through a series of pre-cancerous
lesions into a metastatic tumour.
Once transformed, a malignant tumour can become invasive and can spread into the
surrounding tissue. In some cases cancerous cells migrate away from the primary
tumour often via the lymphatic system. These micro-metastases can attach to new tissue
elsewhere in the body and form secondary tumours (Hanahan & Weinberg, 2000).
1.1.1 Incidence and Mortality
Each year more than a quarter of a million people are newly diagnosed with cancer in
the UK. Overall it is estimated that more than one in three people will develop some
form of cancer during their lifetime. Of the different types of cancer, four types
including breast, lung, large bowel (colorectal), and prostate account for over half of all
new cases. Breast cancer is the most common cancer in the UK. The latest available
mortality statistics for the United Kingdom (UK) are for 2004. In that year 153,397
people were registered as dying from a malignant neoplasm. Cancer is the cause of
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approximately a quarter of all deaths in the UK of which over one fifth (22%) are
caused by lung cancer. Colorectal cancer was the second most common cause of death
from cancer (11%). Breast cancer is the third most common cause of death from cancer
in all persons (8%).
1.2 Neuroendocrine tumours
Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that
derive predominantly from cells of the diffuse endocrine system of the gut and pancreas
and can be found anywhere in the body (Rindi et al., 1999). This system includes
endocrine glands, such as the pituitary, the parathyroids and the adrenal medulla, as
well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells
disseminated between exocrine cells, such as endocrine cells of the digestive and
respiratory tracts (Arnold et al., 1994; Kaltsas et al., 2004). Neuroendocrine tumours
were thought to rise from the so called APUD cells as they have the ability for Amine
Precursor Uptake and Decarboxylation (Somogyi et al., 2000). APUD cells are a group
of unrelated endocrine cells found throughout the body with similar characteristics,
which make a number of hormones with similar structures including serotonin (5-
hydroxytryptamine, or 5-HT) and neurotensin. This idea has now been abandoned and
the term neuroendocrine cell is defined by the cell’s secretory products and cytoplasmic
proteins, rather than its localisation or embryological derivation.
Neuroendocrine cells have distinctive characteristics presenting marker proteins and
cell type-specific hormonal products. The cells have uniform nuclei with abundant
granular or faintly stained cytoplasm and membrane-bound dense-core secretory
granules in the cytoplasm. Neuroendocrine cells form small organs, distinct cell clusters
within other tissues or a network of cells dispersed in thymus, thyroid, lung and gut.
Consequently, common properties of NETs include ectopic hormone and bioamine
release, the presence of tumour-associated antigens, and isozyme composition
(Bombardieri et al., 2001; Jensen, 2000).
1.2.1 Classification
NETs classification was traditionally based on site of origin and whether they are
functioning (with a clinical syndrome) or non-functioning (without a clinical
20
syndrome). There are many types of neuroendocrine tumours including the medullary
thyroid cancers, paragangliomas, phaeochromoctomas, but the most common NETs are
the gastro-entero-pancreatic neuroendocrine (GEP NE) tumours. GEP NE tumours are
divided into:  a) carcinoid tumours originating in the foregut (lung, thymus, stromal and
proximal small bowel), midgut (ileum, caecum, proximal colon) or hindgut (distal
colon, rectum), b) pancreatic neuroendocrine tumours (PNETs) or islet cell tumours,
named after their main secretory product, including insulinomas, gastrinomas, VIPomas
(vasoactive intestinal peptide tumours), and glucagonomas, and c) non-functioning
tumours, which secrete peptides that do not cause any clinical syndrome (Solcia et al.,
1999). This old classification has been replaced by the new World Health Organisation
(WHO) classification which divides NETs according to histomorphology, size and the
presence of metastases into:
1. well-differentiated endocrine tumours
2. well-differentiated endocrine carcinomas
3. poorly differentiated endocrine carcinomas
4. mixed exocrine and endocrine carcinomas
5. tumour-like lesions
The old classification though, is still in use in clinical practise and in research papers
(Jensen, 2000; Oberg, 2004) and for practical reasons is used in this study.
NETs occur most commonly in the digestive system. But they can also be found in
other parts of the body. The commonest type of NET is the carcinoid tumour which
accounts for 55% of GEP NE tumours. This cancer mainly arises from neuroendocrine
cells of the appendix (38%), ileum (23%), rectum (13%), and bronchus (11.5%). But it
can also grow in the pancreas, kidney, ovaries and testicles. 10% of carcinoids usually
present with the so-called carcinoid syndrome characterised by flushing, diarrhoea,
bronchoconstriction and right-sided heart disease due to excessive secretion of
serotonin in the systemic circulation. The second type of NET is the group of pancreatic
NETs (PNETs). According to data from the Surveillance, Epidemiology and End
Results (SEER) registry on PNETs in the United States over the period from 1973-
2000, the most common PNET is the non-functional type (90.8%). The next most
common type of PNET is the gastrinoma (4.2%), a gastrin-releasing islet cell tumour of
the pancreas (30-40%) or duodenum (60-70%) that is associated with peptic ulceration
and the Zollinger-Ellison syndrome, which is caused by the over-production of gastrin,
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followed by the insulinoma (presented with hypoglycaemic syndrome) (2.5%), an islet
cell tumour that secretes excess insulin, the glucagonoma (1.6%) and the VIPoma
(0.9%) (Jensen, 2000; Oberg, 2004; Halfdanarson et al., 2008; Modlin et al., 2008).
1.2.2 Incidence and Mortality
NETs are rare, mostly benign or slow growing tumours (although a proportion
demonstrates aggressive tumour growth) with often differing phenotypes in their
clinical behaviour (Mignon, 2000). Neuroendocrine tumours account for only 2% of all
malignancies. In the last decades, the incidence of NETs has been rising. The incidence
is approximately 5/100,000 with more female patients under the age of 50 and with
metastases occurring in more than 80% of patients. According to the SEER registry on
NETs in the United States over the period from 1973-2004, the primary sites of NETs
differed considerably with sex and race. In total, 41% of NETs were foregut, 26%
midgut and 19% hindgut, whilst the rest 13% had unknown primary site. Most
neuroendocrine tumours are mainly sporadic, but association with the multiple
endocrine neoplasia type 1 (MEN-1) syndrome and clustering within families is known.
Survival is rated at 5-years according to stage: 93% in local disease, 74% in regional
disease and 19% in metastatic disease. In metastatic disease, survival increased since
1992, when treatment with octreotide became largely available in the Netherlands
(Taal, 2004; Yao et al., 2008; Srirajaskanthan et al., 2009).
1.2.3 NET markers
Most NETs produce and secrete a variety of cell type-specific peptide hormones and
amines which cause clinical syndromes and are used as markers for the diagnosis of
NET patients (Eriksson et al., 2000). Diagnosis was historically based on silver
stainings; the argyrophil staining by Grimelius, which is a general neuroendocrine
marker, and the argentaffin staining by Masson, which demonstrates the serotonin
content (Wilander et al., 1989). In the absence of any symptoms diagnosis is based on
detection of general NET markers, including the secretory granule proteins
chromogranins A, B, and C, (of which chromogranin A is increased in 70-90% of all
NETs), the synaptic vesicle membrane glycoprotein synaptophysin, the pancreatic
polypeptide which is mainly increased in PNET patients, the cytosolic neuron-specific
enolase, and the carcinoembryonic antigen (Lamberts et al., 2001, Eriksson et al.,
2000). Specific neuroendocrine markers include insulin, gastrin, glucagon, vaso
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intestinal polypeptide, urinary 5-hydroxyindoleacetic acid (5-HIAA), which is the main
breakdown product of serotonin, and somatostatin (Tomassetti, 2001). The presence of
somatostatin receptors has greatly aided the imaging of NETs.
1.2.4 Diagnosis and Treatment of NETs
The diagnosis of NETs is based on measurement of general or specific hormone and
biochemical marker levels in the plasma, as well as the histological immunostaining
including detection of the nuclear antigen Ki-67, which indicates the proliferative
capacity of NETs. Localisation of these tumours is based on imaging tests such as
ultrasound, computerised tomography (CT), magnetic resonance imaging (MRI), and
somatostatin recepror scintigraphy (SRS or Octreoscan®). SRS is a very useful imaging
modality as more than 80% of these tumour cells express somatostatin receptors, which
will be discussed in more detail later.
Treatment options for NETs include the use of somatostatin analogues (which are used
for the management of clinical symptoms caused by excessive hormone secretion),
alpha interferons1, chemotherapy, embolization, radionuclide receptor targeted therapy,
new agents including e.g. tyrosine kinase inhibitors and mTOR inhibitors, and surgery
(Jensen, 2000; Srirajaskanthan et al., 2009; Desai et al., 2009). The initial management
of NETs is surgical excision of the tumour, if possible. This is the only form of
treatment that cures NETs and is sufficient in the majority of benign tumours; however,
the majority of GEP tumours are recurrent, malignant or disseminated tumours and thus
require further treatment (Oberg et al., 2004).
SST analogues and interferon-alpha (IFN-) can achieve disease stabilization by
symptomatic control in functional tumours and rarely shrinkage of tumour may occur,
but in most cases, patients become refractory to therapy and additional treatment is
required. Other options for therapy in these cases include systemic chemotherapy or
radiotherapy (Oberg et al., 2004; Srirajaskanthan et al., 2009; Desai et al., 2009).
1 The mechanism of action for alpha interferon involves direct effects on the tumour cells by inhibiting
the cell proliferation via cell cycle arrest at the G1/S phase. Furthermore, INF-modulates the immune
system by stimulating natural killer cells, macrophages and also presents anti-angiogenetic effects.
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Chemotherapy can temporarily produce response in patients with fast-growing poorly
differentiated NETs, but many well-differentiated NETs are relatively chemoresistant
(Oberg et al., 2004). However, some types of NETs particularly those of foregut origin
e.g. pancreatic NETs may be sensitive to chemotherapy and using a streptozocin based
regimen may have a partial response rate of 30-50%, and similar responses have been
demonstrated with a combination of cisplatinum and etoposide. On the other hand,
chemotherapy in patients with slow growing NETs such as midgut carcinoids has
produced little response, and these tumours are mainly managed with somatostatin
analogues, interferon therapy, and more recently radionuclide receptor therapy (Oberg,
2001; Srirajaskanthan et al., 2009; Desai et al., 2009). Chemotherapy has significant
side effects including immunosuppression and myelosuppression and its use must be
weighed against potential adverse effects (Kaltsas et al., 2004).
Radionuclide therapy involves coupling a radioisotope to a peptide (e.g. somatostatin
analogue), which will be internalised with the peptide-receptor complex through
receptor uptake, and deliver a cytotoxic radiation dose to the tumour without damaging
the surrounding healthy tissues (Krenning et al., 1999). Aspects taken into
consideration include the amount of radiolabelled ligand that can be concentrated inside
tumour cells and the rates of internalization, degradation and recycling of the ligand-
receptor complex (Wiseman & Kvols, 1995). Examples of radiolabelled molecules
include the radionuclide labelled octreotide or octreotate (octreotide acid) with 111In
(Indium-111), 90Y (Yttrium-90) or 177Lu (Lutetium-177), as well as 131I-MIBG (Iodine-
131 labelled meta-iodobenzylguanidine).
Radionuclide labelled octreotide is generally used in neuroendocrine tumous, especially
GEP NETs. Indium-111 was initially the most commonly used radioisotope, but has
been replaced by Yttrium-90 and Lutetium-177. Therapy with 90Y-octreotide caused
stabilization of tumour growth and partial response in approximately 20% of NET
patients (Waldherr et al., 2002). 177Lu-octreotate was used in 504 patients with
gastroenteropancreatic tumours with complete response in 2% of patients, partial
response in 28% and minor tumour response in 16%. The overall survival was extended
by 40 to 72 months from time of diagnosis compared to previous controls
(Kwekkeboom et al., 2008). 131I-MIBG has been used to treat patients with
pheochromocytoma, neuroblastoma, carcinoid tumours, medullary thyroid carcinoma,
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and paragangliomas. The tumour responses have been variable with the most
encouraging results being in patients with pheochromocytoma (Wiseman & Kvols,
1995). The main side effect of radionuclide therapy is bone marrow suppression, which
is usually seen after a number of treatment cycles.
NET metastases are often found in the liver. Liver resection is carried out especially
when the tumour is isolated in one area of the organ, but is also considered when the
metastasis is more extended in order to slow the progression of the disease. In total,
liver resection is performed in approximately 10% of patients with a 5-year survival in
60-85% of the cases. Non-resectable liver metastases can also be treated with hepatic
artery embolization (HAE), with a 5-year survival in more than 50% of patients
(Srirajaskanthan et al., 2009; Desai et al., 2009). HAE is based on the observation that
tumor cells get nearly all their nutrients from the hepatic artery, while the normal cells
of the liver get about 75 percent of their nutrients (and about half of their oxygen) from
the portal vein, and thus can survive with the hepatic artery effectively blocked
(Pommier, 2003). HAE leads to tumour reduction by induction of ischaemia and
therefore decrease of hormone secretion. Embolisation can be achieved with
radionuclides or chemotherapeutic agents such as cisplatin and doxorubicin
(Srirajaskanthan et al., 2009; Desai et al., 2009).
Based on the above, it is clear that neuroendocrine tumours present a heterogeneous
group of tumours with different biological features and their treatment has been
challenging to physisians worldwide. Forms of treatment should be individualised for
each patient with consideration of the molecular biology and history of each tumour,
especially in patients with well-differentiated slow-growing NETs, as such patients can
have prolonged survival in the presence of extensive disease (Oberg et al., 2004).
Lately, treatment options for many types of tumours include targeting of specific
growth factors and their receptors. A number of different traditional growth factors
have been identified in neuroendocrine gut and pancreatic tumours such as IGF-1,
PDGF-, b-FGF, TGF-, and the TGF- family (Oberg, 1996), but the role of these
growth factors and their receptors in NETs is still under investigation. The limited
therapeutic options for NETs and the expression of growth factor receptors on the
surface of NET cells provided the rationale for my study, which focuses on
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identification of receptor proteins as potential therapeutic targets in neuroendocrine
tumours. The receptors analyzed are members of two large receptor families; the
protein tyrosine kinases (PTKs) and the G protein-coupled receptors (GPCRs). The
protein tyrosine kinases investigated for their role in NET growth include the epidermal
growth factor receptor (EGFR), which is expressed in a variety of cancer types, and C-
KIT, which is mainly expressed by gastrointestinal stromal tumour cells. The GPCRs
examined include the somatostatin receptors (SSTRs), which are well known markers
of neuroendocrine differentiation. Analysis of the therapeutic potential of each
receptor-target was mainly based on the efficacy of specific inhibitors, in the form of
synthetic compounds or antibodies, which block the expression of each receptor-target.
The receptors investigated as well as their respective inhibitors are analysed in detail in
the following sections.
1.3 Protein Tyrosine Kinases (PTKs)
More than 20 years ago animal tumour viruses were found to encode for protein
tyrosine kinases (Sawyers, 2002). PTKs play a fundamental role in multiple cellular
mechanisms such as cell proliferation, differentiation, migration as well as apoptosis,
all of which can lead to oncogenesis when deregulated. PTKs’ function, which is
literally the transfer of phosphate from ATP to tyrosine residues of target proteins
needed for their activation or inactivation, is tightly controlled under physiological
conditions (Skorski, 2002).
1.3.1    PTKs and Oncogenesis
Changes in more than 30 PTKs have been implicated in the development of neoplastic
diseases (Blume-Jensen & Hunter, 2001). There are four general mechanisms by which
tyrosine kinases become constitutively activated (figure 1). The first is as a result of
chromosomal translocation. In this case, reciprocal chromosomal translocations
generate fusion proteins, where the amino-terminal portion is responsible for
oligomerisation, and this enables constitutive activation of the catalytic activity of the
kinase domain located on the carboxy-terminal portion.
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Figure 1: Genetic alterations leading to uncontrolled activation of PTKs in cancers
Source: T Skorski, Nature Reviews Cancer, 2002
The second mechanism is as a result of overexpression of the cell-membrane receptor
tyrosine kinase which leads to spontaneous (or autocrine ligand-dependent)
dimerisation and constitutive kinase activation. Third, point mutations in the
juxtamembrane region of a receptor tyrosine kinase may cause constitutive ligand-
independent dimerisation of the receptor and activation of its kinase activity. Finally,
truncation of the carboxy-terminal portion may prevent phosphorylation of a tyrosine
residue that is involved in protein folding and stabilize tyrosine kinase in its active
conformation (Skorski, 2002). An overview of protein tyrosine kinases implicated in
human cancer is shown in Table 1. The PTKs investigated in our study, EGFR and C-
KIT, are analysed below.
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Table 1: Oncogenic Tyrosine Kinases
Adapted from Skorski T, Nature Reviews Cancer, 2002
1.3.2    EGFR (Epidermal Growth Factor Receptor)
Among the various families of growth factors known to contribute to the growth of
tumour cells are the EGF-related peptides and their receptors. The EGFR family is
another subset of the Receptor Tyrosine Kinase (RTK) super family. EGFR is also
known as Human Epidermal Growth Factor Receptor (HER1) or c-erbB1 (Wells,
1999).
1.3.2.1    EGFR structure and function
The ErbB family or EGFR family consists of four structurally related RTKs: EGFR
(ErbB1/HER1), ErbB2 (HER2/Neu in rodents), ErbB3 (HER3) and ErbB4 (HER4).
Activation of the EGFR family is accomplished by a multitude of ligands creating a
signal diversity that is critical to EGFR function (Holbro and Hynes, 2003). Three
ligand groups have been identified so far (Yarden and Sliwkowski, 2001). Receptors
and their ligands are illustrated in figure 2.
Members of the EGFR family contain an extracellular domain of approximately 620
amino acids involved in ligand binding and receptor dimerization, a single
transmembrane spanning region, and a cytoplasmic tyrosine kinase domain in all
receptors except for ErbB3 which lacks intrinsic kinase activity (Yarden, 2001). The
extracellular region is made up of four subdomains, L1, CR1, L2 and CR2, where L
OTK Cancer type Mechanism
ABL, ALK, FGFR,
JAK2, PDGFR-,
TRKC
Acute and chronic
leukaemias
Dysregulated by fusion
with BCR, TEL or NPM
causing oligomerisation
and activation of the
kinase by cross-
phosphorylation
ERBB1-4, IGF1R,
PDGFR-, FGFR 1-4
Breast and ovarian
carcinomas, lung cancer,
glioblastomas, gastric
and prostate carcinomas
Enhanced expression
causes receptor
dimerisation and
activation of intrinsic
kinase activity
Src, C-KIT
Gastrointestinal tumours,
leukaemias, lung cancers,
colon cancer
C-Terminal truncation or
gain-of-function point
mutations causing
increased kinase activity
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signifies a leucine rich repeat domain and CR a cysteine-rich region. These subdomains
are also referred to in literature as domains I-IV respectively (Garrett, et al., 2002;
Ward et al., 2007).
In EGFR, the intracellular domain is split into a short juxta-membrane domain, a
tyrosine kinase domain and a long carboxyl tail with autophosphorylation sites (Wells,
1999). The tail also has three internalisation sites, for when ligand occupied EGFR is
internalised and degraded. The ligands (secreted or membrane-bound glycoproteins)
constitute a group of proteins with diverse function, which have an important role in
early mammalian development (Salomon et al., 1995). These include proteins such as
EGF, TGF-a, amphiregulin, heparin-binding EGF-like growth factor, betacellulin, and
epiregulin (Toyoda et al., 1997; Wells, 1999). The related ErbB3 and ErbB4 receptors
are activated by neuregulins (NRGs). ErbB2 has no known direct activating ligand, and
may be in an activated state constitutively.
Figure 2: The EGFR family members
Adapted from PM Harari, Endocrine Related Cancer, 2004
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Activation of the receptor results in the initiation of a diverse array of cellular
pathways. In response to toxic environmental stimuli, such as ultraviolet irradiation, or
to receptor occupation, receptors form homo- or heterodimers with other family
members (Yarden, 2001; Harari, 2004). Ligand induced activation leads to activation of
a number of signalling pathways which cease after endocytosis or receptor
internalisation culminating in recycling or degradation of the receptor.  EGFR is the
only member of the family able to form a heterodimer with all other members of the
EGFR family. ErbB2 does not have a ligand and may be in an activated state
constitutively, but it is the preferred partner for the formation of a heterodimer. EGFR
dimerisation leads to autophosphorylation of five tyrosine (Y) residues in the C-
terminal domain of the receptor. These are Y992, Y1045, Y1068, Y1148 and Y1173.
Each dimeric receptor complex will initiate a distinct signalling pathway by recruiting
different Src homology 2 (SH2)-containing effector proteins. EGFR dimerization
results in autophosphorylation of tyrosine residues in the cytoplasmic C-terminal tail of
the receptor, initiating a downstream cascade of events, which produce an array of
cellular responses including cell proliferation, differentiation, adhesion, migration, or
apoptosis (Cohen, 2003; Wells, 1999).
1.3.2.2 EGFR signalling
The EGFR intracellular signal transduction pathways include the Ras/MAPK, the
phosphatidyl inositol-3 kinase (PI3K), the STAT pathway, and the phospholipase C
(PLC) pathways (Carpenter, 2000; Grant et al., 2002). Figure 3 shows a schematic
diagram of the EGFR intracellular signalling cascades.
The best known pathway is the serine/threonine mitogen-activated protein kinase
(MAPK) cascade (Schlessinger, 2004). Phosphorylated EGFR (ErbB1) is known to
recruit the adaptor proteins Shc and Grb2, which act through the exchange factor Sos to
activate Ras. This leads to the phosphorylation of the MAP kinase ERK1/2, which in
turn induces the expression of selected transcription factors including Elk-1 and c-fos
(Yarden & Sliwkowski, 2001). This pathway is associated with cell division and its
abnormal activity may be involved in the uncontrolled cell proliferation occurring in
tumours (Pal & Pegram, 2005).
Activation of the lipid kinase phosphotidylinositol-3 kinase (PI3K) leads to cell
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division and survival. In this pathway, the Gab1 adaptor protein activates PI3K which
initiates a positive feedback loop for Gab1 recruitment to the receptor. PI3K also
phosphorylates AKT (PKB, protein kinase B) leading to an anti-apoptotic response
through the transcription factor nuclear factor (NF)-B. This is also activated through
PKC, a pathway associated with cell cycle progression (Prenzel et al., 2001).
A third pathway is mediated by the cytoplasmic tyrosine kinase c-Src which is involved
in a number of cellular processes, including mitogenic signalling (Hynes & Lane,
2005). Amongst the known c-Src substrates, the signal transducer and activator of
transcription (STAT) family of transcription factors is known to be of particular
importance in the proliferation and survival of cancer cells. In fact, activation of
STAT3 initiates a TGF-induced autocrine growth of transformed epithelial cells (Yu &
Jove, 2004).
Figure 3: The EGFR signal transduction pathways
Source: G Atalay et al., Annals of Oncology, 2003
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Interestingly, ErbB mediated activation of STAT3 has also been implicated in the
resistance of tumour cells to cytotoxic therapy (Masuda et al., 2002). Furthermore,
ErbB-induced activation of the phospholipase C (PLC) pathway has been linked to
increased cell motility (Fedi et al., 1994). The interaction of the erbB receptor family
and the integrin signalling pathway is mediated by the focal adhesion kinase (FAK) and
is important for tumour invasion and metastasis. Here, EGFR inactivates FAK, leading
to the disturbance of cell–cell and cell–matrix interactions thus promoting cell motility
and invasiveness (Lu et al., 2001). EGFR also promotes angiogenesis. An example of
this is the STAT3 regulated production of the angiogenic factor vascular endothelial
growth factor (VEGF) (Niu et al., 2002). Other proto-oncogenes activated include fos,
jun and myc as well as a family of zinc-finger-containing transcription factors such as
Sp1, Egr1 and Ets family members (e.g. GA-binding protein (GABP)) (Yarden, 2001).
1.3.2.3 EGFR (ErbB) family regulation and signalling specificity
The family of ErbB RTKs is involved in a wide variety of cellular processes such as
proliferation, survival, angiogenesis and metastasis. ErbB RTKs activate multiple
signalling pathways and different second messengers may mediate the same cellular
response. In addition, the same ligand bound to the same receptor can activate multiple
signalling pathways. The mechanism leading to the activation of a specific signalling
pathway is complex and dependent on many parameters.
Activation of a specific pathway may occur in a tissue-specific or tumour-specific
manner, as overexpression of individual ErbB types results in activation of specific
groups of genes (Alaoui-Jamali et al., 2003; Amin et al., 2004). ErbB receptors upon
activation form homo- or heterodimers in which different combinations of receptors
activate distinct signalling pathways (Riese & Stern, 1998; Olayioye et al., 1998). The
specificity of the signalling cascade activated is also regulated by many other factors
including: a) the ligand binding to the receptor (Amin et al., 2004), b) the interaction
with distinct substrates through different autophosphorylation sites of EGFR (Yarden &
Sliwkowski, 2001), and c) the rate of endocytosis activated by ligand binding, which
acts as a negative feedback leading to downregulation of the receptor (Bogdan &
Klambt, 2001).
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Ligand binding to a receptor can modulate its activity in many ways. Apart from the
type of ligand, the concentration of ligand (or of the receptor itself) and the binding
affinity of the ligand can modulate the potency and duration of signalling as well as the
signalling pathway activated. Furthermore, it has been documented that the C-terminals
of ligands (e.g. heparin binding-EGF), which result from cleavage of transmembrane
ligand precursors, may translocate into the nucleus and regulate cell proliferation
(Yotsumoto et al., 2009).
The autophosphorylation sites in the kinase domain of EGFR serve as docking sites for
various substrates which can be adaptor proteins or enzymes. EGFR
autophosphorylated sites activate second messengers containing SH2 (Src homology
domain 2) or PTB (phosphotyrosine binding) domains. On the other hand, EGFR can
also be phosphorylated by other kinases such as PKC (protein kinase C), which
regulates EGFR membrane distribution, or the JAK (Janus kinase) protein for the
initiation of the JAK-STAT signalling pathway (Bogdan & Klambt, 2001; Yarden &
Sliwkowski, 2001).
Phosphorylation and internalisation of EGFR leads to desensitization and
downregulation of the receptor respectively. The mechanism of internalization
employed also regulates EGFR signalling as trafficking via clathrin-coated pits
(activated by EGF) leads to EGFR degradation within lysosomes, whereas
internalization into early endosomes (activated by TGF-) leads to receptor recycling.
It is worth noting that EGFR actually remains active till its storage inside late
endosomes (Bogdan & Klambt, 2001). The rate of receptor endocytosis may also
influence the duration and potency of distinct signalling pathways (Baulida et al.,
2009).
Finally, the signalling pathway activated is also influenced by the cross-talk between
EGFR and other membrane receptors including IGF-1R (insulin like growth factor
receptor) and GPCRs (G-protein coupled receptors), which may activate EGFR directly
via phosphorylation or indirectly by activating downstream members of EGFR
signalling pathways (van der Veeken et al., 2009; Bhola & Grandis, 2008).
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1.3.2.4 EGFR and cancer
Excessive ErbB signalling is associated with the development of a wide variety of types
of solid tumour. ErbB-1 and ErbB-2 are found in many human cancers and their
excessive signalling may be critical factors in the development and malignancy of these
tumours (Cho HS and Leahy DJ, 2002). EGFR activity has an important role in tumour
development and progression by promoting cell proliferation, angiogenesis, metastasis,
invasion, and inhibition of apoptosis. Enhanced activation of EGFR in cancer is either
due to activating mutations, or overexpression and coexpression with its ligands which
leads to constitutive autocrine stimulation of the receptor (Yarden Y, 2001).
Table 2: Tumour types with EGFR overexpression
Tumour Type Percentage of Tumours
Bladder 31-48
Breast 14-91
Cervix/uterus 90
Colon 25-77
Oesophageal 43-89
Gastric 4-33
Glioma 40-63
Head and Neck 80-100
Ovarian 35-70
Pancreatic 30-89
Prostate 40-80
Renal cell 50-90
Non small-cell Lung 40-80
Source: PM Harari, Endocrine Related Cancer, 2004
EGFR and its receptors are involved in a large number of tumours, mainly epithelial
malignancies such as bladder, brain, breast, prostate, ovary, gastrointestinal tract and
brain cancers (Levitzki, 2003; Salomon et al., 1995) (table 2). Overexpression of EGFR
has also been identified in squamous cell carcinoma of the head and neck (SCCHN)
and in non small cell lung cancer (NSCLC). In NSCLC, mutations are found in the
intracellular portion of EGFR involving exons 17 to 21 (amino acids 712-979), and
especially exon 19. Finally, mutations leading to EGFR overexpression have been
associated with glioblastoma multiforme in which a more or less specific mutation of
EGFR called EGFRvIII, where exons 2-7 (amino acids 6-273) are deleted, is often
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found. Consequently, EGFR has been identified as a molecular target with high
therapeutic potential in a variety of cancers. However EGFR overexpression alone does
not predict response to anti-EGFR therapy (Bishop et al., 2002).
1.3.3 C-KIT
C-KIT, the second receptor target studied, is a receptor tyrosine kinase (RTK) encoded
by a 5-kb gene in chromosome 5 of mice and in chromosome 4q12 of humans. Initial
characterisation was carried out on the viral oncogene v-KIT, a component of the
Hardy-Zuckerman strain of feline sarcoma virus (HZ4-FeSV) (Besmer et al., 1986).
This viral gene was shown by cDNA cloning to be a truncated version of the cellular
proto-oncogene C-KIT, the cleavage of which is thought to induce the activation of the
oncogene (Yarden et al., 1987; Qiu et al., 1988).
1.3.3.1 C-KIT structure and function
Spontaneous mutations in murine loci W (white spotting) and Sl (steel locus) resulted in
anaemia, lack of mast cells, pigmentation defects and infertility. These loci encode the
C-KIT protein (Chabot et al., 1988; Geissler et al., 1988) and its ligand, stem cell factor
(SCF, also known as mast cell growth factor, KIT ligand, steel factor) (Williams et al.,
1990; Zsebo et al., 1990). The nature of the mutations between the two loci showed
complementarity, suggesting the proteins encoded belonged to a receptor- ligand pair.
The receptor was shown to be expressed in haematopoietic cells, melanocytes, and
germ cells, whereas the ligand, which exists in either membrane-bound or soluble form,
was produced by accessory environmental cells (e.g. bone marrow stromal cells or
fibroblasts) that regulate the survival, proliferation, differentiation as well as the
secretory function of the receptor-bearing cells (Galli et al., 1994; Linnekin, 1999).
C-KIT belongs to the family of type III transmembrane receptor kinases that includes
the platelet derived growth factor receptor (PDGFR) and the macrophage colony
stimulating factor receptor (CSF-IR) (Besmer et al., 1986; Yarden et al., 1986). This
family of receptors is a subset of the Protein Tyrosine Kinase (PTK) super family,
comprising of transmembrane receptors with intrinsic protein tyrosine kinase activity.
A schematic diagram of C-KIT is shown in figure 4.
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Figure 4: The structure of C-KIT
Source: MC Heinrich et al., Journal of Clinical Oncology, 2002
The extracellular region of C-KIT contains five immunoglobulin domain repeats, three
of which are involved in ligand binding.  The binding of homodimerised ligand induces
receptor dimerisation, activation of the receptor’s intrinsic tyrosine kinase activity with
subsequent autophosphorylation and activation of signal transduction pathways. The
intracellular region of C-KIT contains two tyrosine kinase domains, TK1 and TK2, as
well as a juxtamembrane domain which negatively regulates the TK1 and TK2
domains. The TK1 contains the ATP binding site while TK2 has possible
autophosphorylation sites (Linnekin, 1999).
1.3.3.2 C-KIT signalling
Signalling downstream of C-KIT has been studied extensively using mast cells that
express C-KIT endogenously as a model system. In cells whose survival depends on C-
KIT signalling, apoptosis is inhibited through the PI3K/Akt pathway, while
proliferation is promoted by the Ras/Erk, and the JAK/STAT pathways (Linnekin,
1999) as shown in figure 5.
1. The PI3-K pathway
C-KIT signalling through phosphotidyl inositol-3 kinase (PI3K) induces a mitogenic
response via activation of Akt and phosphorylation of Bad pro-apoptotic protein in vivo
(Blume-Jensen et al., 1998). C-KIT also induces resistance to apoptosis by upregulation
of the anti-apoptotic protein Bcl-2 and Bcl-xL (Blume-Jensen et al., 1998). PI3K binds
tyrosine residue 721 of C-KIT via its p85 subunit. D816V, an activating mutation
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present in acute myelogenous leukaemia (AML) and mastocytosis, is characterised by
ligand- independent activation and transforming abilities and is associated with
constitutive phosphorylation of tyrosine residues on PI3K. The significance of PI3K in
the transforming ability of mutated D816V C-KIT was shown in immortalised murine
progenitor cells transduced with the Y721F mutant D816V C-KIT, a mutant incapable
of recruiting PI3K, where it was shown that tumourigenicity is PI3K-dependent (Chian
et al., 2001).
Figure 5: C-KIT signal transduction pathways
2. The Ras/Erk pathway
In a basic view of the Ras/Erk pathway, activated C-KIT recruits SH2-containing
adapter proteins such as Grb2 to associate to its intracellular domain. Grb2 is bound in
a complex with Sos, which then shifts to the plasma membrane and activates Ras.
Activation of Ras is followed by phosphorylation of downstream kinases Mek and Erk.
Erk kinases translocate to the nucleus and phosphorylate transcription factors such as c-
Fos, which induce proliferation (Lennartsson et al., 2005).
3. The JAK/STAT pathway
Ligand stimulation of C-KIT also leads to activation of the JAK (Janus kinase) protein
tyrosine kinases. This is followed by phosphorylation and activation of the signal
transducer and activators of transcription (STAT) proteins, which are transcription
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factors containing DNA binding domains. Upon activation, STATs dimerise and
translocate to the nucleus where they regulate the expression of genes promoting
proliferation and survival (Linnekin, 1999; Lennartsson et al., 2005).
1.3.3.3 C-KIT and Cancer
The association of C-KIT and its ligand SCF with defects in multiple cell lineages was
followed by an extensive analysis and characterisation of its expression in human
malignancies, shown in table 3. Normally C-KIT promotes the differentiation, survival
and proliferation of tissues affected by W locus mutations such as erythropoietic cells,
melanocytes, germ cells (Nocka et al., 1989), tissue mast cells (Mayrhofer et al., 1987),
and bone marrow progenitor cells especially of the myeloid lineage (Ashman et al.,
1991; Escribano et al., 1998). C-KIT immunoreactivity was more recently
acknowledged in the well documented interstitial cells of Cajal (ICC), the pacemakers
of the GI system (Torihashi et al., 1995; Huizinga et al., 1995).
The C-KIT oncogene has been associated with the aberrant proliferation of many
tumours. Amplification or overexpression of C-KIT has been reported in AML (acute
myeloblastic leukaemia) and in some cases of CML (chronic myelogenous leukaemia)
(Kanakura et al., 1993; Escribano et al., 1998). Somatic activating mutations of C-KIT
were also found in germ cell tumours (seminomas and dysgerminomas) (Ashman,
1999). Gain-of-function mutations of the receptor have been involved in the increased
numbers of mast cells in mastocytosis, and in the malignant transformation of mast
cells (Boissan et al., 2000; Feger et al., 2002; Tsujimura 1996). Activating mutations of
C-KIT have been identified in many gastrointestinal tumours (Hirota et al., 1998).
These mutations lead to constitutive, ligand-independent phosphorylation of C-KIT,
producing a growth and survival signal that is involved in the pathogenesis of the
disease. In other cases though, which include small cell lung carcinoma and ovarian
cancer the growth of the tumour was promoted by the paracrine or autocrine activation
of the receptor by its ligand SCF and not by mutation (Parrott et al., 2000; Krystal et
al., 1996).
Interestingly, gain of function mutations in the C-KIT gene occur at different sites in
different neoplastic disorders, suggesting that the pathologic phenotype is determined
both by the domain of mutation of the gene as well as the cell type in which the
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mutation occurs. Exons 1-9 constitute the extracellular domain of the C-KIT protein.
Mutations in this domain lead to ligand independent activation of the receptor and they
have been identified in AML and GISTs. Exon 10 encodes the transmembrane domain
with no mutations identified yet (Heinrich et al., 2002; Lennartsson et al., 2005).
Table 3: C-KIT expression in human malignancies
Tumour Type % Positive for KIT % C-KIT Mutation
Mastocytosis/mast cell
leukaemia 100 >90
Gastrointestinal stromal
tumour 100 >70
Sinonasal natural killer/T-
cell lymphoma NR 17
Seminoma/dysgerminoma 78-100 8.7
Thyroid carcinoma 100 NR
Small-cell lung carcinoma 91 NR
Malignant melanoma 0-90 NR
Adenoid cystic carcinoma 80-90 0
Ovarian carcinoma 71-87 NR
Acute myelogenous
leukaemia 60-80 Rare
Anaplastic large-cell
lymphoma (CD30+) 68 NR
Angiosarcoma 56 0
Endometrial carcinoma 44-100 NR
Paediatric T-cell ALL/
lymphoma 43 NR
Breast carcinoma Up To 81 NR
Prostate carcinoma 2 NR
Source: MC Heinrich et al., Journal of Clinical Oncology, 2002
The juxtamembrane domain of the receptor, which is encoded by exon 11, serves as an
antidimerisation domain and negatively regulates the two tyrosine kinase domains.
Mutations in the juxtamembrane domain promote ligand independent dimerisation of
the receptor and are found most commonly in GISTs. Exons 11-17 comprise the
intracellular domains, with exons 13 and 17 encoding the tyrosine kinase domains.
Mutations in exons 13 and 17 have been detected in systemic mastocytosis, GISTs and
AML. Mutations in these domains affect the ATP binding ability of C-KIT and can
yield gain of function or loss of function tyrosine kinase activity (Heinrich et al., 2002;
Lennartsson et al., 2005).
39
The next group of receptors targeted includes the somatostatin receptors, which belong
to the group of G protein coupled receptors.
1.4 G Protein-Coupled Receptors (GPCRs)
G protein-coupled receptors (GPCRs) are the largest family of transmembrane
receptors with more than 800 members found in higher eukaryotes, including yeast,
plants, and, especially, animals. This class of membrane proteins can respond to a wide
range of agonists, including photon, odors, pheromones, amines, hormones,
neurotransmitters and proteins, and vary in size from small molecules to peptides to
large proteins. Their function is crucial, based on regulation of a wide range of
molecular mechanisms including neurotransmission, endocrine and exocrine secretions,
immune responses, cardiac and smooth muscle contraction, and blood pressure. GPCRs
are involved in many diseases and represent the target of around half of all modern
medicinal drugs (Dorsam & Gutkind, 2007).
1.4.1 GPCR Structure and Function
GPCRs are integral membrane proteins that possess seven membrane-spanning
domains or transmembrane helices, therefore are also known as heptahelical receptors.
The extracellular parts of the receptor may be glycosylated. These extracellular loops
also contain two highly conserved cysteine residues which build disulfide bonds to
stabilize the receptor structure. Some agonists bind to the extracellular loops of the
receptor while others may penetrate into the transmembrane region (Pierce et al., 2002).
The transduction of the signal through the membrane by the receptor is not completely
understood. In its inactive state the receptor is bound to an inactive G protein, a
heterotrimer of  and  subunits. Ligand binding induces a change in the receptor
conformation that mechanically activates the G protein, which detaches from the
receptor (Dorsam & Gutkind, 2007).
It is believed that a receptor molecule exists in a conformational equilibrium between
active and inactive biophysical states. The binding of ligands to the receptor may shift
the equilibrium toward the active receptor state. If a receptor in an active state
encounters a G protein, it may activate it. Some evidence suggests that receptors and G
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proteins are actually pre-coupled. For example, binding of G proteins to receptors
influences the receptor's affinity for ligands (Rubenstein & Lanzara, 1998).
1.4.2 GPCR Signalling
Inactive G proteins have GDP bound to the subunit. Agonist-induced interaction
between the GPCR and G protein causes the replacement of GDP for GTP in the
subunit and dissociation between  and  subunits of the G protein. The separated
 and  subunits stimulate distinct downstream intracellular targets. The  subunits of
G proteins are divided into four subfamilies: Gαs, Gαi, Gαq and Gα12, and a single
GPCR can couple to either one or more families of Gα proteins. Each G protein
activates several downstream effectors as shown in figure 6 (Neves et al., 2002).
Figure 6: G protein-coupled receptor signalling
Source: RT Dorsam & JS Gutkind, Nature Cancer Reviews, 2007
Typically Gαs stimulates adenylyl cyclase and increases the levels of cyclic AMP
(cAMP), whereas Gαi inhibits adenylyl cyclase and decreases cAMP levels and Gαq
binds to and activates phospholipase C (PLC), which cleaves phosphatidylinositol
bisphosphate (PIP2) into diacylglycerol and inositol triphosphate (IP3). The β and γ
subunits function as a dimer to activate many signalling molecules, including
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phospholipases, ion channels and lipid kinases. Besides the regulation of these classical
second-messenger generating systems, Gβγ subunits and Gα subunits such as Gα12 and
Gαq can also control the activity of key intracellular signal-transducing molecules,
including small GTP-binding proteins of the Ras and Rho families and members of the
mitogen-activated protein kinase (MAPK) family of serine-threonine kinases, including
extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK), p38 and
ERK5, through an intricate network of signalling events that has yet to be fully
elucidated (Pierce et al., 2002; Marinissen & Gutkind, 2001).
1.4.3 GPCR  regulation
GPCRs become downregulated after exposure to their ligand for a prolongued period of
time. Two types of downregulation exist; the first one is homologous desensitization, in
which the activated GPCR is downregulated by intracellular kinases and the
heterologous desensitization, where an activated GPCR causes downregulation of a
different GPCR. Downregulation is caused by phosphorylation in the cytoplasmic
domain of the receptor by protein kinases. Phosphorylation is performed by c-AMP
dependent kinases or by G protein-coupled receptor kinases (GRKs).
 Phosphorylation by cAMP-dependent protein kinases
Cyclic AMP-dependent protein kinases (i.e. protein kinase A) are activated by the
signalling pathway initiated by ligand binding to GPCRs leading to activation of G
proteins and consequently adenylate cyclase and cyclic AMP. In a feedback
mechanism, these activated kinases phosphorylate the receptor. The longer the receptor
remains active, the more kinases are activated, and thus more receptors are
phosphorylated.
 Phosphorylation by GRKs
The G protein-coupled receptor kinases (GRKs) are protein kinases that phosphorylate
only active GPCRs. Phosphorylation of the receptor results in translocation of the
receptor, where the receptor is internalised into plasma membrane vesicles where it is
dephosphorylated and then brought back to the surface (recycling). This mechanism is
used to regulate long-term exposure, for example, to a hormone. The phosphorylated
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receptor may also become connected to arrestin molecules that prevent it from binding
to and activating G proteins for a short period of time.
(http://en.wikipedia.org/wiki/GPCR and references therein)
1.4.4 GPCRs  and Cancer
The critical role of GPCRs in cancer progression is based on a number of experimental
and clinical data. Constant GPCR stimulation by agonists produced and released from
tumour or surrounding stromal cells leads to autocrine and paracrine activation and
overexpression of the receptors in most tumour types (Heasley, 2001). Unregulated
GPCR function has recently been correlated with the ability of malignant cells to
proliferate independently, evade detection by the immune system, amplify their nutrient
and oxygen supply, and spread to surrounding tissues and other organs (Castellone et
al., 2005; Dorsam & Gutkind, 2007). Activating mutations of G proteins and GPCRs
were shown to promote the growth of some endocrine tumours, and constitutively
active GPCR expression has been found in the genomes of human oncogenic DNA-
viruses (Lyons et al., 1990; Sodhi et al., 2004). In colorectal cancer, GPCRs are also
stimulated by prostaglandins, the products of enzymes cyclooxygenases 1 and 2 that
cause inflammation, therefore providing a probable link between chronic inflammation
and cancer (Brown & Dubois, 2005; Gupta & Dubois, 2001). Finally, GPCRs have a
central role in tumour-induced angiogenesis, and tumour metastasis might involve the
GPCR-guided migration of cancer cells to their target organs (Richard et al., 2001).
Consequently, targeting GPCRs would be therapeutically valuable for patients with
GPCRs-driven cancers. The receptors targeted in this study are the group of
somatostatin receptors.
1.4.5 Somatostatin and Somatostatin Receptors
The group of GPCRs that have been targeted in this study includes the somatostatin
receptors. Somatostatin was discovered and its hormonal function was defined more
than 30 years ago. The wide range of anatomical distribution and actions of
somatostatin and its receptors have motivated intense scientific and clinical interest.
These receptors are strongly overexpressed in neuroendocrine tumours (NETs), therapy
of which is the objective of our research, which will be discussed later in this chapter.
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1.4.5.1 Structure and Function
Somatostatin (SST) is a cyclic disulphide-containing peptide hormone that was first
discovered in the hypothalamus as an inhibitor of growth hormone (GH) secretion
(Brazeau et al., 1973). Somatostatin is a mixture of two peptides, one of 14 amino acids
(SST-14), and the other of 28 (SST-28). They are produced throughout the central
nervous system and in other peripheral organs such as the pancreas, gut, thyroid and
adrenal glands, with a primary role in regulation of cell secretions (Patel, 1999). Both
forms of somatostatin are generated by proteolytic cleavage of prosomatostatin, which
itself is derived from preprosomatostatin (Patel, 1999). The relative amounts of SST-14
versus SST-28 secreted depend upon the tissue. For example, SST-14 is the
predominant form produced in the nervous system and apparently the sole form
secreted from pancreas, whereas the intestine secretes mostly SST-28. In addition to
tissue-specific differences in secretion of SST-14 and SST-28, the two forms of this
hormone can have different biological potencies. SST-28 is roughly ten-fold more
potent in inhibition of growth hormone secretion, but less potent that SST-14 in
inhibiting glucagon release (Tannenbaum et al., 1982).
SST acts on various targets to produce a broad spectrum of biological effects.  In the
brain SST acts as a neurotransmitter and a regulator of paracrine and autocrine
secretions (Epelbaum et al., 1994). It also inhibits the basal and stimulated release of
growth hormone and of the thyroid-stimulating hormone (TSH) (Patel & Srikant,
1986). Furthermore, it inhibits secretion of prolactin in vitro and diminishes elevated
prolactin levels in acromegaly (Reichlin, 1983; Patel & Srikant, 1986).
SST is also secreted by cells in the pancreas and in the intestine, where it inhibits the
secretion of a variety of other hormones.  In pancreas, SST appears to act primarily in a
paracrine manner to inhibit the secretion of both insulin and glucagon. It also has the
effect in suppressing pancreatic exocrine secretions, by inhibiting cholecystokinin-
stimulated enzyme secretion and secretin-stimulated bicarbonate secretion (Patel,
1999). SST is secreted by scattered cells in the GI epithelium, and by neurons in the
enteric nervous system. In the GI tract, SST inhibits the release of virtually every gut
hormone that has been tested, including gastrin, cholecystokinin, secretin and
vasoactive intestinal peptide. In addition to the direct effects of inhibiting secretion of
other GI hormones, SST has a variety of other inhibitory effects on the GI tract, which
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may reflect its effects on other hormones, plus some additional direct effects. SST
suppresses secretion of gastric acid and pepsin, lowers the rate of gastric emptying, and
reduces smooth muscle contractions and blood flow within the intestine. Collectively,
these activities seem to have the overall effect of decreasing the rate of nutrient
absorption (Schubert, 2003; Patel et al., 1995).
Five somatostatin receptors have been identified and characterized, all of which are
members of the G protein-coupled receptor superfamily (Reisine & Bell, 1995). They
are termed SSTR1-SSTR5 with SSTR2 receptor giving rise to two isoforms SSTR 2A
and SSTR 2B through alternative splicing of the mRNA (Schindler et al., 1998). These
receptors are expressed in a variety of tissues including the brain, pituitary, pancreas
and gastrointestinal tract (Patel, 1999). Each of the receptors activates distinct
signalling mechanisms within cells, although all inhibit adenylyl cyclase (Benali et al.,
2000). Four of the five receptors do not differentiate SST-14 from SST-28. (Csaba &
Dournaud, 2001)
1.4.5.2 Somatostatin Receptors and Cancer
A large variety of tumour cells exhibit SSTR expression and more than one isoform is
usually present in each tumour. Most human tumours originating from SST target
tissues such as gastroenteropancreatic, brain tumours, and pituitary tumours have their
SSTRs conserved. SSTRs were first described in growth hormone producing adenomas
and TSH-producing adenomas (Reubi et al., 1992). Only half of endocrine inactive
adenomas display somatostatin receptors. While brain tumours contain SSTRs, the
receptor content varies with the tumour type. Medulloblastomas, oligodendrogliomas,
and differentiated astrocytomas display somatostatin receptors. High grade
glioblastomas lack SSTRs, whilst meningiomas express these receptors (Lamberts,
1991). A proportion of breast, prostate, colorectal and lung tumours also exhibit SSTRs
on their surface (Reubi et al., 1990). The expression of SSTRs and in particular of
SSTR2 in high densities is found in 55-95% of NETs (Behr & Behe, 2002).
Specifically, small cell lung cancer, medullary thyroid carcinomas and carcinoids
contain a high density of homogeneously distributed SSTRs (Reubi et al., 1990;
Bousquet et al., 2004).
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SST has been implicated as having an anti-proliferative effect on a wide range of cell
types. This may be an indirect effect, through suppression of secretion of growth factors
and hormones vital for tumour growth or by blocking angiogenesis (Bousquet et al.,
2004). SST antineoplastic activity has also been shown in vitro against various cancer
cell lines, in which cell cycle arrest or apoptosis is induced depending on the SSTR
subtype as well as the target cell (Pollak & Schally, 1998). This anti-proliferative
activity of SST led to the synthesis of analogues to the peptide that mimic the action of
SST but can be more selective in their binding affinity to SSTR subtypes and more
potent in their cytotoxic activity.
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CHAPTER 2
TARGETING OF ENZYME AND RECEPTOR PATHWAYS:
OVERVIEW AND IMPLICATIONS FOR THERAPY
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The aim of my thesis is the study of enzyme and receptor pathways and this chapter
provides an overview of the targets which I have explored.
2.1 Protein Tyrosine Kinases and Resistance to Genotoxic Therapies
PTKs can promote cancer through activation of the signalling pathways they control,
which promote uncontrolled proliferation (independently of environmental survival
factors such as growth factors), protection from apoptosis in the absence of external
growth signals, inhibition of differentiation, and even supporting invasion and
metastasis of cancer cells by deregulation of adhesion (Porter &Vaillancourt, 1998).  In
addition, it has recently been discovered that PTKs may also provide resistance to
chemotherapy and radiotherapy, which could explain the failure of many anti-tumour
treatments (Yu & Hung, 2000; Slupianek et al., 2001). This was initially thought to be
due to rapid detoxification, inactivation and efflux of drugs (El-Deiry, 1997). This was
not proved to be the case, as these mechanisms arise late in the tumour development as
a result of the selection of the tumour cells able to resist the genotoxins, whereas PTK-
induced drug resistance is an early event in the transformation of cells which increases
along with tumour progression and adds to its drug resistance (Masumoto et al., 1999;
Cambier et al., 1998). PTK-transformed cells can accumulate additional genetic
abnormalities, such as mutations or deletions of p53, p73, MSH2 or MLH1 which
further increase genotoxic resistance (Strano et al., 2001; Skorski, 2002). Resistance to
genotoxic therapies can be induced by means of at least three mechanisms:
1. Enhanced DNA Repair
Cells transformed with the PTK can repair DNA lesions more rapidly than non-
transformed cells. This was shown to be dependent on PTK activity (Majsterek et al.,
2002). The repair pathways activated by PTKs in cancer cells depend on the cytotoxic
agent used and the types of DNA damage it causes (Skorski, 2002). Cells transformed
by oncogenic fusion proteins such as the Bcr-Abl-like tyrosine kinases show
upregulation of homologous recombination (HR) repair, responsible for DNA DSBs.
This is through deregulated expression and phosphorylation of RAD51 (Slupianek et
al., 2002).  Increased levels of RAD51 proteins have been observed in many tumours
and correlate with drug resistance (Raderschall et al., 2002; Vispe et al., 1998). In
contrast non-homologous end joining (NHEJ), which also repairs double strand breaks
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(DSBs), appears to be downregulated in Bcr-Abl expressing cells (Deutsch et al.,
2001).
2. Checkpoint activation
Src PTK can dissociate cyclin-dependent kinase 2 (CDK2) from cyclin A in response to
etoposide thus inducing S-phase arrest (Chen & Hitomi, 1999). In addition, Bcr-Abl-
related PTKs induce pronounced G2/M-checkpoint activation in response to various
agents, including cisplatin (Raderschall et al., 2002). The mechanism of G2/M-
checkpoint arrest in PTK-transformed cells is not known, but probably involves
regulation of CDC2 phosphorylation (Slupianek et al., 2002). It is thought that by
prolonging the G2/M phase, PTKs allow for HR to repair more DSBs and allow tumour
cells to escape from the apoptotic pathway (Skorski, 2002).
3. Resistance to apoptosis
PTKs were shown to modulate the expression and post-translational modification of
members of the BCL-2 family in order to protect cancer cells from apoptotic signals.
Anti-apoptotic members such as Bcl-xL and Bcl-2 are stimulated, but proapoptotic
members such as Bad and Bax are inhibited (Skorski, 2002). Bcr-Abl was shown to
activate STAT5, a signal transducer and transcriptional activator responsible for BclXL
overexpression (Gesbert & Griffin, 2000). Additionally, Bcr-Abl also activates Akt
which associates with Bad and keeps it away from the mitochondria. Akt can also
stimulate the MDM2-dependent, ubiquitin-mediated degradation of p53 and subsequent
downregulation of Bax and upregulation of Bcl-2 (Zhou et al., 2001). C-KIT also
induces resistance to apoptosis by upregulation of the Bcl-2 anti-apoptotic protein, and
phosphorylation and inactivation of the pro-apoptotic Bad.  As a result, cytochrome c
release from mitochondria and consequent activation of caspase-3, events which are
vital to induction of cell death by apoptosis, are inhibited (Carson et al., 1994; Blume-
Jensen et al., 1998).
Resistance of cancer cells to chemotherapy or radiation due to overexpression of
oncogenic protein tyrosine kinases has led to the selective targeting of these receptors
as a new modality in the treatment of cancer patients.
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2.2 Tyrosine Kinase Inhibitors
Approximately 200-300 PTKs are present in every cell. The ATP binding site is highly
conserved within groups and this was initially a problem for the design of compounds
with high specificity (Traxler et al., 2001). The first drugs to be used against PTKs
were broad-spectrum compounds such as herbimycin and sraurosporin which inhibited
ATP binding at the active site of the enzyme targets.  These drugs showed anti-
proliferative activity against tumour cells expressing tyrosine kinases, but inactivation
of multiple PTK targets was lethal and was considered less advantageous for clinical
use than substrate based inhibitors (e.g. antibodies) (Sawyers, 2002).
Enormous progress in molecular, biochemical and cell biology technologies as well as
advances in synthetic chemistry on natural products, crystallography and computerised
molecular modelling have led to rational drug design of compounds with selective
kinase inhibition (Traxler et al., 2001, Sawyers, 2002). Screening for low molecular
weight therapeutic agents against various cancers has become an important component
of drug discovery. Recently, development of drugs such as imatinib (STI-571) which
preferentially binds the inactive ATP binding site of the Abl protein preventing its
activation, has led to a very important discovery: although the active binding site may
be common among PTKs, in their inactive state proteins have a different conformation
and therefore the binding site can be distinct allowing for selective drug targeting
(Sawyers, 2002). Over the past few years, the number of receptors and in particular
tyrosine kinases, being investigated as molecular targets in drug discovery has greatly
increased. As a consequence, a growing number of compounds have been developed
and used in clinical trials, as shown in table 4.
The extracellular domain of PTKs found in the plasma membrane is targeted with
monoclonal antibodies that bind and inhibit activation of the receptor by its ligand. This
may prevent receptor dimerisation, or promote receptor degradation. With the
extracellular region of each receptor being unique, these agents are highly specific and
do not cross react with other receptor tyrosine kinases. On the other hand, small
molecule tyrosine kinase inhibitors target the intracellular ATP-binding region of the
receptor and prevent its tyrosine kinase activity. These small molecule inhibitors have
the advantage of being able to enter the cell, thus acting also against non-membrane
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bound protein tyrosine kinases as well as receptors. The interaction with the target
protein can be studied more easily using X-ray crystallography and computer
modelling. As a result, their structure can be engineered in order to increase specificity
as well as pharmacokinetic characteristics (Traxler et al., 2001).
Table 4. Compounds targeted against tyrosine kinases
Source: CL Sawyers, Current Opinion in Genetics and Development, 2002
Clinical studies conducted over the past decade have established several of these drugs
as part of the standard treatment regimen for specific tumour types. These include
imatinib (directed against Bcr-Abl and other kinases), trastuzumab (trade name
Herceptin against HER2/ErbB2 receptor), and cetuximab (C225), erlotinib (OSI-774)
and gefitinib (ZD1839), which are directed against the EGFR/ErbB1. Analysis of all
the oncogenic tyrosine kinases and their inhibitors is beyond the scope of this
discussion. However, the tyrosine kinases targeted and the inhibitors used in this study
are outlined in detail below.
2.2.1 EGFR as a therapeutic target
Many types of EGFR inhibitors have been developed in the last decade, targeting
different parts of the receptor protein structure or the synthesis of the protein itself. Of
these, the most extensively studied drugs include monoclonal antibodies (table 5)
binding the extracellular domain of the receptor such as cetuximab (Erbitux; ImClone/
BMS/Merck KGaA), or small molecule tyrosine kinase inhibitors (TKIs), that target the
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intracellular (catalytic) tyrosine kinase domain of the receptor inhibiting downstream
signalling effects, such as gefitinib (Iressa; AstraZeneca Pharmaceuticals) and erlotinib
(Tarceva; ImClone Systems) (Harari, 2004).
Table 5.Monoclonal antibodies against EGFR
Agent Type Generic/Trade name Institution
IMC-C225 Chimeric IgG1 Cetuximab/Erbitux Imclone/BMS/Merck KGaA
ABX-EGF Fully human IgG2 Panitumumab Abgenix/Amgen
EMD72000 Humanized IgG1 Matuzumab EMDpharms/Merck KGaA
MDX-447 Humanized bispecific:
EGFR/FcRγ1
HuMab-Mouse Medarex/Merck KGaA
h-R3 Humanized TheraCIM YM biosciences/CIM
Mab 806 Anti-EGFR VIII - Ludwig Institute
Source: PM Harari, Endocrine Related Cancer, 2004
TKIs are synthetic, predominantly quinazoline derived molecules with low molecular
weight and interact with the ATP binding domain of EGFR (Ciardiello et al., 2000). A
number of classes of TKI exist; reversible, irreversible, reversible dual ErbB1/2 TKIs
and pan ErbB inhibitors (table 6) (El-Rayes and LoRusso, 2004). In July 2007 it was
discovered that the blood clotting protein fibrinogen inhibits EGFR, thereby blocking
re-growth of injured neuronal cells in the spine (Schachtrup et al., 2007).
Table 6. EGFR tyrosine kinase inhibitors
Agent Type Generic/trade name Institution
ZD1839 erbB1 Gefitinib/Iressa AstraZeneca
OSI-774 erbB1 Erlotinib HC1/Tarceva oSI/Genentech/Roche
CI-1033 Pan erbB1 Canertinib Pfizer
EKB-569 erbB1/2 - Wyeth Ayerst
GW2016 erbB1/2 - GlaxoSmithKline
PKI-166 erbB1/2 - Novartis
Source: PM Harari, Endocrine Related Cancer, 2004
52
2.2.1.1 Gefitinib (Iressa, ZD1839)
Gefitinib (figure 7) is an orally active, synthetic quinazoline-derived reversible EGFR
inhibitor that interacts with the ATP-binding domain of EGFR, blocking its ligand-
induced phosphorylation which leads to receptor activation (Ciardiello, 2000).
Inhibition of EGFR by gefitinib has been shown both in cell lines and in xenograft
models both as a single agent or in combination with a variety of chemotherapeutic
agents, radiation therapy, or anti-sense oligonucleotides where additive or synergistic
effects were identified (Ciardiello et al., 2000; Ciardiello et al., 2001a; Huang 2002;
Friedmann et al., 2004). The antiproliferative effect was shown to be due to cell cycle
arrest or apoptosis. Inhibition of EGFR by gefitinib causes a reduction of the
transcription factor, cFOS, mRNA which forms part of the AP1 complex, and a shift of
cells from S phase into G0/G1 (Raben et al., 2002). Gefitinib also causes reduction of
VEGF, bFGF, and TGF-thereby inhibiting angiogenesis in a colon, breast, ovarian
and gastric cells in vitro (Ciardiello et al., 2000).
Gefitinib has shown antitumour activity and has been approved in many countries as a
single treatment for refractive NSCLC (Harari, 2004). Research in gefitinib-sensitive
patients with NSCLC showed that a mutation in the EGFR tyrosine kinase can facilitate
efficacy of the drug. This mutation leads to activation of the anti-apoptotic Ras pathway
which promotes cell proliferation. Malignant cell proliferation is inhibited by blocking
of the Ras signal transduction pathway by gefitinib as well as other tyrosine kinase
inhibitors (Lynch et al., 2004; Paez et al., 2004).
Figure 7: The chemical structure of gefitinib
Although the initial preclinical studies with gefitinib showed promising results a large
study undertaken for the efficacy of gefitinib in patients with NSCLC failed to show
improved survival in patients, and has been replaced in the United States by erlotinib,
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which functions in a similar manner to gefitinib and has shown a survival benefit in the
treatment of lung cancer in phase III trials (Shepherd et al., 2005). Erlotinib has been
approved by the FDA in November 2004 for the treatment of locally advanced or
metastatic non-small cell lung cancer that has failed at least one prior chemotherapy
regimen (Smith, 2005). In November 2005, the FDA approved the use of erlotinib in
combination with gemcitabine for treatment of locally advanced, unresectable, or
metastatic pancreatic cancer (Rocha-Lima et al., 2007; Moore et al., 2007).
2.2.1.2 Cetuximab (Erbitux, IMC-C225)
The first and most extensively studied antibody against EGFR is cetuximab (Erbitux;
ImClone Systems, Inc). Cetuximab is a chimeric human/mouse mAb composed of the
Fv (variable) regions of a precursor murine anti-EGFR antibody (mAb 225) with
human IgG1 heavy and kappa light chain constant regions produced in mammalian
(murine myeloma) cells. This recombinant antibody reduces the possibility of an anti-
mouse immunological reaction in patients (Herbst and Shin 2002).
As other anti-EGFR antibodies, cetuximab operates by binding to the extracellular
domain of EGFR, preventing ligand binding and activation of the receptor, and induces
receptor internalisation and downregulation (Kim et al., 2001). Studies in cell culture
cells as well as xenograft models have also shown that cetuximab has an anti-
angiogenic effect through inhibition of the vascular endothelial growth factor (VEGF),
interleukin-8, and basic fibroblast growth factor (bFGF), resulting in growth inhibition
of tumour cells (Perrotte et al., 1999; Huang & Harari, 1999). Cetuximab has also been
shown to mediate antibody dependent cellular cytotoxicity (ADCC) (Naramura et al.,
1993; Mendelsohn, 2001).
Studies of cetuximab in combination with various agents indicate dose-dependent
additive or synergistic increase in growth inhibition. Several in vitro experiments and in
vivo animal studies have also shown an enhancement of tumour response to radiation
by cetuximab in human epidermoid, head and neck, and colon cancer xenografts (Saleh
et al., 1999; Milas et al., 2000; Bianco et al., 2000; Prewett et al., 2002).
In 2004 cetuximab was approved by the Food and Drug Administration (FDA) to treat
patients with advanced or metastatic colorectal cancer and is often given concurrently
54
with the chemotherapy drug irinotecan (Camptosar), a DNA topoisomerase I inhibitor,
or alone for the treatment of irinotecan-resistant colorectal cancer (Harari, 2004). A
large phase III randomised clinical trial showed that compared to radiation alone,
combined treatment of cetuximab and radiation therapy increased the median survival
and improved the duration of locoregional disease control in patients with head and
neck cancer that has not spread to other parts of the body (Bonner et al., 2006).
Cetuximab was approved by the FDA in March 2006 for use in combination with
radiation therapy for the treatment of locally or regionally advanced squamous cell
carcinoma of the head and neck (SCCHN) or as a single agent for the treatment of
patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy
has failed (Rocha-Lima et al., 2007).
2.2.2 C-KIT inhibitor: Imatinib (STI571, Glivec, Gleevec)
Imatinib is an inhibitor against C-KIT, which has been extensively studied in literature.
Imatinib (Glivec or STI571 by Novartis Pharmaceuticals) is a tyrosine kinase inhibitor
that was initially developed to act against the fusion oncoprotein Bcr-Abl, a protein
resulting from the Philadelphia chromosome translocation between chromosomes 9 and
22, which occurs in 95% of chronic myelogenous leukaemia (CML) patients. It
suppresses CML primitive progenitors by decreasing their abnormal proliferation
without increasing their apoptosis. Inhibition of Bcr-Abl by imatinib reinstates normal
haematopoiesis. The drug also inhibits the tyrosine kinase activity of the normal Abl
protein, C-KIT, and PDGFR (both  and ), (Holtz et al., 2002; McGary et al., 2002).
In vitro studies have shown that imatinib inhibits growth of cell lines expressing Bcr-
Abl as will as primary cells (Druker et al., 1996; Le Coutre et al., 1999; Deininger et
al., 1997). Growth of cell lines transformed by Bcr-Abl, Tel–Abl, or Tel-PDGFR,
where Tel is a putative transcription factor which like Bcr activates Abl and is required
for the transforming function of the fusion protein, was inhibited by imatinib in the
absence of exogenous growth factors (Carroll et al., 1997). Imatinib also repressed
SCF-mediated C-KIT activation and growth of the small cell lung cancer cell line
H526. Growth reservation was accompanied by induction of apoptosis in media
containing SCF as the only exogenous factor, but not in serum containing media where
the effect of cell proliferation was cytostatic. Furthermore, imatinib efficiently blocked
55
SCF-mediated activation of C-KIT and of the MAP kinase and Akt, downstream target
proteins involved in cellular proliferation and survival. The same effect was obtained
by treatment with imatinib using the murine lymphoid Ba/F3 cell line transfected with
various types of activating C-KIT mutant (Krystal et al., 2000; Chen et al., 2003).
Imatinib is a 2-phenylaminopyrimidine derivative (figure 8) that specifically inhibits
activation of receptor tyrosine kinases by competitive binding to the ATP-binding site
needed for autophosphorylation and stabilising the receptor in its inactive form
(Gambacorti-Passerini et al., 2003). Therefore, the drug can be effective in
malignancies where the above tyrosine kinase receptors are the driving force for
proliferation, and in mutations that do not affect the ATP-binding pocket conformation.
Indeed, in the case of C-KIT, imatinib was shown to be effective against activating
mutations in the juxtamembrane domain of the receptor (GISTs, mastocytosis) but not
as effective against mutants in the tyrosine kinase domain (Chen et al., 2003). The most
notable example is the D816V mutant (exon 17), found in AML and mastocytosis,
which results in constitutive activation of the receptor and resistance to imatinib due to
increased affinity of this isoform to ATP or possibly due to conformational changes that
inhibit binding of the drug (Heinrich et al., 2002; Lennartsson et al., 2005).
Figure 8: Chemical structure of imatinib
Addition of imatinib decreased the proliferation of GISTs and induced apoptosis in
preclinical experiments (Demetri, 2001; Dematteo et al., 2002). The drug is currently
being used for the treatment of chronic-phase CML patients in whom interferon therapy
has failed and for accelerated-phase and blast-crisis disease (Cohen et al., 2005).
Imatinib has also been approved for treatment of patients with unresectable and/or
metastatic GISTs (Dagher et al., 2002; Demetri et al., 2002), with prolonged
progression-free survival reported (Verweij et al., 2004). Imatinib can induce high rates
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of clinical response in patients with unresectable or metastatic dermatofibrosarcoma
protuberans (DFSP; a tumor that forms under the top layer of skin). This has led to the
approval of imatinib by the U.S. Food and Drug Administration for treating
unresectable DFSP (McArthur, 2007).
One study demonstrated that imatinib was effective in patients with systemic
mastocytosis, including those who had the D816V mutation (Droogendijk et al., 2006).
Imatinib is also increasingly being used in laboratory settings as an experimental agent
to suppress PDGF by inhibiting its receptor PDGFROne of its effects is delaying
atherosclerosis in mice with diabetes (Lassila et al., 2004). Recent mouse animal
studies at the Emory University in Atlanta have shown that imatinib and related drugs
may be valuable in treating smallpox (Reeves et al., 2005). Imatinib is also being used
in the treatment of certain brain tumours including high grade glioblastoma.
2.3 Resistance to Tyrosine Kinase Inhibitors
Despite the promising preclinical data in various cell lines and animal models, as well
as the initial responses of patients to single treatments using drugs against protein
tyrosine kinases, the developing resistance of patients to these agents is a recognised
problem. Mechanisms mediating resistance to TKI therapies include the presence of
redundant tyrosine kinase receptors, increased angiogenesis, constitutive activation of
downstream receptors, and development of specific mutations (Camp et al., 2005).
2.3.1 Resistance to EGFR inhibitors
EGFR promotes survival and proliferation through downstream signalling pathways.
Other tyrosine kinases also influence similar downstream pathways. An example of this
is IGF-1R (Insulin like Growth Factor Receptor-1), a tyrosine kinase that activates the
PI-3K/Akt downstream signalling pathway (Kulik et al., 1997). IGF-1R over
expression has been shown in EGFR inhibitor resistant cell lines (Chakravarti et al.,
2002). Activation of alternative tyrosine kinases such as IGF-1R allows tumour cells to
bypass the EGFR pathway and develop resistance to EGFR targeting therapies.
EGFR mediated pathways promote tumour angiogenesis via VEGF upregulation. The
EGFR ligands EGF and TGFα have been implicated in this process. Chronic
57
administration of monoclonal antibodies or TKIs to athymic mice bearing GEO colon
cancer xenografts leads to development of resistant colon cancer cell lines showing a 5-
10 fold increase in VEGF expression (Ciardiello et al., 2003). These findings indicate
increased expression of angiogenic mediators such as VEGF cause resistance against
EGFR targeting therapies.
Constitutively active mediators of downstream signalling pathways cause resistance to
EGFR targeting therapies in cancer. Downstream constitutive activation allows tumour
cells to bypass the requirement for EGFR activation, decreasing the efficacy of EGFR
inhibition (Camp et al., 2005). Loss of PTEN phosphatase function commonly leads to
downstream constitutive activation within the EGFR signalling pathway. PTEN is a PI-
3K/Akt regulating tumour suppressor. Loss of PTEN causes over activation of the PI-
3K/Akt pathway, promoting expression of the anti apoptotic genes Bcl-2 and Bclx
(Marmor et al., 2004). Akt has a major role in resistance to EGFR therapies and is
implicated in resistance against both leading tyrosine kinase inhibitors gefitinib and
erlotinib (Ramsay Camp et al., 2005).
EGFR mutations such as the EGFRvIII mutation generate constitutively active EGFR.
Compared to wild type EGFR this mutation is resistant to gefitinib (Learn et al., 2004).
Some EGFR activating mutations have been shown to confer sensitivity to EGFR
targeting therapies such as gefitinib (Lynch et al., 2004). Unfortunately these tumour
cells have gone on to develop further mutations that confer resistance to gefitinib
(Kobayashi et al., 2005).
2.3.2 Resistance to imatinib
Resistance to imatinib is mainly due to mutations leading to constitutive
phosphorylation and ligand-independent activation of C-KIT. The most prominent
mutation associated with imatinib resistance is the D816V substitution, which is found
in the activation loop of the kinase domain (exon 17) and has been implicated in the
increased proliferation of cells in AML, germ cell tumours and mastocytosis (Kanakura
et al., 1993; Escribano et al., 1998; Ashman, 1999; Boissan et al., 2000; Feger et al.,
2002). Identification of such gain of function mutations in the cytoplasmic domain of
C-KIT by Hirota and co-workers in 1998 helped identify C-KIT as a potential target in
GISTs (Hirota et al., 1998). In fact, C-KIT is now used for the diagnosis of GISTs and
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for the differentiation between GISTs and other soft tissue sarcomas of the GI tract
(Jiang et al., 2008).
GIST-associated mutations have been identified in exons 9, 11, 13, and 17 of the
receptor. The most common mutations are found in exon 11, which is the intracellular
juxtamembrane domain of C-KIT, and they actually improve the response of patients to
imatinib. However, mutations in exon 9, which is the extracellular juxtamembrane
domain of C-KIT, are linked with decreased sensitivity to imatinib and shorter survival
rates in patients (Heinrich et al., 2006; Debiec-Rychter et al., 2004).
Another implication in GISTs relates to the activation of other tyrosine kinases as an
alternative route to signal transduction. Candidate proteins include the receptor tyrosine
kinase AXL. Analysis of gene expression in imatinib resistant cell lines showed
overexpression of AXL and not C-KIT compared to imatinib sensitive cells
(Mahadevan et al., 2007).  Using the same cell models, it was also shown that the PI3-
kinase pathway remains active in imatinib resistant cells probably through a different
receptor and that inhibition of the PI3-K signalling alone promoted inhibition of cell
growth (Bauer et al., 2007).
By far the biggest setback in GISTs is the acquisition of secondary mutations in
imatinib-treated patients (Braconi et al., 2008; Jiang et al., 2008). The most prevalent
mutation in relapsing patients is the V654A substitution found in the kinase domain
(exon 13), with the rest of the mutations occurring in exon 17, which corresponds to the
second tyrosine kinase domain of the receptor. These mutations lead to conformational
changes in the receptor which affect binding of imatinib (Heinrich et al., 2006). To
overcome this secondary resistance in GISTs, new tyrosine kinase inhibitors with
multiple targets are being developed. Sunitinib is such an alternative to imatinib,
targeting C-KIT, PDGFR, VEGFR, and FMS-related tyrosine kinase 3 receptor, and
has shown efficacy in a number of relapsing patients (Braconi et al., 2008; Jiang et al.,
2008).
Although most of our study has focused on protein tyrosine kinases and their inhibitors,
we also examined the therapeutic potential of somatostatin receptors.
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2.4 Somatostatin analogue: Octreotide (Sandostatin, SMS201-995)
Octreotide (Novartis, Basel, Switzerland) is an octapeptide synthetic analog of
somatostatin (SST, figure 9) that possesses the same pharmacological properties as
SST, except that it is cleared from the circulation at a much slower rate by being
resistant to plasma degradation. The half life is 117 minutes as compared to
approximately 3 minutes for SST, making it more suitable for therapeutic and imaging
purposes (Degen & Beglinger, 1999). Octreotide, like SST, has been shown to inhibit
exocrine and endocrine secretions of the digestive system, including gastrin, serotonin,
growth hormone, insulin and glucagon. A number of signal transduction proteins are
regulated by somatostatin and its analogues, and these include cyclic AMP,
diacylglycerol (DAG), calcium and potassium channel proteins and tyrosine
phosphatases (Oberg, 1996). Octreotide is used for the symptomatic control and
inhibition of tumour growth in NET patients. It can also adjust the motility of the GI
tract and biliary system and has been shown to induce apoptosis.
Figure 9: Chemical structure of octreotide
Octreotide binds SSTR2 and SSTR5 with high affinity, SSTR3 with low affinity, and
has no affinity for SSTR1 and SSTR4 (Kulaksiz et al., 2002). Two long acting SST
analogues with similar efficacy to octreotide now in use in NETs include lanreotide
(Ipsen, Paris, France) and octreotide-LAR (long-acting release), which are both
administered monthly. SST analogues have shown anti-neoplastic activity in mammary,
pancreatic, colorectal and lung cancers (Weckbecker et al., 1993). Octreotide has also
shown anti-proliferative effects in vitro against gastric and pancreatic adenocarcinoma
cells (Hofsli et al. 2002, Wang et al., 2003). It has been introduced for the treatment of
60
endocrine tumours of the gastrointestinal tract as it was shown to effectively control
symptoms resulting from excessive hormone release in patients with carcinoid, Verner-
Morrison and glucagonoma syndromes. In this way it improves the quality of life of
patients whose tumours produce the above hormones. SST analogues may also have
anti-tumour activity in a minority of carcinoid patients (Caplin, 1998). SST analogues
have also been used for the treatment of insulinomas, as they inhibit insulin secretion
(Bertherat et al., 2003).
Octreotide is registered in most countries for the treatment of patients with carcinoid
syndrome and also for glucagon and VIP producing tumours (Oberg, 2001). Long-term
studies have shown that somatostatin analogues are safe and that the most important
adverse effect is the development of gallstones. The antiproliferative potency of SST
and its analogues in vitro and in experimental tumour models prompted a number of
studies in patients with metastatic endocrine tumours that are generally unresponsive to
conventional chemotherapeutic protocols. Stabilisation of tumour growth lasting for
months to a few years was the most favourable result, occurring in 30 – 70% of patients
(Behr et al., 2002). In addition, a recent phase III PROMID study in patients with
midgut carcinoid tumours using octreotide-LAR showed that time to progression was
twice as long compared to placebo patients. These results indicate a possible anti-
tumour effect by octreotide in well differentiated midgut NETs (Rinke et al., 2009).
2.4.1 Somatostatin Receptor-Mediated Imaging and Therapy
The development of SST analogues such as octreotide has been very useful in the
treatment of endocrine diseases and cancer. The molecular cloning of five distinct
subtypes of SSTRs in the 1980s has led to the design and development of subtype-
selective peptides and nonpeptide agonists and antagonists. The development of in vivo
somatostatin receptor-mediated imaging known as somatostatin receptor scintigraphy
(SRS or Octreoscan) is a valuable tool for the identification and localization of NETs
and their metastases, and particularly GEP tumours, which mainly express SSTRs
(Breeman et al., 2001; Gibril & Jensen, 2004). This is based on visualisation of
radiolabelled octreotide or lanreotide, binding to SSTRs. The next step was the
exploitation of somatostatin analogues labelled with radionuclides emitting  or 
particles, including Auger or conversion electrons, for neuroendocrine tumour
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treatment, a technique called somatostatin receptor-targeted radiotherapy or peptide
receptor radionuclide therapy (PRRT). These types of radionuclide labelled octreotide
accumulate within tumour cells through receptor-peptide internalisation and are rapidly
cleared from the blood due to their relatively small size (Reubi, 2004).
The radioisotopes used include 111In (Indium-111), 90Y (Yttrium-90) or 177Lu
(Lutetium-177). The peptide labelled with a radioisotope is covalently linked to a
chelator, which stabilises the molecule. The chelator used for 111In is diethylene-
triamine-pentaacetic acid (DTPA) and 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-
tetraacetic acid (DOTA) for 90Y and 177Lu. Octreotide labelled with 111In is very
effective in localising NETs (Kaltsas et al., 2004), whilst 90Y and 177Lu are preferred
for therapy (Srirajaskanthan et al., 2009; Desai et al., 2009).
Both 90Y-octreotide and 177Lu-octreotate have shown promising results in patients with
GEP NETs (Kaltsas et al., 2005). The use of 90Y-(DOTA)0-Tyr3-octreotide (90Y-
DOTATOC), resulted in 10–30% tumour response rates, and appears to be particularly
effective in generally large tumours (Waldherr et al., 2002). On the other hand, 177Lu-
(DOTA)0-Tyr3-octreotate (177Lu-DOTATATE) is better in small tumours. In a large
study of more than 500 patients 177Lu-DOTATATE produced 2% complete and 28%
partial tumour response, with a survival benefit of several years (Kwekkeboom et al.,
2008). A combination of these drugs could therefore be beneficial in patients carrying
both large and small tumours (Kaltsas et al., 2005).
2.5 Chemotherapeutic Drugs for Anticancer Therapy
Cancer therapy is a major area of research and new treatments are actively being
studied to target the leading cancers e.g. breast, lung, prostate and colon. Chemotherapy
or radiotherapy is usually most effective against fast proliferating tumour cells.
Neuroendocrine tumour cells are generally slow growing, so chemotherapy is therefore
considered to be helpful in a minority of tumour patients. This has created the need for
use of drugs with different mechanisms of action to treat patients, and the need to
assess both single agent and combination therapies. One such consideration is the
combination of growth factor inhibitors with chemotherapeutic agents.
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In some uncommon tumours such as childhood cancers, lymphomas and teratomas,
great progress has been made with the use of cytotoxic drugs. In other more common
tumours such as lung and pancreatic carcinoma, the results have been less impressive,
although modest improvements in survival have been obtained with chemotherapy and
endocrine therapy in breast and colorectal cancer (De Vita et al., 2005). Most anti-
cancer agents serve to inhibit tumour cell growth and division although there is
considerable potential for the development of agents which affect invasion,
vascularisation and metastasis. Cytotoxic agents can reduce tumour cell growth and
division by binding to DNA bases or impairing DNA synthesis to inhibit DNA
replication, by damaging the mechanisms of cell division, or by blocking the pathways
involved in cell growth. The main classes of chemotherapeutic agents are shown in
figure 10.
Figure 10: The different classes of anticancer drugs
To review all the chemotherapeutic agents is beyond the scope of this discussion.
However, the agents used in this study are outlined in detail below. The merits of
combination studies using growth factor inhibitors and chemotherapeutic agents will be
discussed in detail and separately for each receptor target in the following chapters.
Anticancer Drugs
Antimetabolites
e.g. Methotrexate
Mitotic
inhibitors
e.g. Paclitaxel
DNA-interactive
drugs
Topoisomerase
poisons
e.g. Etoposide
Non-covalent DNA
binding drugs
e.g. Doxorubicin
Covalent DNA
binding drugs
Nitrogen mustards
e.g. Melphalan
Platinum compounds
e.g. Cisplatin
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2.5.1 Cisplatin
Cisplatin or cis diaminedichloroplatinum (CDDP) is an inorganic compound with a
planar configuration (figure 11) that kills cancer cells by binding to DNA and
interfering with its repair mechanism, eventually leading to cell death by apoptosis. It
exists in cis and trans conformations, of which only the cis isomer is cytotoxic.
Cisplatin was discovered in a study by Barnett Rosenberg (1985) designed to study the
possible effect of electric current on the growth of Escherichia coli. Inhibition of cell
division but not cell growth leading to bacteria forming long filaments was identified
and this was due to the electrolytic product of the platinum electrode. Cisplatin is
clinically used for the treatment of a wide variety of tumours, including testicular,
ovarian, oesophageal, head and neck, and lung cancer (Loehrer & Einhorn, 1984)
Figure 11: The chemical structure of cisplatin
The anticancer properties of cisplatin are similar to alkylating agents and commence
with the substitution of one or both of its chloride ligands with hydroxyl groups after
diffusion into the cell. This aquated complex of cisplatin is a reactive electrophilic
agent that can form covalent bonds with nucleophilic species such as proteins, and
nucleic acid bases of a DNA or an RNA strand (Reed et al., 1999). DNA is the main
target of cisplatin and this function is believed to mainly contribute to its cytotoxicity.
Binding studies have shown a preference for nitrogen 7 (N7) on guanine.
As cisplatin is bifunctional, it can bind to DNA in several different ways. This results in
the formation of inter- and intra-strand crosslinks, monoadducts, or DNA-protein
crosslinks, which distort the shape of DNA, thus interfering with cellular transcription
and replication (Trimmer et al., 1999). The main adducts formed are shown in figure
12. The cisplatin-DNA complex attracts the HMG-1 (high mobility group-1) and other
DNA repair proteins which become irreversibly bound and prevent effective repair.
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Studies in vitro have shown cisplatin to react with DNA to form adducts of which 65%
are 1,2-intrastrand d(GpG) crosslinks (between adjacent N7-guanine sites), 25% are 1,2-
intrastrand d(ApG) crosslinks (between adjacent N7-guanine and N7-adenine sites),
with the remaining 10% of adducts in the form of other intrastrand crosslinks,
interstrand crosslinks, monofunctional adducts and DNA-protein crosslinks (Fichtinger-
Schepman et al., 1985; Dronkert & Kanaar, 2001). Cisplatin is not cell phase specific.
C
C
3'
5'
Pt
NH3
NH3G
G
5'
3'
1,2-intrastrand d(GpG)
T
C
3'
5'
Pt
NH3
NH3A
G
5'
3'
1,2-intrastrand d(ApG) adduct
X
C
5'
C
3'
Pt
NH3
NH3
X
G
5'
G
3'
1,3-intrastrand d(GpXpG) adduct
Pt
NH3
NH3G
C
5'
3'
C
G
3'
5'
Interstrand cross-link
A
C
3'
5'
Pt
NH3
NH3T
G
5'
3'
Mono adduct
Figure 12: Types of DNA adducts formed by cisplatin
2.5.2 Etoposide
Etoposide (VP-16) is a semisynthetic derivative of podophyllotoxin, a toxin found in
the Podophyllum peltatum plant (figure 13). It is used for the treatment of lung cancer,
testicular cancer, lymphoma, non-lymphocytic leukaemia, and is often given in
combination with other drugs. It belongs in the group of chemotherapeutic agents that
inhibit chromatin function by inhibiting topoisomerase II. DNA inside cells is
extensively twisted (supercoiled) to fit inside the nucleus. Topoisomerase II enzymes
are multisubunit proteins that permit selected regions of DNA to untangle to allow
replication and transcription to occur. Untangling involves transient breakage of DNA,
allowing for change of topology by passing an intact helix through the double-stranded
break, and then resealing the breaks.
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Figure 13: Chemical structure of etoposide
The mechanism of action of etoposide is in stabilizing the topoisomerase II-DNA
complex and preventing it from making a topological change. When the replication fork
encounters the DNA-topoisomerase complex it converts the transient break into an
irreversible double strand break which is lethal to cells in S and G2 phases of the cell
cycle. Permanent DNA double strand breaks then trigger apoptotic cell death (Hande,
1998).
2.5.3 Doxorubicin
Doxorubicin is an anthracycline antibiotic produced by the fungus Streptomyces
peucetius (figure 14). Anthracyclines are intercalating drugs which have planar regions
allowing them to stack between paired DNA bases forming tight (non-covalent) drug-
DNA interactions. They include doxorubicin (adriamycin) and daunorubicin and have a
planar ring system attached to an amino sugar.
The drug interacts with DNA by intercalation. The quinone ring is metabolised
producing reactive oxygen species (ROS) which subsequently lead to free radical
cleavage of DNA. This results in partial unwinding of DNA, impaired DNA and RNA
synthesis and single strand breaks in DNA. It is also non-phase specific (Zhong et al.,
2001). It is therefore plausible that these multiple mechanisms which also have
downstream effects on cell-cycle checkpoints have a clinical advantage over an agent
with a single mechanism of action (Hurley, 2002). It has wide clinical activity for a
variety of solid tumours (breast, ovarian and lung cancer) and leukaemia.
66
Figure 14: Chemical structure of anthracyclines
Doxorubicin shows an enhanced selectivity for cancer cells over normal cells.
Intercalation prevents the progression of topoisomerase II and induces protein-
associated strand breaks by stabilising the topoisomerase II – DNA complex after the
enzyme has broken the DNA for replication. Preventing the DNA double helix from
unwinding stops the process of replication (Fornari et al., 1994; Tewey et al., 1984).
Given that these processes  require protein binding to DNA, the selectivity of agents
that target these processes might be dependent on the level of the associated target
protein (for example, topoisomerase I or II), so cells with elevated levels of
topoisomerase would be more sensitive to doxorubicin, and this is the basis for
enhanced cancer-cell selectivity (Henderson & Hurley, 1995).
2.5.4 Melphalan
Melphalan is a chemotherapy drug that belongs to the class of nitrogen mustard
alkylating agents. This includes mechlorethamine; a derivative of war gas sulphur
mustard that was originally used in the 1940’s to treat lymphomas. Melphalan is the
phenylalanine derivative of mechlorethamine (figure 15) and it is used for the treatment
of multiple myeloma, malignant melanoma and carcinoma of the ovary and breast.
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Figure 15: Chemical structure of melphalan
The mechanism of action involves the loss of chloride ions in water resulting in a
carbonium ion that interacts with nucleophilic sites on DNA bases forming mono and
bi-adducts depending on the ionisation of one or both chloride groups. In addition to
N7-guanine adducts, melphalan also forms a large amount of adenine adducts with
properties consistent with the alkylation at the N3 position (Povirk & Shuker, 1994). It
should be noted that the N7-guanine atom faces into the major groove of the DNA
structure while the N3-adenine atom faces into the minor groove. Thus, the melphalan-
induced adduct exerts much greater pressure on DNA conformation than
mechlorethamine.
2.5.5 Methotrexate
Methotrexate is an antimetabolite drug used in the treatment of cancer and autoimmune
diseases. Antimetabolites are structurally related to naturally occurring compounds i.e.
vitamins, amino acids or nucleotides. These drugs interfere with the production of
nucleic acids by inhibiting specific enzymes needed for nucleoside triphosphate
synthesis or by substituting for normal purine or pyrimidine bases. They are usually cell
cycle dependent. Their action results in a decrease in DNA or RNA synthesis, thereby
interfering with cell growth and proliferation (Pratt et al., 1994).
Methotrexate (figure 16), an analogue of the vitamin folic acid, is an indirect inhibitor
of thymidine nucleotide production. It does this by competitively and reversibly
inhibiting dihydrofolate reductase (DHFR), a key enzyme in the biosynthesis of purines
and the conversion of dUMP to dTMP. Methotrexate acts specifically during DNA and
RNA synthesis, and thus it is cytotoxic during the S-phase of the cell cycle. Logically,
it therefore has a greater toxic effect on rapidly dividing cells such as cancerous cells
(Johnston et al., 2005).
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Figure 16: Chemical structure of methotrexate
2.5.6 Paclitaxel
Paclitaxel is a highly complex organic compound isolated from the bark of Pacific yew
tree Taxus Brevifolia. It is one of the most active anticancer drugs effective against
carcinomas of breast, head and neck and is also used in combination with cisplatin in
ovarian and lung carcinomas.  It belongs to the group of microtubule inhibitor drugs
which work by disrupting the equilibrium between polymerised and free tubulin dimers
(Pratt et al., 1994).
Taxanes such as paclitaxel (Taxol, figure 17) bind and stabilise microtubules and allow
for the formation of abnormal bundles. This destroys the cell's ability to use its
cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the b subunit of
tubulin. Paclitaxel is an effective treatment for aggressive cancers because it adversely
affects the process of cell division by preventing the restructuring of the cytoskeleton
(Kumar, 1981). Further research has indicated that paclitaxel induces apoptosis in
cancer cells by arresting the function of the Bcl-2 anti-apoptotic protein.
Figure 17: Chemical structure of paclitaxel
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2.6 Ionising Radiation as Therapy in Cancer
Tyrosine kinase inhibitors were also used in this study in combination with x-rays
(called radiation in the context of this study). X-rays is a type of ionising radiation.
Ionising radiation in general refers to the energy transfer by a subatomic particle (alpha,
beta, or neutron) or by a short-wavelength electromagnetic wave (high-frequency
ultraviolet, X-ray, or gamma ray) which causes the detachment of electrons from atoms
or molecules (DNA in living tissue) and therefore ionises them.
The degree of biological damage depends on the ionisation potency and the energy of
the particle or electromagnetic wave. Alpha particles are heavily ionising and may cause
20 times more biological damage compared to x-rays, but they have little energy and a
low range; they are only harmful when ingested and cannot penetrate the skin. Beta
particles are less ionising than alpha and can penetrate a few millimeters into the tissue.
Gamma rays are very energetic and penetrate tissue easily. X-rays are less energetic
than gamma rays. Soft x-rays (0.12-12KeV) cannot penetrate matter. Hard x-rays (12-
120KeV) can penetrate tissue easily and are largely used in diagnostic radiography
(http://en.wikipedia.org/wiki/Ionising_radiation and references therein).
Ionising radiation is used for the treatment of malignant tumours (called radiation
therapy or radiotherapy). In clinical practice radiotherapy can be used alone, or as an
adjuvant treatment in combination with surgery, chemotherapy, or hormone therapy,
depending on the type, size and locality of the tumour. In cases where cure is not
feasible it can be used as a palliative treatment for the control of the disease and the
associated symptoms. Radiation damages the DNA mainly by the formation of highly
toxic free radicals, particularly hydroxyl radicals, by ionisation of the water molecules.
These radicals damage the DNA structure. The most common result of ionising
radiation is the formation of double strand breaks, which can be lethal to the cell.
Another effect is the production and accumulation of mutations in cancer cells, which
do not repair DNA as efficiently as healthy cells. These inherited mutations will finally
lead to apoptosis of cancer cells.
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2.7 Aims of this study
This study examines novel putative targets in neuroendocrine tumours. Combinations
of growth factor inhibitors with chemotherapy and radiotherapy were undertaken in
order to determine the best treatment options for therapy. This was examined using
various techniques to assess the impact on the putative targets in NETs. The mechanism
of interaction between the different agents used was also analysed with the intention to
understand the biology of neuroendocrine tumour cells and the reason behind the lack
of efficacy of previous treatment protocols in patients with NETs.
 In chapter 4 we combined chemotherapy and the EGFR inhibitor gefitinib with
the intention to identify possible synergies. This was followed by examination
of the effect of chemotherapeutic agents on EGFR activity. The
chemotherapeutic drugs used were cisplatin, etoposide, paclitaxel and
methotrexate. We identified activation of EGFR by cisplatin. This was further
investigated by analysis of EGFR localisation in response to cisplatin.
 In chapter 5 we examined the effect of radiation in combination with EGFR
inhibitors on cellular proliferation, EGFR activity and EGFR cellular
localisation. Activation and concurrent nuclear translocation of EGFR by
radiation was followed by investigation for a possible synergistic effect between
EGFR inhibitors and radiation on DNA repair. The DNA repair mechanism
impaired was investigated using the key DNA repair enzyme DNA-PKCS.
 In chapter 6 we investigated the mechanism of EGFR translocation to the
nucleus using nuclear import/ export inhibitors and analysed the possible role of
the putative nuclear localisation sequence of EGFR in the translocation of the
receptor into the nucleus. Finally, we tried to identify nuclear targets of EGFR
using the nuclear proteins i-NOS (inducible nitric oxide synthase), Rad-51 and
DNA-PKCS.
 In chapter 7 we aimed to immunohistochemically identify C-KIT in NET
patients.
 In chapter 8 we analysed the effect of the somatostatin receptor 2 inhibitor
octreotide in combination with chemotherapeutic agents on cell growth of NET
cell lines.
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CHAPTER 3
MATERIALS AND METHODS
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MATERIALS AND METHODS
3.1 Chemical Reagents and Cytotoxic Drug Source
All reagents and disposables were obtained from Sigma Chemical Co., Poole, UK or
VWR International Ltd., Poole, UK unless otherwise stated.
Cytotoxic drugs (Table 7) were prepared as stocks in advance, or as fresh prior to
individual experiments depending on stability and activity in solution as well as
experimental parameters. The concentration ranges used for experiments were modified
based on previous personal communications on the cytotoxicity of individual agents
where necessary.
Table 7: Cytotoxic drugs used in this study
Drug Chemical Structure StockSolution Solvent Supplier
Cisplatin 3.3mM
Injection
(Sterile
Concentrate)
DBL,
Warwick, UK
Melphalan Fresh
Ethanol +
1% conc.
HCl
Sigma, UK
Etoposide Fresh DMSO Sigma, UK
Doxorubicin 1mM H2O Sigma, UK
Methotrexate 10mM 1M NaOH+PBS Sigma, UK
Paclitaxel
(Taxol) 1mM DMSO Sigma, UK
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3.2 Experimental Cell Lines
The cell lines used are outlined in table 8. CRI G1 (rat islet tumour), NCI-H727 (human
bronchial carcinoid), RIN-5F (rat islet tumour), and SHP-77 (human SCLC) were
obtained from ECACC. HCT-116 (human colon carcinoma), and BON-1 (human
pancreatic endocrine cell line) were kindly provided by Prof. Watson (Cancer Studies
Unit, Nottingham, UK).
NCI-H727 cell line was derived from non small cell carcinoma cells taken from the
lung of a 65 year old female, which expresses p53 mRNA (Takahashi et al., 1989).
SHP-77 cell line was derived from a non encapsulated primary tumour of the lung of a
54 year old male with a modal chromosome number of 54 before and after
1 Cetuximab is supplied at a concentration of 2mg/ml and is formulated in a preservative-free solution containing 8.48
mg/ml sodium chloride, 1.88 mg/ml sodium phosphate dibasic heptahydrate, 0.42 mg/ml sodium phosphate monobasic
monohydrate and water.
Drug ChemicalStructure
Stock
Solution Solvent Supplier
Octreotide 500g/ml(~491M)
Injection vial
(Sterile
Concentrate)
Novartis
Gefitinib
(IressaTM,
ZD1839)
10mM DMSO AstraZeneca
Cetuximab
(Erbitux,
IMC-C225)
- 2mg/ml H2O
1 (Sterile
concentrate)
ImClone
Systems, Inc
Wheat Germ
Agglutinin - 5mg/ml PBS Sigma, UK
Leptomycin
B1 5g/ml
Methanol:
H2O
7:3 (Sterile
Concentrate)
Sigma, UK
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transplantation in nude mice. SHP-77 cell line displays the biochemical properties of
classical SCLC shown by the presence of dense core secretory granules and the
expression of neuroendocrine markers such as NCAM (neural cell adhesion molecule)
and L-dopa decarboxylase (Fisher & Paulson, 1978). CRI-G1 cell line originated from a
NEDH (New England Deaconess Hospital) rat transplantable islet cell tumour, which
secretes insulin and glucagon (Carrington et al., 1986). RIN-5F cell line is a secondary
clone of the rat islet tumour cell line RIN-m (ECACC catalogue no. 95071701), which
expresses L-dopa decarboxylase, secretes insulin, and displays secretory granules
(Chick et al., 1977). BON-1 cell line is a human carcinoid-derived pancreatic tumour
with a modal chromosome number of 57, which expresses somatostatin receptors and
synthesizes serotonin and chromogranin A (Evers et al., 1991; Lopez et al., 2010).
Finally, HCT-116 cell line was one of three strains isolated from a human with colonic
carcinoma and is highly tumourigenic in nude mice (Brattain et al., 1981).
Table 8: Cell lines used in this study
Cell Line Origin
Culture
Conditions Supplier
NCI-H727 Human BronchialCarcinoid-Adult Female RPMI 1640 ECACC
CRI-G1 Rat islet tumour DMEM ECACC
RIN-5F Rat islet tumour RPMI 1640 ECACC
SHP-77 Human Small Cell LungCancer- Adult Male RPMI 1640 ECACC
BON-1 Human pancreaticendocrine tumour
DMEM:F12K
(50:50)
Cancer Studies Unit,
Nottingham, UK
HCT-116 Human ColonCarcinoma- Adult Male RPMI 1640
Cancer Studies Unit,
Nottingham, UK
Cell lines were maintained in Dulbecco’s Minimal Essential Medium (DMEM) (for
CRI G1), RPMI 1640 (for NCI-H727, RIN-5F, HCT-116 and SHP-77 cell lines), or
50:50 DMEM: F-12K (F-12 Ham, Kaighn's Modification Nutrient Mixture) for BON-1
cells. All tissue culture media were supplied by Autogen Bioclear, Calne, UK apart
from the F-12K media which were supplied by Sigma Chemical Co., Poole, UK. All
media were supplemented with 10% foetal calf serum (FCS) (which was previously
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heat-inactivated for 30 minutes at 57oC for SHP-77 cells), and 1% glutamine. The
growth medium described for the routine propagation of exponentially growing cell
lines is referred to as complete growth medium throughout.
3.2.1 Cell line culture – strengths and weaknesses
Cell lines used in research are immortalised cells which can proliferate indefinitely.
Tumour-derived cell lines (like the ones used in this study) are immortalised
spontaneously by random mutations in genes promoting senescence. Normal cells can
also be used to establish cancer cell lines but these need to be immortalised artificially
by the introduction (via a plasmid or a virus) of foreign genes which block senescence.
The transduced genes usually inhibit aging of cells by the induction of oncogenes or the
inhibition of tumour suppressor genes. Immortalisation is commonly induced by the
transduction of normal cells with viral genes such as the gene for large T protein of the
simian virus (SV40), which inactivates tumour suppressor genes p53 and
Retinoblastoma (Rb) (Yeager & Reddel, 1999). Other transduced genes include the E6
and E7 genes of human papillomavirus (HPV), which also inhibit p53 and Rb and
partially activate telomerase, or the entire genome of the Epstein-Barr virus (EBV)
(Katakura et al., 1998). The artificial induction of the telomerase gene, which stabilises
DNA by maintaining the ends of chromosomes (telomeres), is also used for the artificial
immortalization of cells. This is carried out using hTETR (human telomerase reverse
transcriptase) expression vectors. The hTETR immortalised cell lines though are not
cancerous as they retain ‘normal cell’ characteristics (Yeager & Reddel, 1999).
Culturing of cell lines has greatly advanced medicine as it is used for drug testing as
well as the production of therapeutic biological compounds including proteins,
hormones or vaccines on a large scale. Cell lines offer a controlled environment (pH,
temperature, oxygen, carbon dioxide, etc.) in which a single homogeneous population
of cells can be observed and analysed. In this way, an unlimited number of carefully
characterized cells with a desired phenotype can be used in a multitude of applications.
This is in contrast with organs or in vivo models where the function of a number of
different cell types needs to be analysed, making the interpretation of results more
complex. Also, the use of cell lines for drug testing is time- and cost-effective
compared to in vivo models, and is carried out without the manipulation of animals,
which may raise serious ethical issues.
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On the other hand, cross-contamination of cell lines by other cell types (e.g. HeLa cell
line) has been identified in 15-20% of studies which invalidates any results obtained in
these cases. To this end, major cell line repositories such as ATCC (American Type
Culture Collection) and ECACC (European Collection of Cell Cultures) authenticate all
cell lines submitted by HLA typing and DNA fingerprinting using short tandem repeats
(STR) (Cabrera et al., 2006).
Tumour-derived cell lines are also genetically unstable and may present inconsistent
phenotypes over time due to accumulated mutations, leading to changes in morphology,
functions or range of genes expressed. Similarly, artificially immortalized cell lines may
show loss of the differentiated characteristics of normal cells they are derived from as
well as loss of normal cell cycle check-points (Yeager & Reddel, 1999). Genetic
instability of cell lines is difficult to overcome and the recently developed hTETR
immortalised cell lines may avoid unwanted genetic changes when studying normal cell
biology. In our study we examined putative targets in neuroendocrine tumours and
therefore made use of relevant tumour-derived cell lines.
It is a well known fact that differences in response have been observed between in vitro
drug testing and clinical trials in patients making the use of cell lines somewhat
controversial. These differences are generally due to the external environment of cells
in each case. Cancer cells in vitro are cultured in an isolated and externally controlled
environment whereas cancer cells in a patient’s organ receive a multitude of signals
from other cell types in the vicinity and from the entire human body. The acquisition of
mutations associated with the genetic instability of cancer cell lines may also contribute
to the differences seen. In vitro drug testing is therefore an initial step in the drug
screening process and should be validated when possible by in vivo models before
testing in humans.
3.3 Tissue Culture
3.3.1 Maintenance of Cell Lines
All cell lines were grown in 75cm2 (T75) flasks and maintained at 37oC with 5% CO2 in
dry incubators (Forma Scientific, UK). All procedures were carried out in Class II
MDH biological safety cabinet (Intermed MDH, UK) using aseptic techniques.
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Exponentially growing cells were maintained at a cell concentration according to the
European Collection of Cell Cultures (ECACC), Salisbury, UK.
Cells were routinely passaged at 80-90% confluence (biweekly). To this end, cells were
washed with 10ml of 0.01M phosphate buffered saline (PBS) to remove serum. To
detach the cells from the flask 5ml of 1X Trypsin/EDTA (Autogen Bioclear, Calne,
UK) was then added for 5 minutes at 37oC. 5ml of complete growth medium was then
added to inactivate the trypsin and the cell suspension was pelleted by centrifugation at
1,500rpm for 5 minutes at room temperature. Cells were then resuspended in complete
growth medium and re-plated at an appropriate passage ratio for the cell line. The
passage number was increased by one. Cells were discarded after approximately 25
passages and fresh cells were taken from the initial passage number used.
3.3.2 Cell Count
Trypsinised cells were resuspended in 10ml of complete growth medium and counted
using a haemocytometer. To this end, 20µl of cell suspension was mixed with 20µl
trypan blue (Sigma, UK) to exclude dead cells and the cell number was determined for
each of five separate 1mm2 fields. The average was multiplied by 2x104 to give the
number of cells per ml of suspension.
3.3.3 Determination of Cell Doubling Time
Cells were seeded out at an initial total cell number of 1x105 cells per 25cm2 (T25) flask
containing 10ml of complete growth medium with an individual flask for every time-
point. Cells were trypsinised, centrifuged, resuspended and counted using a
haemocytometer as described above and the subsequent concentration used to determine
the total cell count per flask. Further samples were taken every 24 hours until
confluence. The doubling time of each cell line was calculated by reading off the
exponential portion of the growth curve derived by plotting number of hours against
total number of cells counted.
3.3.4 Mycoplasma Testing
Cell cultures were routinely tested for Mycoplasma contamination every 6 months. A
total number of 5x104 cells for each cell line were seeded onto a sterile coverslip placed
in a flat bottom Falcon tube. Cells were allowed to adhere to the coverslips for 24 hours
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at 37oC with 5% CO2. Previously, the cell lines to be Mycoplasma tested had been set
up such that the cells reached confluency concurrently with the set-up of the
Mycoplasma test. Thus, from a flask containing a confluent cell population to be tested,
500µl of the supernatant growth medium was removed and transferred to the
Mycoplasma testing tube. The cell-free supernatant must not contain additives such as
hydrocortisone, cholera toxin or antibiotics that might interfere with Mycoplasma
growth. The cells were incubated until they reached confluence. The medium was
removed and the cells washed once with 0.01M PBS. The cells were then fixed in
absolute methanol for 5 minutes and subsequently washed twice with 0.01M PBS and
stained with 5g/ml of Hoechst 33258 dissolved in 0.01M PBS for 10 minutes.
Following two more washes with 0.01M PBS, the coverslips were carefully removed
from the Mycoplasma testing tube, placed cell surface upwards on a glass microscope
slide and covered with a coverslip. Analysis was performed under a fluorescent
microscope using a x40 objective and ultra-violet (UV) illumination. Control cells
showed intense blue-white staining of the nuclei only. Mycoplasma infected cells would
have been covered in a fine lawn of speckles all over.
3.3.5 Storage and Retrieval of Cells in Liquid Nitrogen
Frozen cell stocks in liquid nitrogen were routinely prepared. Cells were grown in a
175cm2 (T175) flask to semi-confluency. They were trypsinised and resuspended in
media with 20% FCS containing 10% dimethylsulphoxide (DMSO). 1ml aliquots were
frozen slowly in cryotubes in a styrofoam box at -80oC overnight before the cryotubes
were transferred to a liquid nitrogen tank the next day. Each cryotube contained cells at
a 10X higher concentration compared to the concentration at which they were grown.
Cells were recovered from liquid nitrogen by thawing rapidly in a 37oC water bath
before being transferred into a T25 flask containing 10ml of growth medium
supplemented with 20% FCS. Each cryotube was wiped off with paper towel sprayed
with 70% industrial methylated spirit (IMS) to prevent accidental contamination of cell
lines through bacteria and other cells stuck to the outer wall of the cryotube.  Cells were
split after 24 hours to remove any DMSO present in the media.
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3.4 Irradiation treatments
X-radiation is traditionally known to induce DNA damage in the form of double DNA
strand breaks. In our study x-radiation was also used to analyse possible changes in
EGFR and DNA-PKcs activity and location within the cell. In radiotherapy, ionising
radiation potency refers to the measurement of charge deposited in the tissue (unit is
coulomb/kg), which is called the exposure. However, for living tissue the measurement
of energy deposited is more relevant (unit is Gray or Gy, 1 Gy being the amount of
radiation required to deposit 1 Joule of energy in 1 kg of matter) and this is called the
absorbed dose.  The doses used in cancer patients typically range between 20 and 80 Gy
depending on the tumour type.
It is worth noting that an equal amount of absorbed dose (e.g. 1Gy) by different types of
ionizing radiation (alpha or beta particles, gamma rays and x-rays) can cause different
amounts of damage. To measure the biological damage the equivalent dose is
implemented, which is measured in Sievert (Sv). Sievert is the absorbed dose multiplied
by the quality factor, which depends on the radiation type. The quality factor for alpha
particles is 20 while for gamma rays or x-rays is 1. The ionizing radiation chosen for
use in this study is x-radiation as it has a low quality factor. X-ray radiation in our study
is measured in Gy and refers to the absorbed dose (or simply dose) of radiation of
neuroendocrine tumour cells (http://en.wikipedia.org/wiki/Ionising_radiation and
references therein).
For irradiation treatments, cells were placed on ice and irradiated using the General
Electric X-Ray source (250 Kv Newton victor). The x-ray machine was set up and
calibrated by an independent nuclear physicist at the Middlesex Hospital to a dose rate
of 2.35g/min; 212KV/12.5mA. The amount of absorbed dose is dependent on the
exposure, distance from x-ray source, and the use of appropriate filter.
 Cells used in immunofluorescence, electron microscopy, or immunoblotting for
EGFR or DNA-PKcs (in either whole lysates, or cytoplasmic and nuclear
extracts) including transiently transfected cells, were used for analysis of EGFR/
DNA-PKcs activity and cellular localisation. Radiation dose was 4 Gy for all
cells, except NCI-H727 cells which were radiated at 30Gy.
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 Cells used in COMET analysis including transiently transfected cells were used
to measure the amount of DNA damage and rate of repair. Radiation dose was
15 Gy for all cells, except NCI-H727 cells which were radiated at 30Gy.
For these studies cells were treated with either one or two drugs followed by
irradiation.
 Single drug treatments include gefitinib or cetuximab at a fixed concentration
for a period of 3 hours followed by irradiation at the appropriate dose.
 In double drug treatments gefitinib is added first for 3 hours with a second drug
(wheat germ agglutinin or leptomycin B1) added in the last 30 minutes followed
by irradiation.
 Irradiated cells are immediately transferred to a 370C incubator for suitable
intervals: a) 0-20 minutes for immunoblotting and immunofluorescence to
analyse EGFR activity and cellular localisation, and b) 0-120 minutes to
measure the amount of DNA damage and rate of repair.
3.5 In vitro Cytotoxicity Assay and Pharmacological Analysis
3.5.1 Sulphorhodamine B Growth Inhibition Assay
Cytotoxicity of drugs alone or in combination was determined using the
Sulphorhodamine B (SRB) assay in 96-well microtitre plates. As described previously
by Skehan et al., (1990), they developed a rapid, sensitive, and inexpensive method for
measuring the cellular protein content of adherent and suspension cultures based on the
binding of the SRB purple dye to cellular protein. They showed the SRB assay to
produce results linear with the number of cells and with values for cellular protein
measured by both the Lowry and Bradford assays at densities ranging from sparse sub-
confluence to multilayered supra-confluence. The signal-to-noise ratio at 564 nm is
favourable and the resolution is 1000-2000 cells/well. In addition, they showed that the
sensitivity of the SRB assay compared favourably with sensitivities of several
fluorescence assays and was superior to those of both the Lowry and Bradford assays
and to those of 20 other visible dyes. The SRB assay provides a colorimetric end point
that is non-destructive, indefinitely stable, and visible to the naked eye. It provides a
sensitive measure of drug-induced cytotoxicity, is useful in quantitating clonogenicity,
and is well suited to high-volume, automated drug screening. SRB fluoresces strongly
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with laser excitation at 488 nm and can be measured quantitatively at the single-cell
level by static fluorescence cytometry (Skehan et al., 1990; Voigt, 2005).
The optimal cell concentrations were determined from the previously calculated
doubling times in order to achieve a final cell concentration ideal for accurate optical
density (OD) measurement. Cells were plated in 96-well flat-bottomed microtitre plates,
each well containing 100µl cell solution (4 x 103 or 15 x 103 cells/well depending on
cell doubling time). Prior to drug treatment, cells were allowed to adhere at 37oC with
5% CO2 for 24 hours.
Following drug treatment, media was carefully removed and the cells subsequently
fixed with 100µl of 10% trichloroacetic acid solution for 20-30 minutes at 4oC. The
fixed cells were washed three times with tap water and any remaining water flicked out
of the wells. 100µl SRB stain (0.4% in 1% acetic acid) was then added to each well to
allow visualisation of cellular proteins and incubated at room temperature for 20-30
minutes. Any excess SRB was removed by washing 4-5 times with 1% acetic acid.
Plates were air-dried overnight. Finally the dye was dissolved in 100µl 10mM
Tris/1mM EDTA for 10 minutes on a plate shaker. Plates were read at an absorbance of
540nm on a Tecan Microplate reader and analysed using computer spreadsheet
(Microsoft Excel).
Growth inhibition was expressed as a percent proliferation of control and was calculated
using the following equation:
The data shown represents the averages of three different experiments, each performed
in triplicate and includes related standard deviations as calculated.  The IC50 is defined
as the drug concentration needed to produce a 50% growth inhibition. The dose-
response curves obtained for each treatment were used to calculate their respective IC50
values.
Single Agent Treatments
For single-agent studies, drugs were added at a range of concentrations to triplicate
wells. Incubations performed were continuous (24, 48, or 72 hours followed by 2 days
OD (treated)
OD (control) x 100 = Proliferation (%)
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drug-free medium). All drugs were diluted in complete growth medium and 100µl of
the relevant concentration added to the appropriate wells. One solvent control lane was
included in each experiment. The concentration range for each drug was optimised if
necessary following analysis of results from the first experiments. Following the 24, 48,
or 72 hour incubation with the drug, the drug solution was removed and replaced with
200l drug free complete growth medium. Plates were incubated at 37oC with 5% CO2.
Dual Agent Treatments
For combination studies, drugs were added simultaneously for 72 hours followed by 2
days in drug-free growth medium, or sequentially by delivering drug A for 24 hours,
then the drug B for 48 hours, followed by 2 days in drug-free growth medium.
For acute drug exposure, cells were incubated for 2 hours with drug A followed by 72
hours with drug B followed by 2 days drug-free-medium. Control wells were treated in
the same way with aspiration at each period respectively. Again, plates were incubated
at 37oC with 5% CO2.
For determination of synergy, one of the drugs was added at a fixed sub-toxic
concentration (e.g. producing 10% or 20% inhibition of proliferation) to a range of
concentrations for the other drug.
Combination studies with radiotherapy
Radiation doses used in proliferation studies were 4 Gy for all cells except NCI-H727
cells which were radiated at 30 Gy. These doses were chosen for their 50% inhibition of
proliferation.
In combinations treatments, cells were radiated on day 1 at the appropriate dose,
followed by treatment with a drug at a range of concentrations. The reverse order with
drug treatment preceding radiation was also performed. Treatments were followed by 2
days in drug-free growth medium.
3.5.2 Isobologram Analysis
Isobologram analysis can be applied in order to assess whether a combination dose of
any two given drugs behave in a synergistic or additive fashion. The methodology
applied has been previously described by Tallarida, (2001). Briefly, a particular effect
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level is selected, in our case 50% of the maximal inhibition of proliferation (IC50) and
doses of each drug alone that give this effect are plotted as axial points in a Cartesian
plot. This is illustrated in figure 18 where Drug A (x-axis) has an IC50 of 20(µM) and
Drug B (y-axis) has an IC50 of 100(µM). The straight line connecting the IC50s of drugs
A and B is called the additivity line and defines the locus of all dose pairs (or isoboles)
that will produce 50% of maximal inhibition of proliferation in a simply additive
combination. This includes either one drug alone (points 0,100 and 20,0). This line of
additivity allows a comparison with the IC50 obtained when the two drugs are added
together experimentally. Thus, the IC50 for two drugs added together lying well above
this line have a sub-additive or antagonistic effect (illustrated by the letter R). If the IC50
for two drugs added lie on or close to the line they are said to have an additive effect
(illustrated by the letter P). And if they exist well below the line a super-additive or
synergistic effect is achieved (illustrated by the letter Q).
In our combination studies one of the two drugs e.g. drug A is added at a fixed dose,
while drug B is titrated. In this case the IC50 for the two drugs added together is defined
by values x = fixed dose for drug A and y = IC50 for the two drugs.
Figure 18: Illustrated isobologram for some particular effect.
Source: Tallarida RJ, J Pharmacol Exp Ther (2001)
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It is important to note, that the isobologram graph does not allow for absolute statistical
precision. For example, the so-called grey areas such as ‘on or close to the line’ do not
provide the conclusive ideal distinctions and so these values would be subject to further
pharmacological tests such as regression analysis. To continue with these tests is
beyond the aims of this study and the isobologram test provides the necessary
pharmacological analysis required.
3.6 Single Cell Gel Electrophoresis (COMET) Assay
The drug-induced DNA damage in the form of strand breaks and subsequent repair was
assessed using the single-cell gel electrophoresis (comet) assay as described previously
(Spanswick et al., 1999; Olive, 2002). The comet assay was originally developed as a
method for the detection and visualisation of DNA damage within individual cells and
is used extensively for the assessment of strand breaks in a range of applications.
3.6.1 Methodology
Exponentially growing cells were seeded at 2.5x104 cells/ml (5x104cells/well) in six
well plates (Nunclon, VWR) and incubated for 24h at 37ºC in 5% CO2. To examine
the extent of DNA damage and subsequent rate of repair, ideal doses of irradiation were
chosen for each cell line. To this end, cells were treated with a range of irradiation doses
to determine a suitable schedule. Cells were treated with drugs at a fixed concentration
(one drug alone for 3 hours or drug A for 3 hours with drug B added in the last 30
minutes). Cells were then irradiated at a specific dose and then immediately transferred
to a 37oC incubator for suitable intervals to measure the amount of DNA damage and
rate of repair.
All procedures were carried out on ice and in subdued lighting. Cells were embedded in
1% Type VII agarose and placed on precoated microscope slides with 1% Type 1-A
agarose, and lysed for 1 hour in lysis buffer (100mM disodium EDTA, 2.5 M NaCl,
10mM Tris-HCl, pH 10.5) containing 1% Triton X-100 (added immediately before
analysis). Following this, they were washed every 15 minutes in distilled water for 1
hour. Slides were then incubated in alkali buffer (50mM NaOH, 1mM disodium EDTA,
pH 12.5) for 45 minutes, followed by electrophoresis in the same buffer for 25 minutes
at 18 V (0.6 V/cm), 250 mA. The slides were finally rinsed in neutralising buffer (0.5 M
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Tris-HCl, pH 7.5) followed by saline. After drying, the slides were stained with
propidium iodide (2.5µg/mL) for 15 minutes and then rinsed in distilled water.
3.6.2 Analysis
Images were visualised with the use of a NIKON inverted microscope with a high-
pressure mercury light source (NIKON UK Limited, Kingston Upon Thames, UK), 510
to 560 nm excitation filter, and 590 nm barrier filter at x20 magnification.
Figure 19: Sample screen display of comets (with no tails) as seen using the Komet
Analysis Software.
Images were captured by using an on-line charge-couple device (CCD) camera and
analysed with Komet Analysis software (Figure 19) (Kinetic Imaging, Liverpool, UK).
For each duplicate slide 25 cells were analysed. DNA damage and subsequent repair
was measured by the increase in the tail moment (measured in µMetres), a function of
the amount of DNA in the tail and the length of the tail (Spanswick et al., 1999).
Analysis was then achieved using a computer spreadsheet (Microsoft Excel). The data
shown is a representation of three independent experiments, and include related
standard error bars as calculated. As can be seen in Figure 20, irradiating cells induces
strand breaks, which produce a tail moment dependent on the x-ray dose.
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Figure 20: Illustration of DNA tail as a result of irradiation.
The selection of fields for analysis in the comet assay was carried out visually.
Obviously, an effort was made to select representative fields and in two experiments
analysis was performed by Mrs. Janet Hartley, Department of Oncology, UCL, but
nevertheless analysis is subject to bias.
3.7 Detection of Apoptosis - Cell Death Detection ELISA
To address whether inhibition of EGFR leads to the induction of apoptosis, the ELISA
Cell Death Detection Assay was performed. This is a photometric enzyme-
immunoassay (Figure 21) for the qualitative and quantitative in vitro determination of
cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) after
induction of apoptosis. Apoptosis is characterised by membrane blebbing (zeiosis),
condensation of cytoplasm and the activation of an endogenous endonuclease and
specific proteases. The endogenous endonuclease is Ca2+ and Mg2+ dependent and
cleaves DNA at the most accessible internucleosomal linker region generating mono-
and oligonucleosomes. In contrast, the DNA of nucleosomes is tightly complexed with
the core histones H2A, H2B, H3 and H4 and therefore is protected from cleavage by the
endonuclease. The DNA fragments yielded are discrete multiples of an 180 bp subunit
which is detected as a ‘DNA ladder’ on agarose gels after extraction and separation of
the fragmented DNA. The enrichment with mono- and oligonucleosomes in the
cytoplasm of apoptotic cells is due to the fact that DNA degradation occurs several
hours before plasma membrane breakdown.
DNA and histones are targeted using mouse monoclonal antibodies provided. The anti-
histone antibody is conjugated to biotin in order to bind the streptavidin-coated well of
the microplate. The anti-DNA antibody is bound to horse radish peroxidase (HRP)
which is determined photometrically using ABTS as a substrate.
X-Ray
Head Tail
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Figure 21: Apoptosis Detection ELISA Assay.
Source: Cell death detection ELISAPLUS assay, Roche
The experiment was performed according to the instructions of the Cell Death Detection
ELISAPLUS assay from Roche. Cells were plated (at 15 x 103 or  4 x 103 cells/well
depending on cell doubling time) in a total volume of 100l in flat 96-well plates and
left overnight at 37°C. Drug was added for a period of 72 hours. The plates were then
centrifuged at 200 x g for 10 minutes and the supernatant removed. The cell pellets
were resuspended in 200l of Lysis buffer (provided) and left for 30 minutes at room
temperature. Cell lysates were centrifuged at 200 x g for 10 minutes. 20l of each
supernatant was transferred to a streptavidin-coated microplate. 80l of immunoreagent
containing anti-histone-biotin and anti-DNA-HRP in incubation buffer was added per
well. The microplate was then covered in an adhesive foil and incubated on a shaker at
300rpm for 2 hours at room temperature. The solution was removed and unbound
components were removed by rinsing each well three times in incubation buffer. 100l
of ABTS solution was then pipetted into each well and incubated at room temperature
till colour development was sufficient for photometric analysis (approximately 10-20
minutes). Plates were read at an absorbance of 405nm against ABTS solution as a blank
(reference wavelength approx. 490nm) on a Tecan Microplate reader and analysed
using computer spreadsheet (Microsoft Excel).
3.8 Protein Extraction
3.8.1 Cell Lysis for Whole Cell Extracts
Cells cultured and treated in 75cm2 (T75) flasks were washed twice in PBS at room
temperature, drained well and placed in ice. To lyse the cells, 100µl RIPA buffer (1%
Streptavidin-coated
microplate
Anti-histone
biotin
Sample containing
nucleosomes
Anti-DNA
HRP
ABTS
substrate
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deoxycholic acid, 1% Triton X-100, 0.1% SDS, 250 mM NaCl, 50 mM Tris pH 7.5, 100
µg/ml AEBSF, 17µg/ml aprotinin, 1µg/ml leupeptin, 1µg/ml pepstatin, 5µM
fenvalerate, 5µM potassium bisperoxo (1,10-phenanthroline) oxovanadate (V)
(BpVphen) and 1µM okadaic acid) was added to each flask for 10 minutes with
occasional rocking. Cells were then scraped into a 1.5ml Eppendorf tube using a cell
scraper (VWR International Ltd.) and centrifuged at 13,000rpm for 10 minutes at 4oC.
The supernatant (containing total cell protein) was then carefully transferred to a fresh
tube and the pellet discarded. This is the total cell lysate and can be stored at -80oC.
3.8.2 Nuclear and Cytosolic Extraction
To separate out nuclear and cytosolic components of total cell lysates, the TransFactor®
Extraction Kit (Clontech Laboratories, UK) was used according to the manufacturer’s
instructions. Briefly, all steps were performed at 4oC unless otherwise specified.
Reagents were pre-cooled to 4oC, and not used until fully defrosted. Cells were
collected and transferred to an Eppendorf tube centrifuged at 13,000rpm for 10 minutes
at 4oC and the supernatant discarded. The pellet was then washed twice in PBS and the
pellet size estimated. Lysis buffer was prepared as follows: 150ml 10x Pre-lysis Buffer
(Hypotonic) (100mM HEPES pH 7.9, 15mM MgCl2, 100mM KCl), 15ml 0.1M DTT,
15ml Protease Inhibitor Cocktail (Aprotinin, Pepstatin A, Bestatin, trans-
Epoxysuccinyl-Lleucylamido (4-guanidino) butane, and 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride in DMSO) and 1.32ml ddH2O. Cells were
resuspended in a volume of lysis buffer equal to five times the cell pellet volume and
incubated on ice for 15 minutes. Following centrifugation at 13,000rpm for 10 minutes
at 4oC, the supernatant was carefully removed and the pellet resuspended in a volume of
lysis buffer equal to twice the cell pellet volume. Suspension was then slowly drawn
into a syringe through a narrow-gauge (No. 27) needle and then ejected with a single
rapid stroke. This was repeated ten times and centrifuged at 13,000rpm for 10 minutes
at 4oC. The supernatant was then transferred to a fresh Eppendorf tube and is the
cytosolic fraction. This can be snap-frozen and stored at -70oC.
Extraction Buffer was prepared as follows: 147ml Pre-extraction Buffer (20mM HEPES
pH 7.9, 1.5mM MgCl2, 0.42M NaCl, 0.2mM EDTA, 25% (v/v) glycerol), 1.5ml 0.1M
DTT and 1.5ml Protease Inhibitor Cocktail. The crude nuclear pellet was resuspended
in a volume of Extraction Buffer equal to two-thirds of the cell pellet volume. To
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disrupt the nuclei, the suspension was then syringed as before and placed on a shaker at
low speed for 30 min at 4oC. The nuclear suspension was then centrifuged at 13,000rpm
for 10 minutes at 4oC. The supernatant or nuclear fraction was transferred to a fresh
Eppendorf tube and can be snap-frozen and stored at -80oC.
3.8.3 Measurement of Protein Concentration in cellular extracts
To determine the protein concentration of a particular cell lysate (whole cell or
cytoplasmic and nuclear extracts), the Biorad Protein Assay kit was used. Briefly, 2µl
of each lysate is added to 18µl H2O in 1.5ml Eppendorf tubes. In a separate Eppendorf,
20µl Reagent S is mixed with 1ml Reagent A. 100µl of this is added to each 20µl lysate
sample and mixed well with a short spin. 800µl Reagent B is then added to each and
incubated at room temperature for 15 minutes. The optical density (O.D.) for each
sample is then read on a spectrophotometer (Beam PU 8600 Series UV/Vis Single,
Philips®) at 750nm and the protein concentration determined using the following
formula:    O.D. x25 =[ ]/µl (i.e. µg/µl)
3.9 Immunoblotting
3.9.1 Electrophoresis
Protein concentrations of total cell lysates were determined using the protein assay
outlined in Section 2.8. For each sample the required volume containing 30-50µg of
protein was transferred to a fresh Eppendorf tube. Loading (Laemmeli) buffer (4% SDS,
10% -Mercaptoethanol, 20% glycerol, 0.02% bromophenol-blue and 100mM Tris HCl
(pH 6.8)) was then added to each lysate before heating at 95oC for 4 minutes to denature
the proteins. Samples are then centrifuged at 13,000rpm for 10 minutes at 4oC and the
pellet discarded.
The NuPAGE® Electrophoresis System (Invitrogen, UK) was used. For analysis of
proteins with a molecular weight of between 120 and 410 KDa, lysates and
immunoprecipitates were loaded onto NuPAGE® Novex 3-8% Gradient Tris-Acetate
Pre-Cast Gels which were placed in the XCell SureLockTM Mini-Cell (two gels per cell)
and included an appropriate marker (Kaleidoscope pre-stained standards, BioRad,
Hemel-Hempstead, UK) or a positive protein control (A431+EGF cell lysate; BD
Biosciences, UK). Upper (200ml) and lower (600ml) buffer chambers were then filled
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with 1x NuPAGE® Tris-Acetate SDS Running Buffer (diluted from a 20x stock: 50mM
Tricine, 50mM Tris base, 0.1% SDS, pH 8.24) and Mini-Cells were run at 150V
constant at 4oC for approximately 1h 30min (Expected 40-55 mA/gel at start; 25-40
mA/gel at end).
For analysis of proteins with a molecular weight of between 10 and 180 KDa lysates
and immunoprecipitates were loaded onto NuPAGE® Novex 4-12% Gradient Bis-Tris
Pre-Cast Gels and placed in Mini-Cells as above. Upper (200ml) and lower (600ml)
buffer chambers were then filled with 1x NuPAGE® MOPS SDS Running Buffer
(diluted from a 20x stock: 50mM MOPS, 50mM Tris base, 0.1% SDS, pH 7.7) and
Mini-Cells were run at 200V constant at 4oC for approximately 50min (Expected 100-
125 mA/gel at start; 60-80 mA/gel at end).
3.9.2 Protein Transfer and Immunoblotting
Proteins were electrically transferred to ImmobilonTM polyvinylidenedifluoride (PVDF)
membranes (Millipore, UK). These extremely hydrophobic membranes will not wet in
aqueous solution and so were prepared as follows: blots were immersed in 100%
methanol for three seconds and then placed in H2O for 2 minutes to elute the methanol.
To equilibrate, membranes were then soaked in protein transfer buffer (diluted from a
10x stock: 3% TrisBase, 14.4% glycine and 20% methanol). Gels and prepared
membranes were then placed into the X-Cell IITM Blot Module (Novex®) as illustrated
in Figure 22.
Transfer was achieved at 40V for 2h using the XCell SureLockTM Mini-Cell (two blots
per cell) and filled with protein transfer buffer as described in the NuPAGE Novex®
protocol. Membranes were then blocked in 3% casein blocking buffer [(3% skimmed
milk powder (Marvel, UK) in TBS-Tween (TBS-T) (20mM TrisBase, 0.15M NaCl pH
7.5 in Elga H2O with 0.1% Tween-20)] for at least 1 hour on a shaker at 4oC.
Membranes being probed for phosphorylated proteins were blocked in 5% Bovine
Serum Albumin (BSA) in TBS-T. This is due to the fact that milk contains a number of
phosphorylated proteins which interfere with a phosphotyrosine antibody’s ability to
bind specific proteins of interest. Blots were then probed with primary antibody against
proteins of interest for at least 2h on a roller at room temperature. Antibodies used in
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this study are detailed in Table 9. All were diluted in a 1:1 mix of either Milk-TBS-T or
BSA-TBS-T and TBS as necessary. Following this, membranes were washed three
times for 5 minutes in TBS-T followed by three more washes for 5 minutes with TBS.
Membranes were then probed with an appropriate horseradish peroxidase conjugated
secondary antibody for at least 1h and washed as before.
Figure 22: Gel/Membrane sandwich for 2 gels.
Source: NuPAGE® Technical Guide, Invitrogen, UK
Immunocomplexes were visualised using the enhanced chemiluminescence (ECL)
system (Amersham Pharmacia, Little Chalfont, UK) by incubating the membranes in
the ECL system solution for 1 minute before wrapping the moist blots in cling film and
exposing the blots to Kodak X-OMAT™LS film for varying exposure times (two
seconds to 24h) (Sambrook et al., 1989).
In order to remove or ‘strip’ pre-bound antibody, membranes were rehydrated in TBS
for 5 minutes and placed in a hybridiser (Techne, UK) with 100ml of stripping buffer
(100mM -Mercaptoethanol, 2% SDS, 62.5mM Tris-HCl, pH 6.7) and left for 30
minutes at 50ºC. Membranes were then washed twice in TBS-T for ten minutes each,
blocked and reprobed as described above.
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Table 9: Primary and secondary antibodies used in this study.
Primary Antibodies
Antibody Description Supplier Antibody Description Supplier
C-KIT
145KDa
Rabbit,
Polyclonal DAKO, UK
EGFR
170KDa
Mouse,
Monoclonal
Santa Cruz,
USA
C-KIT
145KDa
Mouse,
Monoclonal
Novocastra,
UK
EGFR
170KDa
Rabbit,
Polyclonal Abcam, UK
C-KIT
145KDa
Rabbit,
Polyclonal
Santa Cruz,
USA
P-EGFR
(PY20)
175KDa
Mouse,
Monoclonal
BD
Biosciences,
UK
SSTR-1
60KDa
Rabbit,
Monoclonal
Gramsch
Laboratories,
Germany
P-EGFR
(Tyr-1068)
175KDa
Rabbit,
Polyclonal
Cell Signaling
Technology,
USA
SSTR-2A
80KDa
Rabbit,
Monoclonal
Gramsch
Laboratories,
Germany
iNOS
130KDa
Rabbit,
Polyclonal
BD
Biosciences,
UK
SSTR-3
45,80KDa
Rabbit,
Monoclonal
Gramsch
Laboratories,
Germany
Rad51
37KDa
Rabbit,
Polyclonal
Santa Cruz,
USA
SSTR-5
65KDa
Rabbit,
Monoclonal
Gramsch
Laboratories,
Germany
P-AKT
(Ser-473)
70KDa
Rabbit,
Polyclonal Abcam, UK
DNA-PKCS
460KDa
Mouse,
Monoclonal Sigma, UK
P-MAPK
43KDa
Rabbit,
Polyclonal Abcam, UK
-Tubulin
170KDa
Mouse,
Monoclonal Sigma, UK
Lamin B1
67KDa
Mouse
Monoclonal Abcam, UK
3.10 Densitometric Analysis
To mathematically compare the intensity of particular bands produced by
immunoblotting, densitometric analysis was used. Briefly, blots were placed in the
imaging densitometer (Imaging Densitometer GS-670 BioRad, UK) and the bands of
interest selected. Intensity was then measured by computer and the background
Secondary Antibodies
Antibody Supplier Antibody Supplier
HRP-Conjugated
Goat Anti-Mouse BD Biosciences, UK
FITC-Conjugated
Goat Anti-Mouse Abcam, UK
HRP-Conjugated
Goat Anti-Rabbit Abcam, UK
Biotinylated goat anti-
mouse/rabbit antibody DAKO
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subtracted. Data is represented as a percentage of control band intensity. The screen-
grab shown in Figure 23 illustrates the methodology. In this case V5 serves as a
background, V1 is the control and bands V2-4 represent different drug treatments.
Figure 23: Sample screen display of densitometric analysis as seen using the BioRad
Imaging Densitometer Software.
3.11 Immunofluorescent Staining
Exponentially growing cells were seeded at 2x104 cells per well on rectangular glass
slides with 8 chambers (Nunclon, VWR) and incubated for 24h at 37oC in 5% CO2.
Cells were then treated as required, the media subsequently removed and the cells
washed twice with cold PBS. Cells were then fixed using 500µl/well of 50% methanol /
50% acetone mix at 4oC for 8 minutes. Following this the slides were then washed twice
with cold PBS and permeabilized using 500µl/well of 0.5% TritonX-100 in PBS. Slides
were then blocked in 3% casein blocking buffer [(3% skimmed milk powder (Marvel,
UK) in TBS-Tween (TBS-T) (20mM TrisBase, 0.15M NaCl pH 7.5 in Elga H2O with
0.1% Tween-20)] overnight at 4oC.
Slides were then washed 3 times in cold PBS following which the cells were incubated
with anti-EGFR (1:50 dilution) or anti-DNA-PKCS antibody (1:100 dilution) for 1 hour.
Slides were then washed 3 times with washing buffer (0.1% TritonX-100 in PBS) and
then incubated for 1 hour at room temperature with FITC-labelled secondary antibody:
Alexa fluoro 488 goat anti-mouse IgG (green) (1:1000 dilution). Nuclear
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counterstaining was performed using 2µg/ml propidium iodide (red) for 3 minutes
followed by destaining with distilled water for 20 minutes. Slides were mounted using
VectaMount™ AQ mounting medium (Vector Laboratories) and covered with
coverslips before being viewed and photographed using a confocal microscope.
3.12 Transient Transfection Assay
Wild-type EGFR and a selected nuclear localisation sequence (NLS) - mutant EGFR
construct were transiently transfected into RIN-5F and CRI-G1 cells using the
GeneJuice® transfection reagent (Novagen® EMD Biosciences Darmstadt, Germany).
Exponentially growing cells were seeded at 1x104 cells per well on rectangular glass
slides in 8 well plates (Nunclon, VWR) or 1 x105 cells in six well plates (Nunclon,
VWR) and incubated for 24 or 48h at 37ºC in 5% CO2 prior to transfection. The
optimum amount of Genejuice® reagent recommended for successful transfection of
1µg of DNA is 3µl. This was added to eppendorf tubes containing 100µl of serum free
medium and allowed to incubate at room temperature for 5 minutes. Following this 1µg
DNA was added to each tube and incubated at room temperature for 15 minutes after
which the entire mixture was added slowly over the surface of the appropriate well.
Cells were then incubated for 24 or 48h allowing both cell recovery and transfection to
take place. The plasmid DNA used was the pUSEamp vector (Upstate Cell Signaling
Solutions, NY, USA) and its map is illustrated in Figure 24 with the key sites
highlighted.
The different EGFR constructs were kindly provided by Gianmaria Liccardi, Oncology
Department, UCL. There were two constructs made using the pUSEamp vector and
encoded wild-type EGFR and the NLS EGFR mutant. The NLS sequence in the
juxtamembrane domain of EGFR is RRRHIVRKRTLRR (Hsu SC & Hung MC, 2007),
which was changed into AAAHIVAKATLAA. In addition to using untransfected cells
as a control, cells transfected with the parental pUSEamp vector were also studied.
Transiently transfected cells at 48 hours were chosen for further experiments. After 24
hour incubation with the plasmid, cells were washed with complete media and
incubated for a further 24 hours before treatment. Cells were then treated with gefitinib,
irradiation or both, at appropriate concentrations and doses, based on previous studies
with the cell lines, and used for immunofluorescence and COMET analysis.
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Length 5400 bp
Figure 24:Map of the pUSEamp vector used for expressing various EGFR constructs.
Source: Upstate Cell Signaling Solutions
http://search.cosmobio.co.jp/cosmo_search_p/search_gate2/docs/UBI_/21147.2004020
4.pdf
3.13 Flow cytometry- FACS Analysis
This procedure utilizes ethanol to fix the cells and permeabilize the membrane, which
allows the dye (Propidium Iodide) to enter the cells. Propidium Iodide (PI) is a DNA-
binding fluorochrome that intercalates in the double-helix. Ribonuclease-A is used to
eliminate the staining of double-stranded RNA. This procedure uses DNA staining for
analysis of the cell cycle.
Collection and fixation
Exponentially growing cells were seeded at 2.5x104 cells/ml (5x104 cells/well) in six
well plates (Nunclon, VWR) and incubated for 24h at 37ºC in 5% CO2. Cells were
drug treated for 24 or 72 hours, the media subsequently removed and the cells washed
with PBS. 1ml of trypsin was added per well for approximately 2 minutes followed by
addition of 1ml of complete media. The cells were collected in 15ml sterile falcon tubes
and centrifuged for 5 minutes at 1500rpm. The pellets were resuspended in 1ml of ice-
cold 0.02% sodium azide –PBS per sample. Cells were fixed by addition of 7ml of 70%
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ethanol to each sample. For proper fixation and to prevent cell aggregation, gentle
vortexing was employed while fixing. The cells were wrapped in silver foil and left to
fix for one hour at 4oC. The cells can be left in this stage at 4oC for up to 3 days before
being stained.
Staining DNA for Cell Cycle Analysis
The fixed cells were centrifuged as above and washed in 7ml ice-cold 0.02% sodium
azide –PBS then centrifuged again. Each pellet is then resuspended in 50l propidium
iodide, 9l DNase-free RNAse A, and 941 l 0.02% sodium azide –PBS to make a total
of 1ml per pellet. Cells were gently mixed and left at 4oC or on ice (covered with silver
foil to protect from light) for a minimum of 30 minutes. The cells were analysed on a
FACSCalibur cytometer (Becton Dickinson, UK).
Figure 25 below shows an example of a graph derived using flow cytometry for cell
cycle analysis. The y-axis demonstrates the number of cells whereas the x axis shows
the intensity of fluorescence designated as FL2-H. ‘FL2-H’ denotes DNA content by
propidium iodide staining, Cells at the beginning of the FL2-H axis (below 140),
denotes cells with sub-G1 DNA content, indicative of apoptosis. The cells under normal
growth conditions form two populations designated by the bars M1 and M2, which are
shown by the two peaks. Cells in G1/S phase of the cell cycle are represented by the
first peak, whereas the second peak represents cells in the G2/M phase of the cell cycle.
Note that the peaks are respectively at 200 and 400.The intensity in the second peak is
double which signifies the presence of duplicated DNA in the cells of the G2/M phase.
Figure 25: DNA analysis of cells by flow cytometry on a FACSCalibur cytometer.
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3.14 Immunohistochemistry
Patient Sections
Tissue from 85 consecutive unselected patients at the Royal Free Hospital with
neuroendocrine tumours in various organs including liver, pancreas, small bowel, lung
and brain and normal control tissues for each patient whenever possible were assessed.
Tissue samples were fixed in formalin and embedded in paraffin. Sections were cut 3
m thick and placed on a water bath at 45oC before being positioned on top of
microscope slides. GIST sections were used as positive control. The presence of mast
cells in tissue samples was also used as an internal positive control. Negative controls
included omission of the primary antibody.
Immunohistochemistry
Tissue sections were dewaxed in xylene (Chemicon, UK) for 10 min, dehydrated in
100% alcohol and then rinsed in distilled water for 5 min. All sections were incubated
in 3% hydrogen peroxide for 10 min to inhibit endogenous peroxidase enzyme activity.
For exposure and detection of the C-KIT protein with both antibodies, the slides were
microwaved in prewarmed 0.01 M citrate buffer for 5 min and washed in distilled water
to cool the slides down. From this point onwards, the slides must be kept wet at all
times to facilitate staining. The sections are circled with a hydrophobic pen to prevent
drying of the slides.
Slides are incubated in tris-buffered saline (TBS) for 5 minutes to equilibrate. Non-
specific binding of the antibody to Fc fragments in the tissue was blocked by incubating
the sections in 10% normal goat serum (DAKO, UK) in TBS for 15 min. The serum is
tipped off and approximately 100l of anti-human C-KIT antibody (dilution 1:50 in
TBS) was added to each section for 1 hour. Negative control studies for each tissue
section were performed without primary antibody. Binding was detected using
biotinylated goat anti-mouse/rabbit antibody (DAKO) at a dilution of 1:200 in TBS for
30 minutes at room temperature, followed by 30 min with streptavidin-biotin/ horse
radish peroxidase mix (DAKO, 1:200 in TBS each). Sections were washed in TBS for 5
min then visualised using diaminobenzidine tetrahydrochloride (DAB; Vector
laboratories), a chromagen- substrate for HRP, by incubating the slides at room
temperature for 10 min. Sections were counterstained in Carrazi's haematoxylin (which
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stains nuclei blue), dipped in acid alcohol and blueing solution, dehydrated in alcohol
and xylene and mounted in DPX, a xylene-based adhesive.
Scoring of immunohistochemistry
All sections were scored independently by myself and two independent
histopathologists. Intensity of staining was made in comparison to the GISTs tumour
samples, which were used as positive control. Immunostaining was scored as follows:
strong 3; moderate 2; weak 1; no staining 0.
3.15 Electron Microscopy
Cells were left to reach 80-90% confluence in 75cm2 (T75) flasks. Cells were then
treated with gefitinib for 3 hours prior to irradiation at 4Gy. Control unirradiated
samples were also used.
Fixing and embedding:
Cells were fixed in 4% PFA/0.1% gluteraldehyde in 0.1M Phosphate buffer for 2 hours
at RT, and washed in 20mM glycine at RT. Cells were then scraped in 1% gelatin and
collected into 1.5ml eppendorf tubes, followed by spinning horizontally at 1500rpm for
1 min. Supernatant was removed and the pellet was resuspended in 12% gelatin at 37°C
and left to infuse for a few minutes at 37°C. The cells were then centrifuged
horizontally at 5000rpm for 1 min, the supernatant was removed and the tubes were
placed on ice for 15 minutes. The ends of the tubes were cut off and the pellet was
sliced in half into PBS in ice. The pellet was cut into blocks (block faces should be
approx 0.6 -0.4 x 0.3-0.4 mm) and infused with 2.3M sucrose overnight at 4°C on
rotation. Blocks were mounted onto pins (Agar) and stored in liquid nitrogen. 70nm
sections were cut at -120°C, picking the sections up in 2% methyl cellulose/ 2.3M
sucrose (1 / 1) onto formvar/carbon-coated copper grids. Sections were then stored at
4°C.
Staining:
Grids were placed on 2% gelatin in phosphate buffer and incubated at 37°C for 20
minutes and rinsed in PBS + 0.1% glycine 5 times for 1min. Sections were then blocked
in PBS +1% BSA/0.1% BSA-c for 5min, followed by incubation in primary sheep anti-
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EGFR antibody (Fitzgerald, 1:250 in 1% BSA) overnight at 4°C. Sections were then
washed in PBS 4 times for 2 minutes each and incubated in secondary anti-goat IgG
coupled to 15nm colloidal gold particles (1:40 in 1% BSA) for 45 minutes at RT.
Sections were rinsed in PBS 3 times for 5 seconds each, and washed as before in PBS 4
times for 2 minutes each. Sections were stabilised with 1% gluteraldehyde in PBS for 5-
30 minutes at RT, and washed in water 10 times for 1 minute. Cells were then stained in
methyl cellulose / uranyl acetate (9 / 1) on ice in the dark for 5 minutes and after excess
methyl cellulose / uranyl acetate was drained off on filter paper, sections were allowed
to air dry for 10 minutes (or left overnight) at RT.
Location of EGFR was analysed by viewing samples on a JEOL 1010 Transmission
Electron Microscope, and gathering images with a Gatan OriusSC100B CCD camera.
Staining of samples and viewing of images was performed by Emily Eden, UCL
Institute of Ophthalmology, London, UK.
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CHAPTER 4
INVESTIGATION OF COMBINATION TREATMENTS
USING EGFR INHIBITORS WITH CHEMOTHERAPEUTIC
AGENTS IN NET CELLS
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4.1 Introduction
4.1.1 EGFR and Cancer
Epidermal growth factor receptor (EGFR) is expressed in many cancers and is
associated with poor prognosis. EGFR activation pathways have been well
characterised using tumour cell lines and are known to involve EGFR activation
through autophosphorylation (Rusch et al., 1996; Hirono et al., 1995). Phosphorylation
of downstream signalling molecules, such as ERK1/2 (extra-cellular signal regulated
kinase 1 & 2,), and PKB/Akt (protein kinase B), leads to enhanced tumour cell survival
and proliferation (Yarden, 2001).
EGFR is frequently expressed in neuroendocrine tumours (Wang et al., 1997; Nilsson et
al., 1995; Rusch et al., 1996). A potential implication of EGFR in progression of
gastrointestinal carcinoids and PNETs was shown by the presence of activated EGFR in
these cells (Papouchado et al., 2005; Wulbrand et al., 1998; Peghini et al., 2002). Co-
expression of EGFR and TGF-alpha was shown in midgut and hindgut carcinoids,
phaeochromocytomas and MTCs suggesting an autocrine mechanism for tumour-
growth regulation (Nilsson et al., 1995). EGFR expression or overexpression was
shown to affect tumour growth and progression of NETs (Wulbrand et al., 1998;
Peghini et al., 2002).
Recent data suggests that there is no direct correlation between the results of EGFR
immunostaining and the response to anti-EGFR therapy (Dei Tos & Ellis, 2005).
However, a study by Shah et al. found EGFR in >90% of NET tumour patients. They
demonstrated expression of EGFR in 96% of tumour samples, while 63% were positive
for activated EGFR. The subsequent activation of intracellular signalling pathways was
demonstrated by the immunostaining for p-Akt and p-MAPK in NET tissue samples.
Importantly, the histological score for the activation of Akt and MAPK correlated with
the histological score for activated EGFR. These data provide a rationale for
considering EGFR inhibitors in the treatment of NETs (Shah et al., 2006).
4.1.2 EGFR inhibition by gefitinib
Gefitinib (Iressa or ZD1839) is a specific tyrosine kinase inhibitor of EGFR used for the
treatment of non-small cell lung cancer as well as for other solid tumours (Schiller,
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2003; Herbst, 2002; Blackledge & Averbuch, 2004). Antineoplastic activity has been
shown in a variety of human cancers including prostate, breast, ovarian, colon and lung
cancer cells. Gefitinib has been shown to induce apoptosis and cell cycle arrest in a
variety of tumour cells including neuroendocrine gastrointestinal tumour cells (Hopfner
et al., 2003). EGFR targeting in NET cell lines by gefitinib has been investigated by
Hopfner and co-workers. They showed that inhibition of EGFR tyrosine kinase
promoted growth suspension by apoptosis and cell cycle arrest in NE gastrointestinal
tumour cells (Hopfner et al., 2003). Inhibition of EGFR by gefitinib as a single agent
has been shown both in cell lines and in xenograft models. Combination treatments with
a variety of chemotherapeutic agents (including cisplatin, carboplatin, paclitaxel,
etoposide and doxorubicin) or anti-sense oligonucleotides, demonstrated synergistic
effects in inhibition of proliferation, induction of apoptosis, and antitumor activity in
vitro and in vivo (Ciardiello, 2000; Ciardiello, 2001; Sirotnak et al., 2000). Similarly,
combination of gefitinib with radiation showed increased inhibition of proliferation and
had pro-apoptotic effects in vitro, while in human tumour xenografts there was
increased tumour growth delay (Huang et al., 2002; Bianco et al., 2002).
4.1.3 Chemotherapy on EGFR activity
Cisplatin has been shown to induce diverse cellular responses including the activation
of the JNK and p38 MAPK cascades as well as members of the ERK subfamily of
MAPKs (Benhar et al., 2001). It has been shown that cisplatin-induced ERK activation
is significantly elevated in transformed cells, such as NIH3T3 cells that overexpress
EGFR (Benhar et al., 2001). These findings led to further investigations confirming that
apart from cisplatin, other drugs such as doxorubicin, and camptothecin, which is a
topoisomerase I inhibitor, but not paclitaxel, induced activation of EGFR in NIH-3T3
human fibroblast and U87MG human glioma transformed cells lines that overexpress
EGFR (Benhar et al., 2002). EGFR activation by cisplatin was also shown in MCF-7
breast cancer cell line (Friedmann, 2004).
Aims
In the first part of this study we analysed the potential therapeutic value of EGFR in
NETs by proliferation studies. The cell lines used included the NCI-H727 human
bronchial carcinoid, the SHP-77 human small cell lung cancer (with neuroendocrine
features), and the CRI-G1 and RIN-5F rat islet tumour cells. Experiments were also
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performed in the HCT-116 colon cancer cell line, which expresses EGFR at levels
comparable to neuroendocrine cell lines. Initially, we assessed the potentially anti-
proliferative effect of gefitinib alone, or in combination with the widely used
chemotherapeutic drugs cisplatin, etoposide, paclitaxel and methotrexate. The effect of
gefitinib in NET cell lines was analysed further for cell cycle arrest or apoptosis. In the
second part of this study, based on the effect of chemotherapy on EGFR activation
reported in the literature, we also investigated the effect of cisplatin, etoposide,
paclitaxel, and methotrexate on EGFR activity in order to analyse to a greater extend
the mechanism of interaction between gefitinib and chemotherapeutic agents.
4.2    Results
4.2.1    Proliferation studies using gefitinib or chemotherapy as single agents
Cytotoxicity of drugs was determined by the Sulphorhodamine B (SRB) proliferation
assay. Initially, single agent treatments were carried out on all cell lines to obtain
suitable dose ranges for different exposure times. Single agent administration included
addition of drugs for 24, 48, or 72 hours followed by 2 days incubation in drug-free
media. Gefitinib as a single agent added for a period of 72 hours was cytotoxic to all
cells tested and had a dose response effect (figure 26), demonstrating 50% growth
inhibition  at the high doses of 18-20M in 4/5 cell lines and in RIN-5F cells at 32M
(IC50s shown in table within figure 26). The IC50s for the 48 hour treatments were very
similar, while the IC50s for the 24 hour treatment were much lower (data not shown).
Anti-cancer drugs also decreased tumour cell proliferation as single agents in a dose-
dependent fashion in all cell lines. IC50s are shown in table 10 for the standard 72 hour
treatment. The drugs were also administered as single agents for 24 and 48 hours with
lower cytotoxic abilities (data not shown). Paclitaxel was the most effective drug with
IC50s below 0.05M, followed by methotrexate with IC50s of approx. 0.2-25M.
Etoposide and cisplatin give slightly higher IC50s to methotrexate, but are nevertheless
effective in inhibiting proliferation of neuroendocrine cells.
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IC50s of gefitinib in NET cells (M)
SHP-77 CRI-G1 NCI-H727 RIN-5F HCT-116
Gefitinib 20.3 ± 1.42 19.2 ± 1.78 21.1 ± 1.86 32.3 ± 0.95 18.6 ± 2.16
Figure 26: SHP-77, GRI-G1, NCI-H727, RIN-5F and HCT-116 cells were
incubated with gefitinib for 3 days at the indicated concentrations followed
by 2 days incubation in drug-free media. Proliferation was calculated as a
% of control untreated cells. IC50s values shown represent means of 3
independent experiments, each done in triplicate, with standard deviation.
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Table 10 : IC50s of chemotherapeutic agents in NET cells (M)
SHP-77 CRI-G1 NCI-H727 RIN-5F HCT-116
Cisplatin 9 ± 1.12 2.41 ± 0.34 10 ± 1.22 0.48 ± 0.029 12.7 ± 1.32
Etoposide 1.64 ± 0.32 1.3 ± 0.23 6.8 ± 0.86 0.5 ± 0.057 1.3 ± 0.46
Methotrexate 0.43 ± 0.062 0.75 ± 0.078 1.8 ± 0.38 2.6 ± 0.47 0.22 ± 0.051
Paclitaxel 0.033 ± 0.037 0.042 ± 0.036 0.047 ± 0.051 0.031 ± 0.029 0.033 ± 0.028
Note: IC50s of treatments with drugs for a period of 3 days followed by 2 days in
complete media. The values represent means of 3 independent experiments, each done
in triplicate, with standard deviation.
4.2.2    Combination treatments with gefitinib or chemotherapy
As mentioned in section 1.2.4, chemotherapy has shown temporary efficacy in
managing NETs of foregut origin, including pancreatic, but is of limited benefit in mid-
gut and hindgut carcinoid tumours. Therefore, the aim for combining two different
therapies such as chemotherapy and EGFR inhibitors in this study was to find the
conditions that sensitise cells to chemotherapy. The second aim was to use lower drug
concentrations than the ones used in single treatments. As a result, for combination
treatments, the subtoxic and clinically relevant concentration of 10M gefitinib, which
causes up to 20% inhibition of proliferation in all cell lines, was added to a range of
concentrations for chemotherapy. Cells were treated with anticancer drugs with a
variety of mechanisms of action, including the DNA crosslinking compound cisplatin,
the topoisomerase II poison etoposide, the mitotic inhibitor paclitaxel, and the
antimetabolite methotrexate, in order to identify possible synergisms in neuroendocrine
tumours.
Administered schedules included:
 Simultaneous addition gefitinib with cisplatin, etoposide, methotrexate or
paclitaxel, for a period of 72 hours
 Incubation with gefitinib for 24 hours followed by chemotherapy drugs for 48
hours
 Incubation with chemotherapy drugs for 24 hours followed by gefitinib for 48
hours
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o Cytotoxic drugs were added at 0-100M for cisplatin, methotrexate and
etoposide, and paclitaxel at 0-10M.
o Drug incubations were followed by 2 days incubation in drug-free media
before analysis
Cytotoxicity of drugs was determined by the Sulphorhodamine B (SRB) proliferation
assay. The isobologram analysis was used to determine inhibitory, additive or
synergistic effects between the two drugs used in combination. The IC50s of each of the
two agents combined are at the ends of the x and y axis respectively, and are connected
by a straight line called ’additivity line’. This line is the locus of all dose pairs that,
based on these potencies, should give the same effect for these two drugs added
together. Any point of combined IC50 found well below the line denotes positive
synergy, while all points found well above denote negative synergy.
The graphs and the IC50 values shown only include cases with synergistic or
additive effect by dual treatment. The rest of the combination treatments are
shown in the appendix 1A-1E for each cell line.
Etoposide
Etoposide displayed synergy with gefitinib when both drugs were added simultaneously
for 72 hours in 2/5 cell lines, leading to increased cytotoxicity of 20-50% (figures 27-
30). Etoposide with gefitinib combined gave an IC50 of 0.3M in SHP-77 and 0.32M
in CRI-G1 cells, 0.5M in HCT-116 and 1M in NCI-H727 cells respectively (table
11). The synergies were identified in CRI-G1 and SHP-77 cells, where at value 0.5M
of etoposide, simultaneous addition of gefitinib increased the anti-proliferative effect by
50% (figures 27-28). In NCI-H727 and HCT-116 cells (figures 29-30) simultaneous
treatment with both agents increased inhibition of proliferation by 37% and 40%
respectively at value 0.5M of etoposide and displayed an additive effect.
In NCI-H727 and CRI-G1 cells (but not in SHP-77 and HCT-116 cells) synergies were
identified when cells were treated with gefitinib for 24 hours followed by incubation
with etoposide for 48hours (figures 28-29), indicating that weakening of EGFR
signalling before etoposide administration may be of therapeutic value. The rest of the
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combinations analysed, shown in the appendix 1A-1E, did not increase the cytotoxic
effect of etoposide.
Table 11: IC50s  (M)
SHP-77 CRI-G1 NCI-H727 HCT-116
Gefitinib 72h 20.3 ± 1.42 19.2 ± 1.78 21.1 ± 1.86 18.6 ± 2.16
Etoposide 72h 1.64 ± 0.32 1.5 ± 0.23 6.8± 0.86 1.9 ± 0.36
Etoposide and
gefitinib for 72h 0.3 ± 0.052 0.32 ± 0.044 1 ± 0.21 0.5 ± 0.067
Gefitinib 24h, then
etoposide 48h 0.32 ± 0.047 1.7± 0.46
Note: IC50s of treatments with drugs in single or dual treatments for a period of 3 days
followed by 2 days in complete media. The values represent means of 3 independent
experiments, each done in triplicate, with standard deviation.
The isobologram graphs in figures 30-33 indicate the synergistic or additive effects of
etoposide and gefitinib. The IC50 values for etoposide and gefitinib as single agents are
at the ends of the x and y axis respectively, and are connected the ’additivity line’. This
line is the locus of all dose pairs that, based on these potencies, should give the same
effect for these two drugs added together. As can be seen in the figures 30-31, the IC50s
of simultaneous addition of etoposide with 10µM gefitinib for 72hours in SHP-77 and
CRI-G1 cells lie well below this line and therefore indicate a superadditive or
synergistic effect. Points well below the additivity line are also found when gefitinib is
added for 24hours followed by etoposide for 48 hours in NCI-H727 and CRI-G1 cells.
In fact, in GRI-G1 cells the point is the same for both types of double treatments.
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Figure 27: Etoposide and gefitinib combination treatment in SHP-77 cells.
Top graph: Growth inhibition SRB assay. Cells were treated with etoposide at
the indicated concentrations alone, or simultaneously with gefitinib (10M) for
72 hours, followed by 48 hours in drug free medium. Proliferation was
calculated as a % of control untreated cells. Data represents the averages of three
different experiments, each performed in triplicate; bars, SD.
Bottom graph: Isobologram analysis. Red line is additivity line connecting the
IC50s ( ) of the two drugs. Points well below the line demonstrate synergistic
effect, while points close to the line demonstrate an additive effect. Combined
treatment IC50 (  ) of etoposide and gefitinib together.
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Figure 28: Etoposide and gefitinib combination treatment in CRI-G1 cells.
Top graph: Growth inhibition SRB assay.  Cells were treated with etoposide at
the indicated concentrations alone, simultaneously with gefitinib (10M) for 72
hours, or with gefitinib first and then etoposide, followed by 48 hours in drug
free medium. Proliferation was calculated as a % of control untreated cells. Data
represents the averages of three different experiments, each performed in
triplicate; bars, SD.
Bottom graph: Isobologram analysis. Red line is additivity line connecting the.
IC50s ( ) of the two drugs Points well below the line demonstrate synergistic
effect, while points close to the line demonstrate an additive effect. Combined
treatment IC50s (  ) of etoposide and gefitinib together.
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Figure 29: Etoposide and gefitinib combination treatment in NCI-H727 cells.
Top graph: Growth inhibition SRB assay.  Cells were treated with etoposide at
the indicated concentrations alone, simultaneously with gefitinib (10M) for 72
hours, or with gefitinib first and then etoposide, followed by 48 hours in drug
free medium. Proliferation was calculated as a % of control untreated cells. Data
represents the averages of three different experiments, each performed in
triplicate; bars, SD.
Bottom graph: Isobologram analysis. Red line is additivity line connecting the.
IC50s ( ) of the two drugs Points well below the line demonstrate synergistic
effect, while points close to the line demonstrate an additive effect. Combined
treatment IC50s (  ), (  ) of etoposide and gefitinib together.
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Figure 30: Etoposide and gefitinib combination treatment in HCT-116 cells.
Top graph: Growth inhibition SRB assay.  Cells were treated with etoposide at
the indicated concentrations alone, or simultaneously with gefitinib (10M) for
72 hours, followed by 48 hours in drug free medium. Proliferation was
calculated as a % of control untreated cells. Data represents the averages of three
different experiments, each performed in triplicate; bars, SD.
Bottom graph: Isobologram analysis. Red line is additivity line connecting the
IC50s ( ) of the two drugs. Points well below the line demonstrate synergistic
effect, while points close to the line demonstrate an additive effect. Combined
treatment IC50 (  ) of etoposide and gefitinib together.
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Cisplatin
Cisplatin showed synergy when combined with gefitinib in NCI-H727 cells (figure 31).
Treatment with cisplatin and gefitinib concurrently for 72 hours or with gefitinib for 24
hours followed by cisplatin for 48 hours resulted in a 40% increased anti-proliferative
effect at values 0.5 and 1M of cisplatin. When NCI-H727 cells were treated with
cisplatin alone the IC50 was 10M. Addition of gefitinib simultaneously or before
cisplatin gave IC50s of 1M and 2.2M respectively (table 12).
Also, in HCT-116 cells (figure 32), increased inhibition of proliferation was identified
when cisplatin treatment preceded gefitinib, with a joint IC50 of 6.3M compared to
12.7M of cisplatin alone (table 13). Isobologram analysis demonstrated this
combination to result in an additive effect, but no synergy. No synergistic or additive
effects were identified in any other cell line with cisplatin and gefitinib combinations
(data shown in the appendix 1A-1E).
Table 12: IC50s  (M) Table 13: IC50s  (M)
NCI-H727 HCT-116
Gefitinib 72h 21.1 ± 1.86 Gefitinib 72h 18.6 ± 2.16
Cisplatin 72h 10 ± 1.22 Cisplatin 72h 12.7 ± 1.32
Cisplatin and
gefitinib for 72h 1± 0.23
Cisplatin 24h,
then gefitinib 48h 6.3 ± 0.75
Gefitinib 24h,
then cisplatin 48h 2.2 ± 0.30
Note: IC50s of treatments with drugs in single or dual treatments for a period of 3 days
followed by 2 days in complete media. The values represent means of 3 independent
experiments, each done in triplicate, with standard deviation.
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Figure 31: Cisplatin and gefitinib combination treatment in NCI-H727 cells.
Top graph: Growth inhibition SRB assay.  Cells were treated with cisplatin at
the indicated concentrations alone, simultaneously with gefitinib (10M) for 72
hours, or with gefitinib first and then cisplatin, followed by 48 hours in drug free
medium. Proliferation was calculated as a % of control untreated cells. Data
represents the averages of three different experiments, each performed in
triplicate; bars, SD.
Bottom graph: Isobologram analysis. Red line is additivity line connecting the.
IC50s ( ) of the two drugs Points well below the line demonstrate synergistic
effect, while points close to the line demonstrate an additive effect. Combined
treatment IC50s (  ), (  ) of cisplatin and gefitinib together.
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Figure 32: Cisplatin and gefitinib combination treatment in HCT-116 cells.
Top graph: Growth inhibition SRB assay.  Cells were treated with cisplatin at
the indicated concentrations alone, or with cisplatin first and then gefitinib
(10M), followed by 48 hours in drug free medium. Proliferation was calculated
as a % of control untreated cells. Data represents the averages of three different
experiments, each performed in triplicate; bars, SD.
Bottom graph: Isobologram analysis. Red line is additivity line connecting the.
IC50s ( ) of the two drugs Points well below the line demonstrate synergistic
effect, while points close to the line demonstrate an additive effect. Combined
treatment IC50 (  ) of cisplatin and gefitinib together.
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Paclitaxel
Paclitaxel’s effect on tumour cell growth was increased in NCI-H727 cells when
gefitinib and paclitaxel were added together, or when paclitaxel was added first for 24
hours and gefitinib was added second for 48 hours (figure 33). In both combination
treatments inhibition of proliferation was increased by 20% at values 0.05 and 1M of
paclitaxel. Joint treatments gave IC50 values of 0.03 for the simultaneous addition of
drugs, and 0.031M when paclitaxel administration preceded gefitinib, compared to the
IC50 of 0.047M of paclitaxel alone (table 14) demonstrating to an additive effect for
this combination. NCI-H727 was the only cell line where the combined treatment of
gefitinib and paclitaxel had an increased effect in inhibition of proliferation. No effect
was seen in the rest of the cell lines used.
Table 14: IC50s  (M)
NCI-H727
Gefitinib 72h 21.1 ± 1.86
Paclitaxel 72h 0.047 ± 0.051
Paclitaxel and
gefitinib for 72h 0.03 ± 0.004
Paclitaxel 24h, then
gefitinib 48h 0.031 ± 0.003
Note: IC50s of treatments with drugs in single or dual treatments for a period of 3 days
followed by 2 days in complete media. The values represent means of 3 independent
experiments, each done in triplicate, with standard deviation.
Methotrexate
Methotrexate showed no synergy with gefitinib in any of the cells tested and in any of
the administered schedules. Gefitinib had no effect in the anti-proliferative effect of
methotrexate as a single agent.
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Figure 33: Paclitaxel and gefitinib combination treatment in NCI-H727 cells.
Top graph: Growth inhibition SRB assay.  Cells were treated with paclitaxel at
the indicated concentrations alone, simultaneously with gefitinib (10M) for 72
hours, or with paclitaxel first and then gefitinib, followed by 48 hours in drug
free medium. Proliferation was calculated as a % of control untreated cells. Data
represents the averages of three different experiments, each performed in
triplicate; bars, SD.
Bottom graph: Isobologram analysis. Red line is additivity line connecting the.
IC50s (  ) of the two drugs Points well below the line demonstrate synergistic
effect, while points close to the line demonstrate an additive effect. Combined
treatment IC50s (  ) of paclitaxel and gefitinib together.
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4.2.3 Gefitinib induces apoptosis in NET cell lines
To investigate whether the antineoplastic effect of gefitinib in neuroendocrine tumour
cells is associated with the induction of programmed cell death, we investigated the
presence of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates,
which indicates apoptosis. Apoptosis is primarily characterised by DNA fragmentation,
a phenomenon that is followed several hours later by plasma membrane degradation and
this results in the enrichment of the cytoplasm with mono- and oligonucleosomes (for
details on apoptosis see section 3.7). Mono- and oligonucleosomes were identified
using the ELISA cell death detection assay (figure 21), which is a quantitative
sandwich-enzyme immunoassay using a biotin-conjugated antibody against histone and
an anti-DNA antibody bound to horse radish peroxidase (HRP), which is determined
photometrically.
Cells were treated with 0-50M gefitinib for 72 hours as in the proliferation
experiments. As shown in figure 34, at the highest concentration of gefitinib DNA
fragmentation was mostly present in RIN-5F cells, followed by NCI-H727 and then
SHP-77 cells. It is worth noting that the results of apoptosis come in concordance with
the proliferation studies. Apoptosis is detected at the high concentrations of 25-50M
that correlate to the IC50s found in the growth inhibition assay (table 15 below taken
from section 4.2.1). In contrast, CRI-G1 cells showed no DNA fragmentation after 72
hours incubation with gefitinib.  Since CRI-G1 cells are the most responsive to gefitinib
(IC50 of 19.2M), a possible explanation would be that CRI-G1 cells undergo apoptosis
more readily than the rest of the cells and by 72 hours they are completely degraded.
Table 15: IC50s of gefitinib in NET cells (M)
SHP-77 CRI-G1 NCI-H727 RIN-5F
Gefitinib 72h 20.3 ± 1.42 19.2 ± 1.78 21.1 ± 1.86 32.3 ± 0.95
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Figure 34: Cells were incubated with 0-50M gefitinib for 72 hours. Absorbance of 0.5
or higher indicates the presence of mono- and oligonucleosomes. Columns represent
averages of three independent experiments, each done in triplicate; bars, SD.
4.2.4 Gefitinib does not induce cell cycle arrest in NET cell lines
To further examine the inhibition of neuroendocrine tumour growth by gefitinib, we
assessed gefitinib for its ability to induce cell-cycle arrest using flow-cytometric cell
cycle analysis. Cells were treated with gefitinib at 0-50M for 72 hours. Propidium
iodide staining of DNA was used to determine the cell cycle status of cells. For more
detailed information please refer to section 3.13 (p.90-92). All experiments were
repeated 3 times and representative graphs are shown in figures 35-38.
No effect on the cell cycle of cells was seen in any of the cell lines used with cells
treated with 10M gefitinib for 72 hours demonstrating the same percentages of cells in
G1 or G2/M phase of the cell cycle as in the control untreated cells (upper left graph in
each page). At the highest concentration of 50M, gefitinib induced apoptosis in RIN-
5F, NCI-H727, SHP-77 and CRI-G1 cells, represented as a movement of cells to the
beginning of the FL2-H axis (fluorescence axis, denotes DNA content by propidium
iodide staining), which indicates apoptosis. The effect was more prominent in CRI-G1
cells that undergo programmed cell death even at 25M gefitinib. This agrees with the
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results obtained from the study of apoptosis in section 4.2.3, where CRI-G1 cells are
completely degraded at 50M gefitinib.
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Figure 35: CRI-G1 cells were treated with gefitinib at 0-50M for 72 hours. ‘FL2-H’
denotes DNA content by propidium iodide staining, while ‘counts’ denotes cell number.
Bars M1 and M2 indicate populations of cells at phases G1 and G2/M of the cell cycle
respectively. Cells at the beginning of the FL2-H axis (below 140), denotes cells with
sub-G1 DNA content, indicative of apoptosis.
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Figure 36: RIN-5F cells were treated with gefitinib at 0-50M for 72 hours. ‘FL2-H’
denotes DNA content by propidium iodide staining, while ‘counts’ denotes cell
number. Bars M1 and M2 indicate populations of cells at phases G1 and G2/M of the
cell cycle respectively. Cells at the beginning of the FL2-H axis (below 140), denotes
cells with sub-G1 DNA content, indicative of apoptosis.
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Figure 37: NCI-H727 cells were treated with gefitinib at 0-50M for 72 hours. ‘FL2-
H’ denotes DNA content by propidium iodide staining, while ‘counts’ denotes cell
number. Bars M1 and M2 indicate populations of cells at phases G1 and G2/M of the
cell cycle respectively. Cells at the beginning of the FL2-H axis (below 140), denotes
cells with sub-G1 DNA content, indicative of apoptosis.
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Figure 38: SHP-77 cells were treated with gefitinib at 0-50M for 72 hours. ‘FL2-H’
denotes DNA content by propidium iodide staining, while ‘counts’ denotes cell
number. Bars M1 and M2 indicate populations of cells at phases G1 and G2/M of the
cell cycle respectively. Cells at the beginning of the FL2-H axis (below 140), denotes
cells with sub-G1 DNA content, indicative of apoptosis.
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4.2.5 Modulation of EGFR activity by chemotherapy drugs
DNA damaging agents such as cisplatin, camptothecin and doxorubicin have been
proposed to activate EGFR in NIH-3T3 human fibroblast and U87MG human glioma
transformed cells lines that overexpress EGFR (Benhar M et al, 2002). EGFR activation
by cisplatin was also shown in MCF-7 breast cancer cell line (Friedmann B et al, 2004).
To investigate whether a similar effect was seen in NET cell lines, two different
experiments were set up:
A. Cisplatin, etoposide, methotrexate and paclitaxel were administered to NCI-
H727, CRI-G1, SHP-77 and RIN-5F cells at the cytotoxic concentration of
100M for cisplatin, etoposide, and methotrexate or at 10M paclitaxel for 0-24
hours. This experiment would assess the effect of drugs (at a specific
concentration) with time on EGFR activity (time-course analysis).
B. Cisplatin, etoposide, and methotrexate were administered at 0-100M, and
paclitaxel at 0-10M for 24 hours to see whether different dosages at the same
time duration have diverse effects on EGFR phosphorylation (dose-response
analysis).
All experiments were repeated at least 3 times with representative blots shown for each
experiment. Results are shown for cisplatin and etoposide with the effects of paclitaxel
and methotrexate added in appendix 1F-1I. For immunoblots of phosphorylated EGFR,
the A431 cells that overexpress EGFR were used as positive control (figure 39). The
amounts of phosphorylated EGFR were calculated by densitometry analysis of the
bands. The figure below shows basal expression of phosphorylated EGFR in all cell
lines tested.
Figure 39: Whole cell lysates of A431 cells (positive control), NCI-H727 human
bronchial carcinoid, SHP-77 human small cell lung cancer, CRI-G1 and RIN-5F rat islet
tumour cells untreated, were immunoblotted for phosphorylated EGFR (PY20,170kDa).
A-tubulin bands (50kDa) were used as loading control.
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A. Time-course analysis
Cisplatin
Cisplatin at 100M induced activation of EGFR in all cell lines, as shown in the
western blots in figure 40. This activation is transient lasting up to 3 hours in NCI-
H727, SHP-77, and RIN-5F cells, or 6 hours in CRI-G1 cells. At 12 hours
phosphorylated EGFR levels are decreased and are less than in the control samples
showing a downregulation of the receptor which is also evident at 24 hours (blots
shown in figure 42). The blots were stripped and immunoblotted for EGFR showing
similar results (data not shown).
Cisplatin at 100M
Figure 40: Tyrosine phosphorylation of EGFR in NET cell lines determined by
immunoblotting for PY20 (170kDa). Cells were treated with cisplatin at 100M for 3, 6
or 12 hours. A-tubulin bands (50kDa) were used as loading control. Amounts of P-
EGFR in percentages were determined by densitometry analysis.
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Etoposide
Etoposide treatment at 100M upregulated EGFR at 3 hours in NCI-H727 and CRI-G1
cells but had no effect in the other cells (figure 41). In RIN-5F cells a transient
downregulation is seen up to 6 hours but is probably due to less amount of lysate being
loaded as shown by the -tubulin control. In all cells the receptor activity is equal to
control levels by 12 hours.
Etoposide at 100M
Figure 41: Tyrosine phosphorylation of EGFR in NET cell lines determined by
immunoblotting for PY20 (170kDa). Cells were treated with etoposide at 100M for 3,
6 or 12 hours. A-tubulin bands (50kDa) were used as loading control. Amounts of P-
EGFR in percentages were determined by densitometry analysis.
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Methotrexate
Interestingly, as seen in appendix 1F, methotrexate induced downregulation of EGFR in
all NET cell lines. By 3 hours, EGFR activation is at lower levels than in control
untreated cells. EGFR downregulation persists at 6, 12 and 24 hours (appendix 1H), and
almost abolishes any EGFR activity. Methotrexate is the only chemotherapeutic agent
that induced downregulation of EGFR in all cell lines.
Paclitaxel
Paclitaxel also induces downregulation of EGFR in NCI-H727, CRI-G1 and SHP-77
cells, (appendix 1G) showing that paclitaxel shuts down EGFR as part of its mechanism
of cell growth inhibition. This downregulation is continued at 24 hours post treatment
(appendix 1I). In RIN-5F cells paclitaxel treatment at 10M shows a very small
activation of EGFR at 6 hours but downregulation of the receptor there after.
B. Dose-effect analysis
Cisplatin
Treating cells for 24 hours with increasing amounts of cisplatin (figure 42) decreased
the amounts of activated EGFR in all NET cell lines tested in a dose-dependent fashion.
This downregulation agrees with the results from the time course analysis, where
activation of EGFR by toxic amounts of cisplatin lasts for 3 hours and EGFR activation
is decreased thereafter. In RIN-5F cells the effect of cisplatin is most dramatic, with
almost complete shut-down of the receptor even at 10M. The downregulation is also
strong in SHP-77 cells. In NCI-H727 cells only the highest dose blocked EGFR activity
completely, while the two highest doses had the same effect in CRIG1 cells.
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Cisplatin for 24 hours
Figure 42: Tyrosine phosphorylation of EGFR in NET cell lines determined by
immunoblotting for PY20 (170kDa). Cells were treated with cisplatin at 0, 10, 25, 50 or
100M for 24 hours. Bottom panel shows -tubulin bands (50kDa) as loading control.
Amounts of P-EGFR in percentages were determined by densitometry analysis.
Etoposide
Increasing the dosage of etoposide led to downregulation of EGFR in CRI-G1 and RIN-
5F cells (figure 43). In NCI-H727 cells the levels of P-EGFR remained relatively
unaffected, while in SHP-77 cells EGFR activity was slightly decreased. As mentioned
previously, etoposide induced activation of EGFR up to 3 hours in NCI-H727 and
CRIG1 cells, but at 12 hours the receptor was back to normal levels. This is in
accordance to these results where in NCI-H727 cells the receptor activity is slightly
decreased, while the downregulation in CRIG1 cells is more evident.
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Etoposide for 24 hours
Figure 43: Tyrosine phosphorylation of EGFR in NET cell lines determined by
immunoblotting for PY20 (170kDa). Cells were treated with etoposide at 0, 10, 25, 50
or 100M for 24 hours. Bottom panel shows -tubulin bands (50kDa) as loading
control. Amounts of P-EGFR in percentages were determined by densitometry analysis.
Methotrexate
At 24 hours of methotrexate treatment (appendix 1H), as in the time course experiment
(appendix 1F), EGFR is downregulated in all neuroendocrine cell lines. The effect of
methotrexate on EGFR is dose-dependent with highest inhibition of EGFR activation at
the highest concentrations.
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Paclitaxel
Increase of paclitaxel concentration induces receptor downregulation in all cell lines
tested (appendix 1I), which agrees with the results obtained from the time-course
experiment. Like methotrexate, the effect of the paclitaxel is dose-dependent and agrees
with the results obtained from the time-course experiment. The effect is most evident in
CRI-G1 cells in both time-course and dose response analyses. The effects on EGFR
activity by chemotherapeutic drugs are summarised in table 16.
Table 16
A: Time-course effect (0-24hours of 100M) of chemotherapy drugs on
activity of EGFR in NET cell lines
B: Dose response effect (0-100M for 24hours) of chemotherapy drugs
on activity of EGFR in NET cell lines
Cisplatin Etoposide Methotrexate Paclixatel
RIN-5F Upregulationup to 3 hours No effect Downregulation
Upregulation
up to 6 hours
NCI-H727 Upregulationup to 3 hours
Upregulation
up to 3 hours Downregulation Downregulation
CRI-G1 Upregulationup to 6 hours
Upregulation
up to 3 hours Downregulation Downregulation
SHP-77 Upregulationup to 3 hours No effect Downregulation Downregulation
Cisplatin Etoposide Methotrexate Paclitaxel
RIN-5F Downregulation Downregulation Downregulation Downregulation
NCI-H727 Downregulation No effect Downregulation Downregulation
CRI-G1 Downregulation Downregulation Downregulation Downregulation
SHP-77 Downregulation No effect Downregulation Downregulation
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4.2.6 Activation of EGFR signalling pathways by cisplatin
Cisplatin is the only chemotherapeutic agent that induces activation of the receptor in
all neuroendocrine cell lines in our study. Activation of the EGFR pathway traditionally
results in downstream signalling pathways including the lipid kinase
phosphatidylinositol (PI) 3-kinase (involving PKB/Akt) and the serine/threonine kinase
(Ras/MAPK) pathways. Based on this and in the correlation between phosphorylated
EGFR and phosphorylated PKB/Akt and MAPK also found recently in NET tissue
samples by immunostaining (Shah et al., 2006), we decided to further investigate the
upregulation of EGFR by cisplatin.
Cisplatin at 100M
Figure 44: Blots for phosphorylated EGFR in NCI-H727 and SHP-77 cell lines were
stripped of antibody and re-blotted for P-Akt and P-MARK. A-tubulin bands (50kDa)
were used as loading control.
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Cisplatin was analysed for its effect in PKB/Akt and MAPK signalling pathways, by
immunoblotting for p-Akt and p-MAPK. Our results (figures 44-45) show that
activation of EGFR by cisplatin leads to activation of the PI-3K and Ras/ MAPK
signalling pathways in a fashion that follows EGFR activation. Therefore Akt and
MAPK are activated up to 3 hours post-treatment in NCI-H727, SHP-77, and RIN-5F
cells and up to 6 hours in CRI-G1 cells, followed by downregulation there after.
Cisplatin at 100M
Figure 45: Blots for phosphorylated EGFR in CRI-G1 and RIN-5F cell lines were
stripped of antibody and re-blotted for P-Akt and P-MARK. A-tubulin bands (50kDa)
were used as loading control.
4.3 Discussion
EGFR aberrant expression is implicated in a variety of human tumours. Blockade
therefore of EGFR signalling pathways represents a promising strategy for anti-cancer
therapy.  Gefitinib, a reversible tyrosine kinase inhibitor of EGFR has shown anti-
proliferative activity in non-small cell lung cancer in vivo, and is now approved for
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clinical use (Harari, 2004). Gefitinib alone or in combination with other anti-cancer
therapies, such as chemotherapy drugs and radiation therapy has demonstrated efficacy
against tumour growth in a variety of cancer cell lines and in xenograft models
(Ciardiello et al., 2000; Ciardiello et al., 2001b; Huang, 2002; Magne, et al., 2002;
Sirotnak, et al., 2000).
4.3.1 Anti-proliferative effect by gefitinib and chemotherapy
In this study, gefitinib demonstrated an antineoplastic effect on a panel of
neuroendocrine tumour cell lines; two rat islet tumour cell lines CRI-G1 and RIN-5F,
the NCI-H727 human lung carcinoid cell line and the SHP-77 human SCLC cell line.
The colorectal cancer cell line HCT-116, expressing moderate levels of constitutively
active EGFR (Cunningham et al., 2006), was also tested. Gefitinib was used both as a
single agent and in combination with the commonly used anti-cancer drugs cisplatin,
etoposide, methotrexate and paclitaxel. Gefitinib showed a dose-response cytotoxic
effect in all cell lines, with an IC50 of 19-32M in neuroendocrine tumour cells and of
18.6M in the colon cancer cells. These concentrations are considerably higher than
the ones used in previous in vitro studies as well as to the clinical dose of gefitinib used
in patients (Ciardiello et al., 2000). Neuroendocrine cells are therefore resistant to doses
which are clinically relevant. A possible explanation would be that the cell lines used by
others had high EGFR levels and therefore increased sensitivity to gefitinib.
Neuroendocrine cells and HCT-116 colon cancer cells have moderate levels of EGFR
expression and are relatively resistant to gefitinib. Also, the cell lines in this study are
generally slow growing and cytotoxic effects are less evident than in fast growing cells.
Finally, the SRB proliferation assay used in our study measures inhibition of
proliferation and is therefore largely dependent on cell growth rate, and could not be
compared with clonogenic assays which measure colonies after a period of 2 weeks
including 6 days of daily replenished drug treatment as performed by other groups.
On the other hand, in a study by McKillop et al., it was shown that the concentration of
gefitinib in tumour tissue of breast cancer patients was 16.7M, which is much higher
than the routinely measured plasma concentration of gefitinib (McKillop et al., 2005).
This value is more agreeable to the values obtained in our study. Moreover, it must be
noted that although the IC50 of gefitinib required for EGFR inhibition is 20nM, the
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concentration needed for tumour growth inhibition in a variety of cell lines is much
higher reaching 20M, and varies considerably between different cell types (Moasser et
al., 2006). The reason for such a higher concentration may rely on the fact that more
than one signalling cascades may be involved in tumour growth inhibition.
Gefitinib demonstrated synergy with etoposide in CRI-G1 and SHP-77 cell lines when
the two drugs were added simultaneously, or when gefitinib preceded etoposide in CRI-
G1 and NCI-H727 cells. Gefitinib also displayed synergy with cisplatin in NCI-H727
cells either when the two drugs were added simultaneously or when gefitinib preceded
cisplatin. This is in agreement with studies on the schedule-dependence of gefitinib and
chemotherapy or radiation, where simultaneous addition or pre-treatment with gefitinib
produced increased tumour growth inhibition ((Magné et al., 2002). Clinical as well as
in vitro studies have previously shown optimal therapeutic effect when chemotherapy
preceded gefitinib which was not shown in this study. The reason for such differences
probably relies on the cell type as well as the dosages, schedules (gefitinib added daily
vs. added once only) and methods used for measurement of tumour growth (Ciardiello
et al., 2000; Sirotnak et al., 2000). Nevertheless, gefitinib can increase the efficacy of
various cytotoxic agents with different mechanisms of action. This co-operation may
not therefore be dependent at the original site of action of each drug but may be
downstream of all drugs’ pathways, at the level of growth control signalling. This
ability of gefitinib to affect the cytotoxicity of various chemotherapeutic agents is
shared by monoclonal antibodies against EGFR, which were shown to  potentiate the
effects of cisplatin or doxorubicin (Baselga et al., 1993; Fan et al., 1993) and by
antisense oligonucleotides  targeting EGFR that showed co-operation with cisplatin,
doxorubicin, paclitaxel and topotecan (Ciardiello et al., 2001a).
Paclitaxel displayed an additive effect with gefitinib in NCI-H727 cells only.
Methotrexate on the other hand, did not synergise or show any additive effect with
gefitinib in any of the cell lines tested, indicating that the mechanism employed by
methotrexate to kill NET cells is probably independent of the EGFR pathway inhibited
by gefitinib. To our knowledge, no synergy between methotrexate and gefitinib has
been demonstrated so far in the literature, confirming that the pathways of the two
drugs may be independent of each other. No synergy or additive effect with any of the
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drugs tested was evident in RIN-5F cells, indicating that EGFR signalling blockade by
gefitinib utilizes a route that does not engage with chemotherapeutic agents at any point
of their cytotoxic pathway.
The same principle applies for all combinations of gefitinib with all four cytotoxic
agents not leading to an additive or synergistic inhibition of proliferation. The anti-
proliferative effect of gefitinib administered with an anti-cancer drug was different for
each cell line. The chemotherapeutic drugs used in our study have well-characterised
and specific mechanisms of DNA damage and ultimately of inhibition of cell growth.
The reason for a synergy seen between an anti-cancer drug and gefitinib in one cell line
but not in another cell line is therefore purely cancer cell type-dependent. Even if the
pathways used by both drugs are the same at the initiation stage where the drug makes
its contact with the cell, proteins downstream their pathways are regulated in different
ways from one cell type to another and probably even more so from one type of cancer
cell to another.
4.3.2 Gefitinib induces apoptosis but no cell cycle arrest in neuroendocrine cells
Gefitinib has demonstrated tumour cell growth inhibition both by arresting cells in the
G1/G0 phase of the cell cycle and by inducing apoptosis in a variety of human cultured
cells (Ciardiello et al., 2000; Hopfner et al., 2003). Hopfner M and co-workers also
postulated that fast growing cells mainly arrested in G1/G0 phase but slow-growing
cells mainly underwent apoptosis when treated with gefitinib (Hopfner et al., 2003).
Based on this, the NET cells used in our study, which are generally slow growing,
would be expected to mainly undergo apoptosis. Using the same dosage with Hopfner’s
published data this phenomenon was demonstrated in all four cell lines. As mentioned
before, CRI-G1 cells show no DNA fragmentation probably because by 72 hours they
are degraded due to apoptotic cell death. Apoptosis is induced at really high
concentrations of gefitinib, which are not specific to EGFR, indicating that other
tyrosine kinase signalling mechanisms may be involved in the gefitinib-induced
apoptosis of neuroendocrine cells. Experiments examining the induction of apoptosis by
gefitinib will be carried out with shorter exposures and concentrations up to 10M of
the drug to these cells. In addition, cell cycle studies showed no cell cycle arrest of NET
cells at 72 hours treatment with gefitinib, but induction of apoptosis in all cell lines,
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which would agree with our results and the results exhibited from by Hopfner and his
co-workers (Hopfner et al., 2003).
Protein tyrosine kinases have been shown to modulate the expression and post-
translational modification of members of the BCL-2 family in order to protect cancer
cells from apoptotic signals. Anti-apoptotic members such as Bcl-xL and Bcl-2 are
stimulated, but proapoptotic members such as Bad and Bax are inhibited (Skorski,
2002). Stimulation of apoptosis by gefitinib has therefore been attributed to inhibition
of anti-apoptotic proteins and induction of pro-apoptotic ones. In a study by Magné et
al. gefitinib induced upregulation of the pro-apoptotic protein Bax and downregulation
of the anti-apoptotic protein Bcl-2 (Magné et al., 2003). Induction of apoptosis by
gefitinib has been proposed to be a general mechanism in sensitising cancer cells to
chemotherapeutic agents. In our study, gefitinib was shown to induce apoptosis but this
did not result in synergy with all cytotoxic drugs used, therefore apoptosis alone cannot
account for the presence of absence of synergy.
4.3.3 Effect of chemotherapeutic agents on EGFR activity
Analysis of the effect of chemotherapeutic drugs on EGFR activity showed activation of
EGFR after 3 or 6 hours of cisplatin treatment in all the NET cell lines, after 3 hours of
incubation with etoposide in CRI-G1 and NCI-H727 cell lines, and after 6 hours of
incubation with paclitaxel in RIN-5F cell line. Activation of EGFR was due to increased
expression and phosphorylation of the receptor. Increased levels of phosphorylated
EGFR in response to cytotoxic drug treatment have also been shown by other groups in
cell lines that express functional EGF receptors (Benhar et al., 2002; Friedmann et al.,
2004). This phenomenon is probably a shock response of the cell to counteract the
cytotoxic effect of the anti-cancer agent. The mechanism involved in upregulation of
EGFR by cisplatin was analysed further for downstream signalling pathways involved.
Activation of EGFR by cisplatin was found to be mediated through the Ras/MAPK and
PI-3K/Akt signalling cascades These signalling cascades have been implicated in a
variety of processes including proliferation, angiogenesis and metastasis of cancer cells
(Carpenter G, 2000; Grant S et al, 2002).Therefore highly toxic amounts of cisplatin
induce EGFR-dependent survival pathways in neuroendocrine tumour cells. The anti-
proliferative effect of gefitinib has been suggested to involve inhibition of PI-3K/Akt,
and this could in part explain the lack of synergy between cisplatin and gefitinib in ¾
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neuroendocrine cells in our study (She et al., 2003; Janmaat et al., 2003).
It is worth noting is that activation of EGFR in the NET cells used is always transient
and not evident in samples treated with the same drug for 6 or 12 hours. In fact by 12 or
24 hours EGFR is downregulated in all cells. This phenomenon indicates that this shock
response lasts up to 3 hours (or up to 6 hours in CRI-G1 cells treated with cisplatin),
after which EGFR signalling is paused along with induction of cell death. Benhar M
showed prolonged EGFR activation for up to 24 hours in transformed NIH3T3 cells that
overexpress EGFR, and this could be because these cells are more drug-resistant than
the ones used in our study (Benhar et al., 2002). Indeed, high levels of EGFR
expression have been found in drug-resistant cell lines (Wosikowski et al., 1997) and
EGFR inhibition can sensitise cells to chemotherapeutic agents. For example, inhibition
of EGFR activation by gefitinib in MCF-7 breast cancer cells led to inhibition of repair
of etoposide-induced DNA damage for more than 24 hours, compared to 4 hours for
complete DNA repair after removal of etoposide. Similar results were obtained with the
repair of cisplatin-induced interstrand cross-links, showing that EGFR activation is
needed for drug-resistance (Friedmann et al., 2004).
Finally, the cytotoxic drugs formed two groups depending on their effect on EGFR
phosphorylation, with methotrexate and paclitaxel mainly causing downregulation of
the receptor, and cisplatin and etoposide mainly causing upregulation of EGFR in a
time-dependent fashion. Methotrexate and paclitaxel are known to induce DNA damage
indirectly by inhibiting DNA synthesis and arresting cells in metaphase respectively,
whereas cisplatin and etoposide promote direct DNA damage in the form of interstrand
cross-links and double DNA strand breaks respectively. This separation indicates that
direct forms of DNA damage such as the mechanisms employed by cisplatin and
etoposide are more toxic to cells and may thus produce the acute response of EGFR
activation, which would explain the fact that this activation is only seen transiently up
to 3 hours post-treatment, but not there after.
4.3.4 Conclusions
This study has shown that sensitivity to chemotherapeutic agents can be enhanced
significantly by inhibition of growth factor pathways such as the EGFR signalling pathway.
In contrast to the preclinical data from other groups and ours, a number of large phase III
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clinical trials in patients with either locally advanced solid tumours or stage IV NSCLC
failed to show any benefit for combined treatment of gefitinib or erlotinib (EGFR tyrosine
kinase inhibitor similar to gefitinib) with cisplatin, carboplatin, gemcitabine or paclitaxel
(Giaccone et al., 2004; Herbst et al., 2004; Gatzemeier et al., 2007; Smith, 2005). The
upregulation of phosphorylated receptor following treatment with chemotherapeutic agents
shown by us and other groups (Benhar et al., 2002) could explain the failure of combination
treatments in clinical trials. Therefore, the investigation of the appropriate agents to be used
in combination, the concentrations the drugs should be added at, and the optimal scheduling
of administration, is vital for the development of suitable therapies in cancer patients.
Furthermore, investigation of the mechanism of interaction between two drugs with
different modes of action may help unravel why certain combinations of drug treatments are
more efficient in promoting cell death than others in human cancer cells, which may help in
the future drug development techniques.
In this study so far, etoposide or cisplatin along with inhibition of EGFR tyrosine kinase
activity by gefitinib have shown promising results, which could help identify a novel
therapeutic modality in neuroendocrine tumour patients. Further advances in EGFR targeted
anti-tumour therapy may follow the full characterisation of EGFR mutations, including the
commonly occurring EGFRvIII deletion mutation, which can determine tumour behaviour
as well as response to anti-EGFR therapy. In particular, a number of mutations have been
discovered, occurring at the region encoding for the ATP binding site of EGFR, which
result in enhanced EGFR activation as well as a higher susceptibility to TKIs (Lynch et al.,
2004; Paez et al., 2004). These mutations however, have been shown not to occur in
neuroendocrine tumours (Gilbert et al., 2005), whereas the role of EGFRvIII in
neuroendocrine tumours has not yet been determined. Whether specific mutations affect
response to a chemotherapeutic agent is still unclear. Although gefitinib has not shown
clinical benefit with the addition of chemotherapy, cetuximab antibody has shown
superadditive effects in chemotherapy-refractory colon cancer (Cunningham et al., 2004).
Cetuximab has been reported to induce sensitisation to chemotherapy through DNA repair
mechanisms, which will be discussed in detail in the next chapter. On the other hand, small
molecule inhibitors of Akt and MAPK are also currently under development. The
demonstration of activated Akt in a majority of NET samples and activated MAPK in
virtually all the NET tissue samples (Shah et al., 2006) signals a promising future for the
role of Akt and MAPK inhibitors in the treatment of NET patients.
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CHAPTER 5
INVESTIGATION OF EFFECTS OF RADIATION AND
EGFR INHIBITORS ON EGFR LOCALISATION IN NET
CELLS
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5.1    Introduction
5.1.1 Cisplatin- and radiation-induced mechanisms of DNA repair
Cisplatin is a widely used chemotherapeutic agent that damages DNA by the formation
of cisplatin-DNA adducts. These adducts are recognised by a number of cellular
proteins, including the DNA damage-recognition factors XPC, hHR23b, MSH2, MSH6
and the high-mobility group protein HMG1 (Wang & Lippard, 2005). Cisplatin-DNA
adducts are subject to repair by several pathways, including nucleotide excision repair,
mismatch repair and homologous recombination. Cisplatin treatment has also been
linked to activation of other repair factors including the DNA-dependent protein kinase
(DNA-PK), a serine/threonine kinase that consists of a 350-kDa catalytic subunit
(DNA-PKCS) and a heterodimeric regulatory complex Ku70/80. DNA-PK is a member
of phosphatidylinositol (PI) 3-kinase superfamily which includes ATM (Ataxia-
telangiectasia mutated) and ATR (Ataxia-telangiectasia and Rad3-related) (Reeves et
al., 1997). DNA-PK is widely known for its participation in the repair of double strand
DNA breaks by the non-homologous end joining (NHEJ) repair pathway. Double
strand DNA breaks can be introduced by external sources such as ionizing radiation, by
chemotherapeutic drugs such as topoisomerase poisons and by normal biological
processes such as V(D)J recombination. DNA-PK has been implicated in both NHEJ
repair pathway and in V(D)J recombination, as mutations in DNA-PKCS cause both x-
ray sensitivity and defective V(D)J recombination (Khanna & Jackson, 2001).
The role of DNA-PK in signalling pathways following DNA damage has been studied
extensively. It has been shown that the Ku70/80 heterodimer can bind to DNA ends at
double-strand breaks and to DNA fragments with cisplatin-DNA adducts (Turchi et al.,
1999). DNA-PKCS is autophosphorylated following exposure to radiation (Ding et al.,
2003; Lou et al., 2004). This modifies its binding with Ku and has been implicated in
the phosphorylation of a wide range of DNA damage/checkpoint proteins (Block et al.,
2004). MDC1, which is generally associated with the regulation of both intra S-phase
and G2/M phase checkpoints, directly binds to DNA-PK via repeat regions and
augments these early auto-phosphorylation events (Lou et al., 2004). DNA-PK has also
been implicated in the phosphorylation of a number of other substrates including c-
ABL, p53, replication factor A and H2AX but as yet there have been no links to
function (Collis et al., 2005). Furthermore, DNA-PK activity has also been shown to be
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regulated by a number of proteins. One such example is the oncogenic tyrosine kinase
c-ABL which phosphorylates DNA-PK thus modulating DNA-PK/Ku/DNA
interactions (Kharbanda et al., 1997).
5.1.2 EGFR is linked to cisplatin- and radio-resistance
Oncogene-transformed cells in vitro are characterised by sensitivity to stress stimuli
such as chemotherapy or radiation. In contrast, cells from advanced tumours often lose
this sensitivity and become resistant to stress-induced apoptosis. To investigate the
mechanism of resistance, the effect of cisplatin was analysed by Benhar et al. who
postulated that transformed mouse embryonic fibroblast NIH-3T3 cells overexpressing
EGFR (DHER14 cells) displayed enhanced sensitivity to cisplatin-induced apoptosis
compared to parental cells. Cisplatin-induced apoptosis was mediated by the induction
of stress kinases including the c-Jun N-terminal kinase (JNK) and the p38 MAPK, and
the associated increased production of reactive oxygen species (ROS). Sensitisation of
EGFR-overexpressing cells to cisplatin through JNK and p38 MAPK was independent
to the overexpressed EGFR (Benhar et al., 2001). In HT29 colon cancer cells, which
derive from a well-differentiated human tumour, these stress kinases are suppressed
indicating that downregulation of JNK and p38 MAPKs may be involved in the
chemoresistance displayed by advanced tumour cells.
On the other hand, cisplatin also induced the activation of downstream effector proteins
ERK1,2 in DHER14 cells and U87MG human glioma transformed cells lines that
overexpress EGFR, and this was found to be mediated by EGFR. The same effect was
produced by other chemotherapeutic agents including doxorubicin and camptothecin,
but not by paclitaxel. In this case though, EGFR activation by cisplatin promoted cell
survival as inhibition of EGFR phosphorylation enhanced the sensitivity of cells to
cisplatin (Benhar et al., 2002). Similar results were obtained using the MCF-7 breast
cancer cells, with cisplatin-induced EGFR activation. In these cells inhibition of EGFR
by gefitinib significantly delayed the repair of cisplatin-induced interstrand cross-links,
enhancing sensitivity of cells to cisplatin (Friedmann et al., 2004). As a result, EGFR
upregulation can be associated to the resistance to DNA-damaging agents.
EGFR has also been linked to radiotherapy resistance. EGFR blockade by cetuximab, a
humanised anti-EGFR antibody, led to increased radiosensitivity of cells and radiation-
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induced apoptosis (Huang & Harari, 2000). Several in vitro and in vivo experiments
with human glioblastoma and head and neck squamous cell cancer xenografts have also
shown an enhancement of tumour response to radiation by cetuximab (Huang et al.,
1999; Eller et al., 2005). The increased sensitivity to radiotherapy induced by
cetuximab may be due to a number of factors including accumulation of cancer cells in
the more radiosensitive cell cycle phases (G1, G2/M), inhibition of radiation-induced
DNA repair mechanisms, and reduction of VEGF which is important for tumour
angiogenesis (Huang & Harari, 2000; Ciardiello & Tortora, 2001). The association of
EGFR to radioresistance was recently proven clinically. A phase III trial in squamous
cell carcinoma of the head and neck (SCCHN) showed that the addition of cetuximab to
radiotherapy improved survival rates and enhanced local control as compared with
radiation alone (Bonner et al., 2006).
Sensitisation to radiotherapy can also be obtained by blocking the signal transduction
downstream of EGFR. Using antisense oligonucleotides to raf-1, or the specific
MEK1/2 inhibitor PD98059 in irradiated human monocytic leukaemia cells
(U937/pREP4) caused a reduced proliferation and increased apoptosis as compared to
single agent treatments (Pirollo et al., 1997; Cartee et al., 2000).
5.1.3 Nuclear EGFR
Further investigation of the radio- or chemoresistance association with EGFR
overexpression was carried out by Dittmann et al. using the A549 human bronchial
carcinoma cells. They showed that cisplatin, hydrogen peroxide, and ionising radiation
induced EGFR phosphorylation (in a ligand-independent manner) and translocation to
the nucleus along with proteins Ku70/80, involved in regulation of DNA-PKCS activity.
Subsequently, complex formation between EGFR and DNA-PKCS was detected in the
nucleus, which was associated with an increase in DNA-PKCS activity (Dittmann et al.,
2005a; Dittmann et al., 2005b). Therefore, in mammalian cells one consequence of
EGFR activation by irradiation is its internalisation and nuclear translocation,
concomitant with nuclear translocation of DNA-PK subunits present in lipid rafts
(Lucero et al., 2003) or cytoplasm. These data suggest modulation of DNA repair by
EGFR possibly via direct activation of DNA- PKCS under stress conditions.
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After exposure to irradiation multiple signalling pathways are activated including
EGFR activation and increased signalling through the Ras/MAPK pathway (Dent et al.,
2003). Thus exposure to irradiation triggers intracellular signalling cascades that
overlap with pathways initiated by ligand binding to EGFR.
5.1.4 EGFR inhibition in DNA repair
It has been demonstrated that cetuximab but not ligand (EGF, TGF-α) treatment
triggers a specific physical interaction between EGFR and DNA-PKCS or its regulatory
heterodimeric complex Ku70/80 in a variety of cell types both in vitro and in vivo
(Bandyopadhyay et al., 1998). Furthermore, it has been shown that the cetuximab-
induced EGFR/DNA-PKCS association was accompanied by a redistribution of DNA-
PKCS from the nucleus to the cytosol, and this caused a decrease in the activity of
nuclear DNA-PK by about 70% with a concomitant increase in the activity of
cytoplasmic DNA-PK (Bandyopadhyay et al., 1998; Huang & Harari, 2000). In
agreement to these studies, Dittmann et al. showed that cetuximab was able to block
radiation-induced EGFR import to the nucleus and activation of DNA-PK. Incubation
with cetuximab for 1 hour prior to irradiation caused the formation of a complex
between EGFR and DNA-PK in the cytoplasm within 10 minutes after irradiation. This
resulted in inhibition of radiation-induced DNA damage repair and sensitization of cells
to radiation (Dittmann et al., 2005a; Dittmann et al., 2005b).
Similar results to cetuximab on EGFR have also been obtained with gefitinib.
Friedmann et al. observed that gefitinib inhibited the repair of DNA damage following
cisplatin and etoposide treatment in cell lines with different EGFR expression levels.
Immunoprecipitation experiments showed an association between EGFR and DNA-
PKCS, which was increased following gefitinib treatment (Friedmann et al., 2004).
Further investigation of the effects of gefitinib on the functional activity of DNA-PKCS
and the interaction between EGFR and DNA-PKCS showed that gefitinib reduced DNA-
PKCS activity in cells expressing high or moderate levels of EGFR. Furthermore,
gefitinib-induced EGFR/ DNA-PKCS association was accompanied by a redistribution
of DNA-PKCS from the nucleus to the cytosol (Friedmann et al., 2006). Figure 46
summarises the events reported in all the above studies in association to EGFR. Based
on the above, molecular blockade of EGFR signalling may influence the ability of
tumour cells to repair DNA lesions effectively after irradiation or cytotoxic damage.
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Aims
The results shown in chapter 4 indicate that synergy between gefitinib and
chemotherapeutic agents in neuroendocrine tumours is possible but appropriate
scheduling of treatments is needed to overcome the upregulation of EGFR signalling
caused by chemotherapeutic agents leading to chemoresistance. Furthermore, targeted
radiotherapy is a major modality of treatment for NET patients with moderate results in
foregut NETs but has no effect in midgut or hindgut NETs. Based on the reported
clinical failure of gefitinib in combination with chemotherapy, and the success of
cetuximab in radiosensitising patients with head and neck squamous cell carcinoma, we
decided to investigate any interaction between radiation treatment and EGFR inhibition
by gefitinib and cetuximab which could be exploited clinically, and to study the
underlying mechanisms. To investigate their interaction, radiation in combination with
EGFR inhibitors were assessed for their collective effect in cell proliferation, EGFR
expression and EGFR localization within the cell.
Figure 46: EGFR pathway in response to radiation or cisplatin-induced DNA damage.
(D-NHEJ: DNAPK-dependent NHEJ; RTKI: receptor tyrosine kinase inhibitors)
Adapted from I Szumiel, Cellular Signalling, 2006
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5.2 Results
5.2.1 Proliferation studies with radiation and EGFR inhibitors
Radiotherapy and EGFR inhibitors (gefitinib and cetuximab) were combined in this
study in order to identify possible synergisms in neuroendocrine tumours. In
proliferation experiments the irradiation dose of 4Gy was used in CRI-G1, RIN-5F and
SHP-77 cells and 30Gy for NCI-H727 cells. These doses cause approximately 30%
inhibition of proliferation as measured by SRB proliferation assays (data not shown).
Administered schedules included:
 Incubation with gefitinib or cetuximab on day1, followed by irradiation on day
2.
 Irradiation on day 1, followed by gefitinib or cetuximab on day 2 (for 24 hours).
o Drugs were added at 0-25M for gefitinib, and at 0-60nM for cetuximab.
o Treatments were followed by 2 days incubation in drug-free media
before analysis.
Growth inhibition was determined by the Sulphorhodamine B (SRB) proliferation
assay. Graphs are shown for CRI-G1 and RIN-5F cells only, with results for the other
cell lines added in the appendix 2A-2B.
As seen in figure 47, gefitinib as a single agent in CRI-G1 cells caused 16% and 60%
inhibition of growth at 10M and 25M respectively, while the doses for cetuximab
(30nM and 60nM) caused 13% and 25% inhibition of proliferation. Irradiation at 4Gy
in CRI-G1 cells combined with gefitinib resulted in increased inhibition of proliferation
by 47% at 10M and 19% at 25M gefitinib. A similar result was obtained in the
combined treatment of radiation and cetuximab, with an increase in inhibition of
growth by 49% at 30nM cetuximab, which stays at 45% with 60nM. Therefore,
radiation effects on proliferation are increased by EGFR inhibition.
In RIN-5F cells (figure 48) gefitinib caused 22% and 35% inhibition of growth at
10M and 25M respectively, while cetuximab at 30nM and 60nM caused 20% and
23% inhibition of proliferation. Combination treatments between radiation and EGFR
inhibitors led to a lesser increase in inhibition of proliferation by 18% and 22% with
gefitinib or by 22% and 20% with cetuximab. No differences were observed between
the two different sequences of administration as shown in figures 47-48.
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The combination treatments of radiation with gefitinib in CRI-G1 and RIN-5F cells
were examined for synergistic or additive effect by isobologram analysis as shown in
figure 49.  Even though isobologram analysis is used to study combinations of two
drugs rather than combinations of drugs with radiotherapy, we used them as a basis for
analysing our results. In RIN-5F cells the point of combination appears very close to
the additivity line, indicating an additive effect, while CRI-G1 cells show the point of
combination below the additivity line, and therefore demonstrate synergy of gefitinib
with radiation.
Figure 47: Growth inhibition SRB assay.  CRI-G1 cells were treated with radiation at
4Gy on day 1 and gefitinib or cetuximab at the indicated concentrations on day 2, or in
reverse order, followed by 48 hours in drug free medium. Proliferation was calculated
as a % of control untreated cells. Data represents the averages of three different
experiments, each performed in triplicate; bars, SD.
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Figure 48: Growth inhibition SRB assay.  RIN-5F cells were treated with radiation at
4Gy on day 1 and gefitinib or cetuximab at the indicated concentrations on day 2, or in
reverse order, followed by 48 hours in drug free medium. Proliferation was calculated
as a % of control untreated cells. Data represents the averages of three different
experiments, each performed in triplicate; bars, SD.
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Figure 49: Isobologram analysis for combination treatment of radiation and gefitinib in
CRI-G1 and RIN-5F cells. Cells were treated with radiation (4Gy) on day 1, followed
by gefitinib on day 2 or in reverse order, followed by 48 hours in drug free medium.
Red line is additivity line connecting the IC50s ( ) of the two drugs. Combined treatment
IC50s ( ) of radiation and gefitinib together.
5.2.2 DNA repair modulation by EGFR inhibitors
To further investigate the interaction between radiotherapy and EGFR inhibitors, we
analysed their effect on DNA repair using the Single Cell Gel Electrophoresis
(COMET) Assay. The comet assay allows for detection and visualisation of DNA
damage within individual cells. As an example, figure 50 shows screen images of
individual CRI-G1 cells after irradiation treatment alone. Irradiation produces DNA
strand breaks causing the DNA to migrate further on an agarose gel than undamaged
DNA. This forms a tail moment which is a function of the amount of DNA in the tail
Radiation (4Gy)
and gefitinib
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and the length of the tail (measured in µmeters). Within 10 minutes after irradiation
treatment, the strand breaks start to be repaired as measured by a shortened tail moment
(bottom left-hand panel). After 80 minutes, almost complete repair is achieved with
very low detectable tail moment (bottom right-hand panel). For analysis, the average
tail moment of 50 individual cells is calculated from two independent slides and plotted
for each time point.
Figure 50: Sample screen display of comet images for irradiation (15Gy) induced
damage and repair after 10 and 80 minutes in CRI-G1 cells. Images were viewed using
an inverted fluorescence microscope and analysed using the Komet Analysis Software.
Radiation-induced DNA damage in the form of double DNA strand breaks is repaired
within approximately 2 hours (figures 47-48). As a result, for our combined studies,
treatment with EGFR inhibitors preceded radiation treatment. Gefitinib and cetuximab
were added (at the low doses of 10M and 30nM respectively, causing no more than
10% growth inhibition at 3 hours) for 3 hours followed by irradiation treatment in order
CRI-G1 unirradiated CRI-G1 irradiated at 15Gy t=0 mins
CRI-G1 irradiated at 15Gy t=10mins CRI-G1 irradiated at 15Gy t=80mins
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to assess the effect of acute drug treatment in DNA repair. Furthermore, for accurate
analysis of DNA repair kinetics, significant DNA damage must be induced. The
radiation dose of 15Gy produces an adequate amount of DNA damage (producing a tail
moment of approximately 16 in the CRI-G1 cell line and 13 in the RIN-5F cell line),
which is needed for accurate analysis of DNA repair kinetics. This dose was used for
all cells except for NCI-H727 cells which were radiated at 30Gy. The doses were
calculated following a titration of radiation treatments in all cell lines (data not shown).
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Figure 51: Measurement of irradiation-induced DNA strand breaks and their repair in
CRI-G1 cells. Strand break formation quantitated as tail moment, plotted against time
after irradiation. Cells were treated with gefitinib at 10M or cetuximab at 30nM for 3
hours, drug was removed, and then cells were irradiated at 15 Gy and incubated for up
to 120 minutes at 37oC. Data represents the averages of three different experiments,
each performed in triplicate; bars, SD.
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As shown in figures 51 and 52, following treatment with radiation alone the repair of
strand breaks is complete at 120 minutes in both cell lines. The repair of strand breaks
starts almost immediately with a 28% decrease in tail moment at 10 minutes post-
treatment and 67% repair at 40 minutes post radiation in CRI-G1 cells. A similar result
is seen in RIN-5F cells which exhibit a 27% and a 62% decrease in tail moment at 10
and 40 minutes after radiation treatment respectively. Incubation of cells with 10M
gefitinib for 3 hours before radiation resulted in delayed repair of strand breaks in the
CRI-G1 cell line (figure 51) by 42% at 40 minutes post radiation and 31% at 120
minutes post radiation.
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Figure 52: Measurement of irradiation-induced DNA strand breaks and their repair in
RIN-5F cells. Strand break formation quantitated as tail moment, plotted against time
after irradiation. Cells were treated with gefitinib at 10M or cetuximab at 30nM for 3
hours, drug was removed, and then cells were irradiated at 15 Gy and incubated for up
to 120 minutes at 37oC. Data represents the averages of three different experiments,
each performed in triplicate; bars, SD.
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Inhibition of DNA repair was also found in SHP-77 and NCI-H727 cells (appendix 2C-
2D). In contrast, gefitinib treatment in the RIN-5F cell line had no effect on the kinetics
of DNA repair. In the CRI-G1 cell line inhibition of DNA repair was found following
treatment with cetuximab with a 27% difference in tail moment at 40 minutes after
radiation, which falls at 11% at 120 minutes. However in the RIN-5F cell line, as with
gefitinib, treatment with cetuximab had no effect on repair of radiation-induced DNA
damage.
5.2.3 Radiation induces EGFR phosphorylation and translocation to the nucleus
Recent reports have associated gefitinib or cetuximab with DNA repair enzyme  DNA-
PKCS (Benhar et al., 2002; Dittmann et al., 2005; Friedmann et al., 2006), via
inhibition of radiation-induced activation and translocation of EGFR to the nucleus.
Based on these reports and our results on DNA repair inhibition by gefitinib and
cetuximab, we decided to investigate whether ionising radiation has such an effect on
EGFR activity and localization in neuroendocrine tumour cells.
For this, cells were irradiated at 4Gy apart from NCI-H727 cells, for which the dose of
30Gy was applied as in the proliferation studies. Expression of EGFR was analysed by
immunoblotting at 5 and 20 minutes after treatment. After irradiation treatment and
incubation at 37oC for 5 or 20 minutes, nuclear and cytosolic fractions were isolated
and immunoblotted for P-EGFR. In addition to the use of -tubulin as a loading
control, blots were stripped and re-probed for lamin 1. Lamin 1 interacts with
nuclear membrane components and nuclear chromatin and is a commonly used as a
loading control for nuclear proteins (Dittmann et al., 2005). The amounts of
phosphorylated EGFR were calculated by densitometry analysis of the bands.
As shown in figures 53-54, basal expression of EGFR was detectable in the nucleus of
all cells although expression was predominantly cytoplasmic. Within 5 minutes after
irradiation treatment, increased EGFR was detectable in the nucleus, and this persists at
20 minutes post-irradiation. This occurs in all cell lines except the RIN-5F cells, where,
nuclear EGFR levels show no significant change. In the cytosolic fractions, EGFR is
decreased in the 3 cell lines showing increase in nuclear EGFR, while RIN-5F cells
show a slight increase in cytosolic EGFR.
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Figure 53: CRI-G1 and SHP-77 cells were irradiated (4Gy) and incubated for up to 20
minutes at 37oC. Cytosolic and nuclear extracts were immunoblotted for P-EGFR.
Alpha-tubulin was used as a loading control. Lamin 1 was used as a nuclear marker.
Amounts of P-EGFR in percentages were determined by densitometry analysis.
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Figure 54: RIN-5F and NCI-H727 cells were irradiated at 4Gy and 30Gy
respectively and incubated for up to 20 minutes at 37oC. Cytosolic and nuclear
extracts were immunoblotted for P-EGFR and EGFR. Alpha-tubulin was used as a
loading control. Lamin 1 was used as a nuclear marker.
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Figure 55: CRI-G1, SHP-77, and RIN-5F cells were irradiated at 4 Gy, and NCI-H727
cells were irradiated at 30 Gy, followed by incubation at 37oC for 5 minutes. Cells were
then fixed and stained for EGFR (green) using a fluorescein isothiocyanate (FITC)
conjugated antibody and nucleus was stained with propidium iodide (red).
IrradiatedNCI-H727 untreated
SHP-77 untreated
CRI-G1 untreated Irradiated
Irradiated
IrradiatedRIN-5F untreated
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The observed translocation of EGFR by irradiation was further validated by
immunofluorescent staining using a confocal microscope (figure 55). Cells were
irradiated as before and the presence of EGFR was identified using a FITC-labelled
antibody. Propidium iodide was used for nuclear counter staining and is shown in red.
EGFR in untreated cells is present in the cytoplasm (shown in green). However, within
5 minutes after irradiation treatment EGFR is redistributed to the nucleus in NCI-H727,
CRI-G1 and SHP-77 cells but not in RIN-5F cells.
5.2.4 Gefitinib or Cetuximab inhibits radiation-induced EGFR nuclear
translocation
To examine whether EGFR inhibitors could prevent radiation-induced EGFR activation
and shift to the nucleus, we treated cells with gefitinib at 10M and cetuximab at 30nM
for 3 hours before irradiation, and detected EGFR by immunofluorescent staining. As
shown in figures 56-59, gefitinib and cetuximab abrogated radiation-induced EGFR
import to the nucleus in cells pre-treated with the above agents prior to irradiation.
Since In RIN-5F cells with no EGFR nuclear translocation, treatment with EGFR
inhibitors had no effect on EGFR locality within the cells, but nevertheless inhibited
activation of the receptor.
Furthermore, gefitinib in unirradiated cells (bottom left pictures) caused a decrease in
EGFR activation in all cell lines. Cetuximab alone (middle left pictures) caused
downregulation of the receptor in all cells except NCI-H727 cells, which might be more
resistant to cetuximab compared to the other cell lines. Interestingly, in RIN-5F cells
incubation with gefitinib or cetuximab alone, not only inhibited EGFR phosphorylation,
but also caused an assembly of EGFR molecules in the perinuclear region (figure 59).
5.2.4.1   Electron microscopy analysis
It has been suggested that nuclear EGFR identified by confocal microscopy may be
contaminated by EGFR present in the endoplasmatic reticulum, which is closely
attached to the nuclear membrane. To investigate this hypothesis, radiation-induced
EGFR import to the nucleus was also analysed by electron microscopy using ultrathin
sections of CRI-G1 and RIN-5F cells and labelling EGFR with 15nm gold particles
(figures 60-61).
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Figure 56: CRI-G1 cells were treated with gefitinib at 10M or cetuximab at 30nM for
3 hours followed by irradiation at 4Gy and incubation at 37oC for 5 minutes. Cells were
then fixed and stained for EGFR (green) and nucleus was stained with propidium iodide
(red).
CRI-G1 untreated +irradiation
+cetuximab
+gefitinib
CRI-G1 untreated +irradiation
+cetuximab/radiation
+gefitinib/radiation
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Figure 57: NCI-H727 cells were treated with gefitinib at 10M or cetuximab at 30nM
for 3 hours followed by irradiation at 4 Gy and incubation at 37oC for 5 minutes. Cells
were then fixed and stained for EGFR (green) and nucleus was stained with propidium
iodide (red).
+irradiationNCI-H727 untreated
+cetuximab
+gefitinib
+cetuximab/radiation
+gefitinib/radiation
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Figure 58: SHP-77 cells were treated with gefitinib at 10M or cetuximab at 30nM for
3 hours followed by irradiation at 4 Gy and incubation at 37oC for 5 minutes. Cells were
then fixed and stained for EGFR (green) and nucleus was stained with propidium iodide
(red).
+gefitinib
SHP-77 untreated +irradiation
+cetuximab/radiation
+gefitinib/radiation
+ cetuximab
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Figure 59: RIN-5F cells were treated with gefitinib at 10M or cetuximab at 30nM for
3 hours followed by irradiation at 4Gy and incubation at 37oC for 5 minutes. Cells were
then fixed and stained for EGFR (green) and nucleus was stained with propidium iodide
(red).
RIN-5F untreated +irradiationRIN-5F untreated +irradiation
+cetuximab
+gefitinib
+cetuximab/radiation
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Figure 60: EGFR nuclear import in CRI-G1 cells (left panels) and RIN-5F cells
(right panels). Cells were prepared for cryo-immuno-EM 5 min after exposure to
10M gefitinib for 3 hours and irradiation at 4Gy. Ultrathin sections were labelled
for EGFR with 15nm gold (arrows). Panel A: control unirradiated cells. Panel B:
irradiated cells and Panel C: gefitinib + irradiation.  EGFR nuclear labelling (large
arrows) and non-nuclear staining (small arrows). Data provided by Emily Eden,
UCL Institute of Ophthalmology, London, UK.
B.
A.
C.
B.
A.
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Staining of samples and viewing of images was performed by Emily Eden, UCL
Institute of Ophthalmology, London, UK. The graph in figure 61 shows that while
treatment with x-ray radiation had no effect on the ratio of nuclear to non-nuclear EGFR
labelling in RIN-5F cells, irradiation in CRI-G1 cells increased the amounts of nuclear
EGFR, making the ratio of nuclear/non-nuclear EGFR increase by a factor of 5 (control
cell ratio=0.46 to irradiated cell ratio=2.28).  This effect was blocked by treatment with
gefitinib, which returned the ratio to control levels (gefitinib-treated and irradiated cell
ratio=0.48).
Figure 61: Effect of x-ray radiation on EGFR distribution.  EGFR distribution was
quantified by cryo-immuno-EM. Non-nuclear (solid bars) and nuclear (striped bars)
EGFR staining is expressed as mean (n=10 cells) numbers of gold particles per m2.
Con, control cells; x-ray, cells exposed to 4Gy radiation; x-ray + gefitinib, gefitinib-
treated and irradiated cells. Data provided by Emily Eden, UCL Institute of
Ophthalmology, London, UK.
5.2.5 Cisplatin induces EGFR nuclear translocation
In chapter 4, treatment with cisplatin in neuroendocrine tumour cells induced activation
of EGFR, which was associated with activation of growth promoting signalling
pathways. To see whether cisplatin (CDDP) had the same effect on EGFR as radiation,
we treated cells with cisplatin at 5M for 5 or 20 minutes (figures 62-63). The
experiment was initially performed using 50M cisplatin, which showed similar results
(data not shown).
CRI con RIN conCRI x-ray CRI x-ray
+ Iressa
RIN x-ray
EG
FR
 lab
elli
ng
(go
ld/
m
2 )
0
1
2
3
4
5
6
7
Non-nuclear
labelNuclear
label
162
EGFR in untreated control cells is mainly detected in the cytoplasm, with small
amounts also present in the nucleus. Cisplatin treatment even at 5M induces activation
and redistribution of EGFR from the cytoplasm to the nucleus within 5 minutes after
treatment in all cells except RIN-5F cells, as with irradiation experiments.
NCI-H727
CRI-G1
Figure 62: NCI-H727 cells (top panel) and CRI-G1 cells (bottom) were treated with
5M cisplatin for 5 or 20 minutes. Cytosolic and nuclear extracts were isolated and
immunoblotted for P-EGFR. Alpha-tubulin was used as a loading control. Lamin 1
was used as a nuclear marker. Levels of P-EGFR were measured by densitometry.
At 20 minutes post-treatment cisplatin-induced activation persists in NCI-H727 and
CRI-G1, but in SHP-77 the levels of nuclear EGFR fall back to control levels.
Cytosolic EGFR expression is decreased in CRI-G1, NCI-H727, and SHP-77 cells,
while RIN-5F cells show activated EGFR, which remains in the cytoplasm.
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SHP-77
RIN-5F
Figure 63: SHP-77 cells (top panel) and RIN-5F cells (bottom) were treated with 5M
cisplatin for 5 or 20 minutes. Cytosolic and nuclear extracts were isolated and
immunoblotted for P-EGFR. Alpha-tubulin was used as a loading control. Lamin 1
was used as a nuclear marker. Levels of P-EGFR were measured by densitometry.
5.2.6 EGFR inhibition and DNA-PKCS expression
Cytosolic translocation of DNA-PKCS following inhibition of EGFR by gefitinib or
cetuximab has been reported by many groups (Bandyopadhyay et al., 1998; Huang &
Harari, 2000; Friedmann et al., 2006). To see if translocation of EGFR is associated
with DNA-PKCS redistribution to the cytosol, we treated cells with gefitinib at 10M
for 3 hours alone or followed by irradiation and analysed DNA-PKCS expression by
immunofluorescent staining (figure 64).
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Figure 64: Cells were left untreated or incubated with 10M gefitinib for 3 hours. Cells
were then fixed and stained for EGFR (green) and nucleus was stained with propidium
iodide (red or blue).
BON-1 untreated +gefitinib
SHP-77 untreated +gefitinib
NCI-H727 untreated +gefitinib
+gefitinibRIN-5F untreated
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DNA-PKCS in untreated cells is detected in the nucleus. Treatment with gefitinib caused
a redistribution of DNA-PKCS from the nucleus to the cytosol in BON-1 cells and to
less extent in SHP-77 cells. Gefitinib did not modify DNA-PKCS expression in RIN-5F
cells. In NCI-H727 there was no sub-cellular redistribution of DNA-PKCS but a
decrease in expression levels was identified.
5.3 Discussion
In the previous chapter, synergy between gefitinib and cisplatin was demonstrated in
neuroendocrine cell lines. In addition, cisplatin induced activation of EGFR which lead
to activation of cell survival pathways, and this could explain the lack of synergy
between gefitinib and chemotherapeutic agents in improving survival of patients in
clinical trials. This chapter examines the use of radiation combined with EGFR
inhibitors as a novel therapeutic strategy for neuroendocrine tumour patients, based on
previous reports of cetuximab and radiotherapy combined effect in prolonging survival
and enhancing local control in patients with head and neck squamous cell carcinoma.
5.3.1 Anti-proliferative effect of EGFR inhibitors and radiation
Combined treatments with radiation and EGFR inhibitors demonstrated synergy in
inhibition of proliferation in CRI-G1, NCI-H727 and SHP-77 cells (NCI-H727 and
SHP-77 cells shown in the appendix 2A-2B). Inhibition of proliferation was increased
by 40-50%, showing that EGFR inhibitors sensitise cells to radiotherapy as shown by
other groups (Huang et al., 1999; Eller et al., 2005). RIN-5F cells showed an additive
effect with a moderate 20% increase of the anti-tumour activity of EGFR inhibitors by
radiotherapy. The dose of irradiation used (4Gy) causes approximately 20% inhibition
of proliferation in both CRI-G1 and RIN-5F cell lines, therefore the differences
observed are probably due to gefitinib or cetuximab, and consequently due to EGFR
and its signalling in RIN-5F cells.
5.3.2 Synergy between EGFR inhibitors and radiation in DNA repair
Synergy between EGFR inhibition and ionising radiation has been correlated to
impediment of DNA repair (Huang & Harari, 2000; Dittmann et al., 2005b). To
understand the mechanism underlying synergism, we investigated radiation and EGFR
inhibition dual treatment for any effect in DNA repair. As in proliferation studies,
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synergy in DNA repair kinetics was shown in CRI-G1, NCI-H727, and SHP-77 cells.
Gefitinib and cetuximab both caused a delay in repair of radiation-induced DNA strand
breaks indicating interference of EGFR in DNA repair mechanisms. Radiation-induced
strand breaks are repaired by the NHEJ pathway, therefore the results indicate that
synergism between gefitinib or cetuximab and radiotherapy is due to modulation of
NHEJ, and this is a novel role of EGFR in response to stress stimuli.
No delay in DNA repair was observed in RIN-5F cells treated with EGFR inhibitors,
which agrees with the lack of synergy found between radiation and EGFR inhibition in
the proliferation assay. This is not the first time a lack of synergy is displayed in RIN-
5F cells as this was the only cell line where EGFR inhibitors did not increase the
cytotoxicity of four different chemotherapeutic agents tested, which was shown in
chapter 4. It seems that the EGFR pathway in RIN-5F cells, which were also the most
resistant to gefitinib (with an IC50 of 32M) as seen in chapter 4, is probably of minor
consequence to the growth of these cells but also the EGFR pathway is likely
independent to the pathways utilized by stress stimuli such as radiation or the
chemotherapeutic agents analysed in our study. To understand why EGFR inhibition
may affect the radiosensitivity of one cell line but not another, we analysed the effect of
radiation on EGFR activity, based on results published by other groups discussed in the
next section.
5.3.3 Radiation-induced nuclear EGFR translocation
EGFR is responsive to irradiation and this has been shown to result in translocation of
the molecule into the nucleus (Dittmann et al., 2005b). Entry of EGFR into the nucleus
in cells exposed to genotoxic stress such as irradiation or cisplatin is done in a ligand-
independent manner. On the other hand activation of EGFR by its ligand EGF, results
in phosphorylation of the receptor but without entry into the nucleus (Dittmann et al.,
2005a). Nuclear EGFR has also been detected in various tissues and cell lines with a
different role, that of a transcription factor, which will be discussed in detail in the next
chapter (Lin et al., 2001). We have clearly shown that after 5 minutes of irradiation
treatment at 4 Gy (or 30Gy in NCI-H727 cells) EGFR enters the nucleus of ¾ NET
cells except in RIN-5F cells. This was shown by three methods: immunoblotting,
immunofluorescent staining, and visualization of cells with the help of electron
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microscopy. The EGFR entering the nucleus is phosphorylated as shown by
immunoblotting, and the increase in total EGFR demonstrated by immunofluorescent
staining is accompanied by activation of the receptor. These results may explain the
association of EGFR with DNA repair reported previously. Furthermore, it accounts for
the absence of delay in repair of radiation-induced strand breaks by gefitinib and
cetuximab in RIN-5F cells. Therefore, in RIN-5F cells EGFR does not enter the
nucleus in response to radiation and there are probably other mechanisms activated.
Different mechanisms can therefore be evoked by stress stimuli, which reflect cell type
specific differences that could form a future step in our study.
5.3.4 Nuclear EGFR translocation is blocked by EGFR inhibitors
EGFR nuclear entry was completely abrogated by gefitinib and cetuximab in CRI-G1,
NCI-H727 and SHP-77 cells, whereas in RIN-5F cells, in which EGFR does not enter
the nucleus, gefitinib as a single agent stimulated gathering of EGFR in the area around
the nucleus. This is a phenomenon not demonstrated before and it is unclear why it
happens. Inhibition of EGFR nuclear import by cetuximab indicates that EGFR
transferred to the nucleus comes from the plasma membrane of cells where the antibody
binds to the extracellular portion of EGFR, and not from cytoplasmic sites of EGFR
synthesis such as ribosomes of the endoplasmic reticulum. One of the events following
irradiation is activation of the intracellular Ras/MAPK signalling pathway which is
traditionally initiated by ligand binding to EGFR (Dent et al., 2003). To examine the
relation between signalling initiated by EGFR and double strand break (DSB) repair
after exposure to ionising radiation Grądzka et al. examined the effect of PD98059,  a
specific inhibitor or MEK1/2 kinases, on two glioma cell lines: M059K and M059J.
M059J cells are deficient in DNA-PKcs and are more sensitive to radiation than the
M059K cells. PD98059 did not significantly affect the rate of DSB repair in both cell
lines, indicating that DNA repair targeted signals initiated by EGFR activation after
irradiation are not transduced to the nucleus by means of the EGFR kinase cascade but
by internalisation and nuclear translocation of EGFR (Szumiel, 2006, reference
therein). Examination of this hypothesis could form the next step in our research.
5.3.5 Effect of EGFR inhibitors on DNA-PK
Blockade of EGFR has been shown to cause redistribution of DNA-PKCS from the
nucleus to the cytosol (Huang & Harari, 2000; Dittmann et al., 2005b; Friedmann et al.,
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2006). This phenomenon was not proven in NET cells. Radiation did not increase
DNA-PK expression, and co-treatment with gefitinib did not stimulate exit of DNA-PK
amounts from the nucleus. Gefitinib alone caused a redistribution of DNA-PK in BON-
1 cells, a human pancreatic endocrine tumour. These cells were then analysed for
radiation-induced EGFR import and synergy with radiotherapy and EGFR inhibitors
showing results similar to CRI-G1 cells (data not shown). Gefitinib also caused
downregulation of DNA-PK in NCI-H727 cells, but this was not associated with DNA-
PK subcellular redistribution. Therefore association of EGFR with gefitinib might
actually exist in our cells but could not be proven under the conditions used. Our results
though, provoked the hypothesis that nuclear EGFR in NET cells might also have a
different role such as that of a transcription factor, which has been reported previously
(Lin et al., 2001). These experiments will be discussed in the next chapter.
5.3.6 Cisplatin-induced EGFR nuclear translocation
Cisplatin was also tested for its effect on translocation of EGFR based on results from
chapter 4 showing phosphorylation of EGFR by cisplatin. In our study cisplatin, like
radiation, induced activation and translocation of EGFR to the nucleus in ¾ NET cell
lines, as shown previously by others (Dittmann et al., 2005; Friedmann et al., 2006).
Since both cisplatin and radiation stimulate entry of EGFR into the nucleus, it is not
double strand breaks that generate this response, but DNA damage in general. In fact,
production of radicals such as reactive oxygen species may have a role since addition of
the radical scavenger acetylcysteine was able to abrogate the radiation-induced EGFR
translocation (Dittmann et al., 2005a; Dittmann et al., 2005b).
The role of DNA-PKCS in repair of DNA crosslinks produced by cisplatin is unclear,
but cellular sensitisation to cisplatin has been related to DNA-PK inhibition by vanillin.
Vanillin, a natural plant-derived compound, inhibited DNA-PK activity via interaction
with specific lysine residues in the active site of the enzyme and was shown to be
specific to NHEJ and selective for DNA-PKCS over other members of the family of
phosphatidylinositol-3 kinase-related kinases (PIKK) such as ATM and ATR (Durant
& Karran, 2003). In RIN-5F cells cisplatin stimulated EGFR phosphorylation, but this
did not result in EGFR transport to the nucleus. A possible explanation could be that
EGFR upregulation by cisplatin in these cells leads to transient activation of EGFR-
dependent cell survival pathways, but this does not include activation of DNA repair
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mechanisms or any other nuclear function by the receptor due to impaired mechanisms
for nuclear transport or mutations in the receptor hindering its nuclear transport, which
could be a future step in our study.
5.3.7 Conclusions
Nuclear EGFR, a phenomenon provoked by cytotoxic drugs or ionising radiation is a
protection mechanism that enhances DNA repair. The discovery of the described
mechanism opens a renewed perspective on factors affecting the intrinsic radiation
sensitivity of mammalian cells. In concert with the initiation of signalling pathways and
EGFR internalisation, nuclear translocation of DSB repair proteins (Ku 70/80 subunits)
from the cytoplasmic stores takes place; therefore agents that disturb trafficking of
EGFR can be expected to act as radiosensitisers. Efficiency of such defence may vary
between cell types, depending on the status of EGFR, on how many supplementary
DNA-PK subunits are stored for use under stress conditions, to what extent does the
cell rely on NHEJ for DSB repair (this also depends on position in the cell cycle) and
how effective is the translocation machinery. Our study proved that anti-EGFR therapy
can block translocation of EGFR to the nucleus and sensitise neuroendocrine tumour
cells to radiotherapy. These results provide a rationale for EGFR inhibition in
combination with radiotherapy for the treatment of neuroendocrine tumours.
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CHAPTER 6
CHARACTERISATION OF NUCLEAR EGFR IMPORT
MECHANISM AND NUCLEAR TARGETS IN NET
CELLS
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6.1 Introduction
6.1.1 Nuclear EGFR function
In the previous chapter results provided evidence for a new mode of action of EGFR in
response to radiation and cisplatin that involves nuclear translocation and modulation of
DNA repair, via interaction with DNA repair genes which could include DNA-PKCS.
Gefitinib and cetuximab both blocked this nuclear translocation, causing a delay in the
repair of radiation-induced DNA damage. This mechanism is different from EGFR’s
well characterised signalling pathway that mediates mitogenic signals through multiple
signalling pathways. However, nuclear EGFR and its ligands have long before been
identified in cancer cell lines, the human placenta and in regenerating liver, but its
function was unknown (Lin et al., 2001). Additionally, EGFR is not the only receptor
tyrosine kinase with nuclear activity. Other kinases including HER-2, HER-3, truncated
C-terminal HER-4, fibroblast growth factor receptor and cytokine receptors have also
been identified in the nucleus of cells, and their nuclear expression has been linked to
enhanced tumour proliferation and progression (Lo & Hung, 2006). Recently,
expression of nuclear EGFR in breast cancer was shown to correlate positively with
increased levels of Ki-67, showing an inverse correlation between high nuclear EGFR
and overall survival. Nuclear EGFR therefore has a prognostic value in breast cancer
(Lo et al., 2005a).
Another role of nuclear EGFR, identified recently, involves regulation of gene
expression by transcriptional activation. Figure 65 summarises reported cytoplasmic
and nuclear EGFR signalling pathways. Nuclear entry of EGFR functioning as a
transcription factor involves translocation of the receptor in a ligand–dependent fashion.
EGFR was shown to activate gene transcription by binding indirectly through its C-
terminal transactivation domain (involving formation of an EGFR complex) to the
promoter of cyclin D1 leading to its increased expression (Lin et al., 2001).
Furthermore, nuclear EGFR was shown to interact with signal transducers and
activators of transcription 3 (STAT3) on the promoter of inducible nitric oxide synthase
(iNOS), or with E2F1 transcription factor on the promoter of B-Myb, leading to their
transcriptional activation (Lo et al., 2005b; Hanada et al., 2006). All the above genes
are frequently overexpressed in human cancers; upregulation of cyclin D1 and B-Myb is
involved in increased cell proliferation by accelerating the G1/S phase progression,
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while elevated iNOS is associated with tumour proliferation, angiogenesis, and
metastasis (Lo & Hung, 2006). Inducible NOS expression has also been found to be a
powerful prognostic indicator in breast cancer and this correlates with nuclear
expression of EGFR (Lo et al., 2005b).
Figure 65: The EGFR cytoplasmic and nuclear signalling pathways.
Source: H-W Lo & MC Hung, British Journal of Cancer, 2006
However, EGFR’s transcriptional activity is not independent to DNA repair as shown
by us and other groups (Huang & Harari, 2000; Dittmann et al., 2005). Nitric oxide
synthase (NOS) activity has been detected in many human tumours and has been shown
to significantly increase expression of DNA-PKCS thus protecting cells from the toxic
effects of NO and DNA-damaging agents such as cisplatin and radiation (Xu et al.,
2000). On the other hand, EGFR interaction with STAT3 in the nucleus was shown to
lead to transcriptional activation of iNOS, thus providing another link between EGFR
and DNA repair following cisplatin and irradiation treatment (Lo et al., 2005b; Xu et
al., 2000). Therefore EGFR inhibition could result in inhibition of the DNA-PK
pathway and subsequently of DNA repair both by physical association with DNA-PKCS
and by transcriptional activation of iNOS.
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6.1.2   Mechanisms of EGFR nuclear translocation
Further investigation of the radiation-induced EGFR nuclear import led to the analysis
of the molecular mechanisms underlying this event. EGFR at the plasma membrane is
known to be localised with caveolin-1 in lipid rafts and caveolae (Pike, 2005). Lipid
rafts are specialised membrane microdomains enriched in sphingolipids and cholesterol
that integrate proteins participating in endocytosis, cholesterol traffic and signal
transduction from receptors. After stimulation by a specific ligand, EGFR is rapidly
internalised into clathrin-coated pits and the signalling continues from the early
endosomes (Miaczynska et al., 2004). EGFR may then either be recycled back to the
cell surface from the early endosomes, or become polyubiquitinated and degraded in
late endosomes fused with lysosomes (Le Roy & Wrana, 2005). Additionally, EGF-
dependent nuclear translocation of EGFR may occur (Lo & Hung, 2006).
The fate of EGFR is different after ligand-independent activation. Phosphorylation of
EGFR is increased at tyrosine 845 and abrogated at tyrosine 1045; the latter is the
docking site for the ubiquitin ligase, c-Cbl. Thus, EGFR is unable to recruit c-Cbl and
be ubiquitinated and degraded (Ravid et al., 2002). Internalisation however was shown
to take place under oxidative stress when caveolin-1 is phosphorylated at tyrosine 14 by
c-Src kinase. In this case EGFR remains complexed with caveolin-1 and is moved to a
perinuclear compartment (Khan et al., 2006).  It seems possible that the same chain of
events takes place after exposure to ionising radiation and it precedes the transport of
EGFR into the nucleus. Dittmann et al. showed that treatment with 20mM -methyl
cyclodextrin, which inhibits the well documented EGFR internalisation from the cell
surface by clathrin-coated pits, had no effect on EGFR nuclear transport suggesting that
nuclear EGFR may originate mainly from the perinuclear region and not only the cell
surface (Dittmann et al., 2005a), which agrees with the results obtained from our study
with confocal microscopy (see figure 83), where EGFR was not specifically localised to
the cell membrane in control untreated cells.
This assumption was supported by a recent observation that Src tyrosine kinase
inhibitor (PP2) suppresses ERK1/2 activation and EGFR transactivation by irradiation
(Li et al., 2006). Figure 66 summarises the fate of EGFR after ligand-dependent or
independent activation, as described in recent reports. Since clathrin-dependent
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internalisation also involves EGFR molecules from lipid rafts (Puri et al., 2005) and
there may be a relation between early endosomes and caveosomes (Helms & Zurzolo,
2004), these two scenarios may not be necessarily exclusive.
Figure 66: The fate of EGFR after ligand dependent or independent activation.
Source: I Szumiel, Cellular Signalling, 2006
An arginine rich putative nuclear localisation signal (NLS) sequence was identified in
amino acids 645-657 of the EGFR’s juxtamembrane region. The EGFR putative NLS
contains a polypeptide sequence with three clusters of basic amino acids, and is
conserved among the EGFR family members (Lin et al., 2001; Hsu & Hung, 2007).
Fusing -galactosidase to this polypeptide led to its nuclear translocation through the
nuclear pore. Thus EGFR nuclear entry could be through the conventional nuclear
importing system, an energy dependent system that is associated with the nuclear pore
complex (ImportinRan pathway3) (Lin et al., 2001). Indeed, two separate studies have
3 Classical NLS-protein importation begins with importin  first binding to the NLS sequence, and acts
as a bridge for importin  to attach. The importin  -importin  - cargo complex is then directed towards
the nuclear pore and diffuses through it. In the nucleus, RanGTP binds to Importin  and displaces it from
the complex. Then CAS, an exportin which in the nucleus is bound to RanGTP, displaces importin 
from the cargo. The NLS-protein is thus free in the nucleoplasm. The Importin -RanGTP and importin
-CAS-RanGTP complex diffuses back to the cytoplasm where GTPs are hydrolyzed to GDP leading to
the release of importin  and importin  which become available for a new NLS-protein import round
(Peters, 2006).
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shown interaction of EGFR with importin  (karypherin Ran, and importin 1,
which are essential for the formation of the nuclear import complex needed for import
of proteins exhibiting the NLS (Dittmann et al., 2005a; Lo et al., 2006). Nuclear pore
entry of proteins can be inhibited by wheat germ agglutinin (WGA), a lectin (sugar
binding protein) which inhibits nuclear import of proteins containing the NLS. WGA
specifically inhibits active protein import rather than passive diffusion of proteins into
the nucleus (Yoneda et al., 1987). Further evidence of a NLS sequence in EGFR was
provided by complete blockade of radiation-induced EGFR nuclear entry by incubation
with WGA (Dittmann et al., 2005a).
In the classical export scheme, proteins with a nuclear export sequence (NES) can bind
inside the nucleus to form a heterotrimeric complex with an exportin (i.e. the exportin
chromosome region maintenance protein CRM1) and RanGTP (Peters, 2006). Export
via the exportin CRM1 can be inhibited by leptomycin B. Leptomycin B is an
unsaturated, branched-chain fatty acid, and is a specific inhibitor of proteins containing
the NES. The suggested inhibition mechanism involves the direct binding of
leptomycin B to exportin CRM1, which blocks the binding of CRM1 to proteins
containing the NES, via the interaction with a cysteine residue in the conserved CRM1
control region (Fukuda et al., 1997). Existence of a NES has not been identified in
EGFR, but association with CRM1 was suggested as inhibition with leptomycin B led
to increased nuclear levels of EGFR (Lo et al., 2006; Dittmann et al., 2005a).
6.1.3 DNA repair protein targets of EGFR
As mentioned previously, iNOS expression can be modulated by nuclear EGFR acting
as a transcription factor and this may lead to increased DNA-PKCS expression and
resistance to stress stimuli such as cisplatin and irradiation. Furthermore, altered
expression of Rad51, a protein involved in homologous recombination of DNA double
strand breaks, was shown by addition of an EGFR inhibitor, erlotinib. Erlotinib used in
combination with radiation inhibited Rad51 expression and increased radiosensitivity,
providing another evidence of modulation of DNA repair mechanisms by EGFR
inhibitors (Chinnaiyan et al., 2005). Therefore, not only non-homologous end joining,
but also homologous recombination can be modulated by anti-EGFR therapy.
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Aims
Based on the above studies and the results from chapter 5 showing EGFR translocation
to the nucleus following irradiation or cisplatin, we decided to investigate the
mechanism of EGFR transport using nuclear import and export inhibitors WGA and
leptomycin B. We also transfected CRI-G1 and RIN-5F cells with an NLS mutant to
enable the mapping of the EGFR regions involved in nuclear translocation. Finally, we
investigated possible activation of iNOS or rad51 by nuclear EGFR.
6.2 Results
6.2.1 DNA repair modulation by WGA and leptomycin B
To investigate the mechanism of EGFR nuclear translocation CRI-GI, RIN-5F, NCI-
H727, and SHP-77 cells were incubated as before with gefitinib at 10M for 3 hours,
and/or WGA or leptomycin for 30 minutes prior to radiation treatment. Cells were then
irradiated at 15Gy, or at 30Gy for NCI-H727 cells and DNA damage was quantitated
using the comet assay (section 5.2.2, figure 50). Figures show results for CRI-GI and
RIN-5F cells only (the rest of the cell lines are shown in appendix 3A-3B).
As shown in figure 67, pre-treatment with WGA alone prior to irradiation, inhibited
DNA repair in CRI-G1 cells by 26% and 16% at 80 and 120 minutes after irradiation. A
double treatment of gefitinib and WGA induced an additional delay in DNA repair by
37% at 80 minutes after irradiation, which remains at 37% at 120 minutes post
radiation. In contrast, leptomycin B in CRI-G1 cells led to a slight increase of 19% in
DNA repair at 40 minutes after irradiation, with DNA repair kinetics falling to levels
similar to radiation alone in later time points. In RIN-5F cells (figure 68) WGA or
leptomycin B had no effect in the kinetics of strand break repair. These results indicate
that radiation-induced EGFR import may utilise proteins associated with the nuclear
pore complex.
177
Figure 67: Measurement of irradiation-induced DNA strand breaks and their repair in
CRI-G1cells. Strand break formation quantitated as percentage of control cell tail
moment, plotted against time after irradiation. Cells were treated with gefitinib at 10M
for 3 hours, with WGA (0.05mg/ml) or leptomycin B (2nM) added in the last 30
minutes. Drug was removed, and then cells were irradiated at 15 Gy (a dose which
produces a tail moment of approximately 16) and incubated for up to 120 minutes at
37oC. Data represents the averages of three different experiments, each performed in
triplicate; bars, SD
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Figure 68: Measurement of irradiation-induced DNA strand breaks and their repair in
RIN-5F cells. Strand break formation quantitated as percentage of control cell tail
moment, plotted against time after irradiation. Cells were treated with gefitinib at
10M, followed by 30 minutes treatment with WGA (0.05mg/ml) or leptomycin B
(2nM). Drug was removed, and then cells were irradiated at 15 Gy (a dose which
produces a tail moment of approximately 16) and incubated for up to 120 minutes at
37oC. Data represents the averages of three different experiments, each performed in
triplicate; bars, SD
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6.2.2 WGA and Leptomycin B effect on EGFR localisation
The effect of WGA and leptomycin B on EGFR localization in CRI-G1 and RIN-5F
cells was established by immunohistochemistry. For this, cells were treated as before
with gefitinib and/or WGA or leptomycin B and irradiated at 4Gy, and EGFR was
detected by immunofluorescent staining using a confocal microscope. Data is shown for
CRI-G1 and RIN-5F cells only with the rest of the cell lines shown in appendix 3C-3D.
As shown in figure 69, WGA alone had no effect on EGFR localization in CRI-GI cells,
but in combination with radiation WGA blocked the radiation-induced EGFR nuclear
entry in a similar fashion to gefitinib. On the other hand leptomycin B as a single agent
had no effect on locality of EGFR in CRI-GI cells, but when it was added prior to
irradiation it led to increased levels of nuclear EGFR compared to untreated cells. In
RIN-5F cells (figure 70) which do not express nuclear EGFR, WGA or leptomycin B
had no effect EGFR locality in the cell. These results confirmed the employment of
nuclear pore complex proteins for EGFR transportation to and out of the nucleus.
The data from comet analysis and immunofluorescent staining were also confirmed by
immunoblotting in cytoplasmic and nuclear extracts. CRI-GI and RIN-5F cells were
treated with WGA or leptomycin for 30 minutes prior to irradiation at 4Gy. After
irradiation treatment and incubation at 37oC for 5 minutes, nuclear and cytosolic
fractions were isolated and immunoblotted for EGFR. In addition to the use of -
tubulin as a loading control, blots were stripped and re-probed for lamin 1, which was
used as a loading control for nuclear proteins (Dittmann et al., 2005). The amounts of
EGFR were calculated by densitometry analysis of the bands.
As seen in figure 71, WGA completely blocked radiation-induced EGFR import to the
nucleus in CRI-G1 cells, while leptomycin led to increased nuclear EGFR levels. Even
as a single agent, WGA led to decreased nuclear EGFR levels. Cytoplasmic EGFR
levels were decreased in irradiated cells, but were unaffected by WGA or leptomycin.
In RIN-5F cells shown in figure 72, no nuclear EGFR is detected. WGA or leptomycin
had no effect on the amounts of nuclear EGFR except for an increase in cytoplasmic
EGFR by WGA as a single agent.
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Figure 69: CRI-G1 cells were treated with gefitinib at 10M for 3 hours and/or WGA
(0.05mg/ml) or leptomycin B (2nM) added in the last 30 minutes. Cells were then
irradiated at 4Gy and incubated for 5 minutes at 37oC. Cells were then fixed and
stained for EGFR (green) and nucleus was stained with propidium iodide (red).
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Figure 70: RIN-5F cells were treated with gefitinib at 10M for 3 hours and/or WGA
(0.05mg/ml) or leptomycin B (2nM) added in the last 30 minutes. Cells were then
irradiated at 4Gy and incubated for 5 minutes at 37oC. Cells were then fixed and
stained for EGFR (green) and nucleus was stained with propidium iodide (red).
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WGA WGA / X-ray
Gefitinib +WGA /  X-ray Leptomycin B
Gefitinib +Leptom /  X-rayLeptomycin B / X-ray
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CRI-G1 CELL EXTRACTS
Cytoplasmic
Nuclear
Figure 71: CRI-G1 cells were treated with WGA (0.05mg/ml) or leptomycin B (2nM)
for 30 minutes, irradiated at 4Gy and incubated for 5 minutes at 37oC. Cytosolic and
nuclear extracts were immunoblotted for EGFR. Alpha-tubulin was used as a loading
control. Lamin 1 was used as a nuclear marker. Amounts of EGFR in percentages
were determined by densitometry analysis.
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RIN-5F CELL EXTRACTS
Cytoplasmic
Nuclear
Figure 72: RIN-5F cells were treated with WGA (0.05mg/ml) or leptomycin B (2nM)
for 30 minutes, irradiated at 4Gy and incubated for 5 minutes at 37oC. Cytosolic and
nuclear extracts were immunoblotted for EGFR. Alpha-tubulin was used as a loading
control. Lamin 1 was used as a nuclear marker. Amounts of EGFR in percentages
were determined by densitometry analysis.
6.2.3 Transfection of wt and mutNLS EGFR
To investigate whether the putative nuclear localisation signal (NLS) sequence was
involved in the transport of EGFR to the nucleus, we transfected CRI-G1 and RIN-5F
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cells with wt EGFR or an NLS mutant to enable the mapping of the EGFR regions
involved in nuclear translocation. The NLS sequence in the juxtamembrane domain of
EGFR is RRRHIVRKRTLRR (Hsu & Hung, 2007) containing three clusters
(underlined) of basic arginine (R) and lysine (K) amino acids. The sequence was
changed into AAAHIVAKATLAA, with hydrophobic alanine replacing the arginine
residue. Replacing any of the three clusters with alanine (one cluster at a time), as
examined by Hsu & Hung, led to inhibition of EGFR entry to the nucleus (Hsu &
Hung, 2007).
CRI-G1 and RIN-5F cells were transfected for 48 hours, followed by treatment with
gefitinib at 10M and irradiation at 15Gy for DNA repair analysis by the comet assay
(figure 73), or at 4Gy for immunofluorescent staining and the use of confocal
microscopy (figures 74-75).
As seen in figure 73, CRI-G1 cells transfected with wtEGFR and irradiated at 15Gy
repair DNA strand breaks in approximately 120 minutes as with untransfected cells
(dark blue). When CRI-G1 cells are treated with gefitinib (light blue), the repair of
radiation-induced DNA damage is delayed by 25% at 80 minutes post irradiation and by
22% at 120 minutes. Irradiation-induced DNA strand breaks in CRI-G1 cells transfected
with the mutant NLS EGFR (dark green) repair more slowly compared to the cells
transfected with wtEGFR showing 15% more strand breaks at 80 minutes after radiation
treatment, but at 120 minutes DNA strand breaks are completely repaired. Addition of
gefitinib before irradiation in cells transfected with mut NLS EGFR (light green) did
not change significantly the kinetics of DNA repair compared to cells transfected with
mut NLS EGFR and irradiated (dark green), but compared to cells transfected with
wtEGFR there is a small delay of 13% at 80 minutes post irradiation which remains at
13% at 120 minutes. This difference is probably due to wt EGFR molecules already
present in the CRI-G1 cell line before and after transfection.
In RIN-5F cells (figure 73), DNA repair kinetics between cells transfected with wt (dark
and light blue) and mutant NLS EGFR (dark and light green) are almost identical, with
the former showing 5-10% increased repair activity at 80 and 120 minutes post-
irradiation compared to the latter. Addition of gefitinib did not produce any further
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delay compared to the respective radiation control cells. These results indicate that the
putative NLS sequence may be involved in EGFR transport to the nucleus in CRI-G1
cells.
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Figure 73: Measurement of irradiation-induced DNA strand breaks and their repair by
comet analysis. Strand break formation was quantitated as percentage of control cell tail
moment, plotted against time after irradiation. CRI-G1 and RIN-5F cells were
transfected with wt or mutNLS-EGFR for 48hours. Cells were then treated with 10M
gefitinib for 3 hours, irradiated at 15Gy and incubated for 0-120 minutes at 37oC. Data
represents the averages of three different experiments, each performed in triplicate;
bars, SD
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The effect of irradiation on CRI-G1 and RIN-5F cells transfected with wt or mut NLS
EGFR was also studied by immunohistochemistry. Cells were transfected as previously
and treated with gefitinib followed by irradiation and labelling for wt and mutant
EGFR.
CRI-G1 cells (figure 74) demonstrated wt EGFR but not mutant EGFR entering the
nucleus at 5 minutes after irradiation. However, amounts of cytoplasmic EGFR were
also present with wt EGFR, probably due to the excess amount of EGFR present inside
the cells. Addition of gefitinib abrogated EGFR nuclear entry in cells transfected with
wt EGFR as with control untransfected cells, but had no effect in CRI-G1 cells
transfected with the mut NLS EGFR.
In RIN-5F cells however (figure 75), no nuclear EGFR was observed after irradiation in
either wt or mutant EGFR transfected cells. As expected, gefitinib had no effect in
EGFR localization but inhibited activation of the receptor in both wt and mutant EGFR
transfected cells.
6.2.4 Nuclear targets of EGFR
Previous reports have stated that EGFR may alter the expression of genes associated
with DNA repair: iNOS and Rad51 (Lo et al., 2005b; Chinnaiyan et al., 2005). Rad51
is involved in homologous recombination and iNOS was shown to lead to activation of
DNA-PKCS, a member of NHEJ. Based on these reports we decided to test this
hypothesis in neuroendocrine tumour cells. Since nuclear EGFR acting as a
transcription factor on the promoter of iNOS needs activation by EGF, we serum
starved cells for 12 or 24 hours and treated them with EGF for 6 hours, a length of time
shown previously to lead to activation of EGFR.
Figure 76 shows immunoblotting for iNOS in six neuroendocrine tumour cell lines.
Serum starvation but not EGF-dependent activation of EGFR caused differences in
expression levels of iNOS in all cell lines tested. For Rad51, we stripped the nuclear
extract blots for EGFR (shown in section 6.2.2) and re-probed the membranes for
Rad51 shown in figure 77. No change in Rad51 expression by irradiation and
consequently radiation-induced nuclear EGFR was identified in any of the cell lines.
WGA or leptomycin had no effect in Rad51 levels in nuclear extracts isolated.
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Figure 74: CRI-G1 cells were transfected for 48 hours with wtEGFR or mutant NLS-
EGFR. Cells were treated with gefitinib at 10M for 3 hours, irradiated at 4Gy and
incubated for 5 minutes at 37oC. Cells were then fixed and stained for EGFR (green)
and nucleus was stained with propidium iodide (red).
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Figure 75: RIN-5F cells were transfected for 48 hours with wtEGFR or mutant NLS-
EGFR. Cells were treated with gefitinib at 10M for 3 hours, irradiated at 4Gy and
incubated for 5 minutes at 37oC. Cells were then fixed and stained for EGFR (green)
and nucleus was stained with propidium iodide (red).
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Figure 76: Cells were serum starved (SS) in 0% serum for 12 or 24 hours followed by
incubation with EGF (100ng/ml) for 6 hours and immunoblotting of whole cell extracts
for iNOS.
Figure 77: Cells were treated with WGA (0.05mg/ml) or leptomycin B (2nM) for 30
minutes, irradiated at 4Gy (or 30Gy for NCI-H727 cells) and incubated for 5 minutes at
37oC. Nuclear extracts were immunoblotted for Rad51.
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6.3 Discussion
The previous chapter demonstrated EGFR movement to the nucleus in cells exposed to
cisplatin and radiation. Radiation-induced nuclear entry of EGFR was blocked by
EGFR inhibitors gefitinib and cetuximab, showing that phosphorylation of EGFR is
needed for the nuclear translocation of the receptor. Anti-EGFR therapy also led to
radiosensitisation of cells by delaying the repair of radiation-induced DNA damage.
Apart from stress-dependent, ligand-dependent nuclear transit of EGFR can occur and
this event leads to activation of genes including iNOS, B-Myb, and cyclin D1, which
have been associated with increased proliferation of tumour cells, as mentioned in
detail in section 6.1.1 (Lo et al., 2005b; Lin et al., 2001; Hanada et al., 2006).
6.3.1 WGA and leptomycin B modulation of DNA repair and EGFR localisation
To understand how EGFR transport occurs, we analysed the effect of two proteins
involved in nuclear trafficking through the nuclear pore complex; wheat germ
agglutinin (WGA), and leptomycin B. The first is a nuclear import inhibitor
cooperating with importins and  and protein Ran, and the second is a nuclear export
inhibitor associated with exportin CRM1 (Yoneda et al., 1987; Fukuda et al., 1997).
Our results demonstrated that WGA works in a similar way to gefitinib or cetuximab,
by inhibiting nuclear entry of EGFR and causing a delay in repair of radiation-induced
DNA strand breaks in all cells except RIN-5F cells, as shown by immunofluorescent
staining and comet analysis respectively. Leptomycin B had no effect as a single agent,
but abrogated the gefitinib-induced delay in the repair of strand breaks. Furthermore,
treatment with radiation and leptomycin led to increased levels of nuclear EGFR. This
is in concordance with previous studies postulating that EGFR nuclear entry is via
interaction with importin  (karypherin Ran, and importin 1, while export is via
association with exportin CRM1, all of which are constituents of the nuclear pore
complex (Dittmann et al., 2005a; Lo et al., 2006).
6.3.2 The role of the NLS sequence in EGFR
The nuclear pore complex facilitated transport is an energy-dependent mechanism that
facilitates import of proteins with a nuclear localisation signal (NLS) sequence.
Interestingly, a putative NLS sequence (RRRHIVRKRTLRR) was identified in the
juxtamembrane domain of EGFR by Hsu & Hung (2007), which contains three clusters
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of basic amino acids. The presence of basic amino acids is characteristic of NLS
sequences indicating their importance in the mechanism of interaction with nuclear
pore importins. Replacing any of the three clusters with the hydrophobic amino acid
alanine (one cluster at a time), led to inhibition of EGFR entry to the nucleus (Hsu &
Hung, 2007). In our study, CRI-G1 and RIN-5F cells were transfected with the wild
type and a mutant EGFR at the NLS (sequence was changed into
AAAHIVAKATLAA). Transfection was performed so that transfected EGFR
molecules would be in excess compared to EGFR expressed naturally in both cell
types. Transfection with wtEGFR, which was used as a control for our experiments,
showed  similar results with confocal microscopy to untreated cells in both cell lines,
with nuclear EGFR presented only in CRI-G1 cells, indicating that its not the receptor
itself but the mechanism for nuclear transport that may be impaired in RIN-5F cells.
Small amounts of cytoplasmic EGFR were also present in irradiated CRI-G1 cells, but
the majority of EGFR molecules were found at the inner side of the nuclear membrane.
Treatment with gefitinib abrogated nuclear transfer of EGFR as in untransfected cells.
Mutant NLS EGFR CRI-G1 cells showed very little nuclear transit which is probably
due to the receptor naturally present in the cells. Gene sequencing analysis of nuclear
EGFR would confirm whether the small amounts of EGFR molecules found in the
nucleus are wild type (already present in the cells) and not mutant, and this would form
the next step in our study.
Measurement of DNA damage repair by the comet assay in cells transfected with the
wild type receptor, as expected showed repair of irradiated cells within two hours after
exposure, and a gefitinib-induced delay in repair in CRI-G1 but not in RIN-5F cells.
CRI-G1 cells transfected with the mutant receptor exposed to irradiation alone also
showed delay in DNA repair, which could not be further increased by gefitinib. This
shows that lack of the NLS inhibits EGFR nuclear entry associated with an increase in
DNA-PKCS activity and this leads to the impediment of DNA repair (Dittmann et al.,
2005a; Dittmann et al., 2005b). In RIN-5F cells, transfection with the wild type or
mutant EGFR had no effect in DNA repair kinetics. Gefitinib did not alter DNA repair
in RIN-5F cells transfected with either EGFR construct, supporting the view that EGFR
does not modulate DNA repair in these cells due to impaired nuclear traffic.
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6.3.3 EGFR nuclear targets?
Further analysis of EGFR nuclear transport led to the search for possible nuclear target
proteins. Of the proteins already identified including iNOS, B-Myb, and cyclin D1 (Lo
& Hung, 2006), the most interesting target for our study was iNOS. EGFR was shown
to interact with STAT3 on the promoter of iNOS and this led to transcriptional
activation of the enzyme (Lo et al., 2005b). INOS has been associated with increased
proliferation as have the other two target proteins, but is the only of the three to be also
associated with DNA repair by increasing the expression of DNA-PKCS, an event shown
to provide protection to cells from the cytotoxicity of nitric oxide and DNA-damaging
agents such as cisplatin and radiation (Xu et al., 2000). Since association of EGFR and
DNA-PKCS was not identified (even though gefitinib caused DNA-PKCS
downregulation in some cells), it was suggested that modulation of DNA repair might
not be by direct physical association of EGFR to DNA-PKCS but indirectly through
transcriptional activation of iNOS. EGF-dependent activation of EGFR did not have any
effect in the expression of iNOS. Minor changes were caused by serum starvation in
some cell lines, but no significant upregulation was seen by EGF. Perhaps, in
neuroendocrine tumour cells ligand dependent activation does not induce nuclear import
of EGFR. This was also shown by Dittmann et al. who found increased phosphorylation
of the receptor by EGF treatment but no increase in nuclear EGFR amounts (Dittmann
et al., 2005a). The next step would thus be to analyse the effect of EGF on EGFR
localisation, as done with cisplatin and radiation. It would be interesting to see whether
this pathway leads to EGFR import in RIN-5F cells, which would prove that the
mechanisms of ligand dependent or independent transport are distinct as previously
postulated (Szumiel, 2006).
EGFF has also been shown to modulate expression of another DNA repair protein,
Rad51 (Chinnaiyan et al., 2005). This protein has a role in homologous recombination,
which also repairs DNA strand breaks. Radiation or gefitinib had no effect in Rad51
expression, indicating that EGFR may not be associated with the homologous
recombination system in neuroendocrine tumour cells.
6.3.4 Conclusions
The results obtained in our study demonstrate that cisplatin and radiation induce EGFR
entry to the nucleus and activation of DNA repair mechanisms that protect cells from
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the toxic effects of radiation. Apart from activating traditional signalling pathways such
as the PI-3 kinase and the MAPK pathway, EGFR probably undergoes internalisation in
caveosomes and transferred to the perinuclear compartment (Khan et al., 2006). From
that area, as shown from confocal microscopy, nuclear transport commences that is
mediated by the nuclear pore complex. EGFR nuclear entry may utilise the putative
NLS sequence of the receptor. Nuclear presence of EGFR is associated with DNA
repair, since gefitinib or cetuximab block EGFR entry, an event leading to the
impediment of DNA repair. Our study has tried to elucidate the mechanism behind
nuclear EGFR. The identification of novel EGFR nuclear targets following radiation
would form a next step in our research which would help understand the role of this
receptor under stress conditions.
In the next chapter we investigate c-KIT, a tyrosine kinase receptor found in
haematopoietic stem cells, as a putative receptor target in neuroendocrine tumour
patients.
194
CHAPTER 7
INVESTIGATION OF C-KIT EXPRESSION IN
NEUROENDOCRINE TUMOUR PATIENTS: COMPARISON
OF MONOCLONAL & POLYCLONAL ANTIBODIES
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7.1 Introduction
Tyrosine phosphorylation by protein tyrosine kinases is of particular importance in
cellular signalling and can mediate signals for major cellular processes, such as
proliferation, differentiation, apoptosis, attachment, and migration. Tumour growth is
based on deregulation of the above tasks, suggesting that targeting these enzymes could
help inhibit cancer growth and induce apoptosis of malignant cells (Traxler et al.,
2001). C-KIT , the human homologue of the v-kit Hardy-Zuckerman 4 feline sarcoma
viral oncogene, codes for a receptor tyrosine kinase normally expressed by a variety of
cell types including the interstitial cells of Cajal, germ cells, bone marrow stem cells,
melanocytes, breast epithelium and mast cells (Besmer et al., 1986). The role of C-KIT
expression has mainly been studied in haematological and solid tumours, such as acute
leukaemias (Cortes et al., 2003), and gastrointestinal stromal tumours (GIST) (Fletcher
et al., 2002). C-KIT may also have a role in germ cell tumours, breast
adenocarcinomas, malignant melanomas, small cell lung cancers, and in the malignant
transformation of mast cells.
The clinical importance of C-KIT expression in malignant tumors relies on the
existence of imatinib (STI571, Gleevec®, Novartis Pharma AG Basel, Switzerland), a
compound which specifically inhibits C-KIT (Lefevre et al., 2004), as well as other
tyrosine kinase receptors such as the fusion BCR-ABL protein in chronic myelogenous
leukaemia (CML). The receptor targets of imatinib are described in detail in section
2.2.2 (p.52). Moreover, a clinically relevant breakthrough has been the finding of
notable anti-tumour effects by imatinib in GISTs, a group of tumours regarded as being
generally resistant to conventional chemotherapy (De Silva & Reid, 2003). Imatinib has
been approved by the United States FDA for the treatment of C-KIT positive GISTs
and Philadelphia chromosome - positive chronic myelogenous leukaemias (Cohen et
al., 2005; Dagher et al., 2002).
On the other hand, the data regarding C-KIT expression by immunohistochemistry have
shown variability with no C-KIT detected in neuroendocrine tumours by various groups
including Tsuura et al., (1994) and Welin et al., (2006). On the other hand, 92% of
PNETs were found immunoreactive to C-KIT by Fjallskog et al., (2003) and 26% of
neuroendocrine carcinomas were found positive for C-KIT by Ishikubo et al., (2006).
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Marked differences in the expression of C-KIT have also been found in other types of
tumours such as pancreatic adenocarcinomas and soft tissue sarcomas which may
resemble GISTs (Sabah et al., 2003; Bateman et al., 2008), and in cases of desmoid
fibromatosis (Hornick & Fletcher, 2003), and this has been ascribed to the differences
in immunostaining protocols as well as antibodies used by each group.
Aims
The purpose of this study was to study the immunoexpression of C-KIT in NET
patients and raise the possibility of treating these tumours with imatinib. The additional
purpose was to determine if there was any difference in expression between the
monoclonal and polyclonal antibodies. For this, we stained a variety of NET tissue
samples using two different antibodies (one polyclonal and one monoclonal), but the
same immunohistochemical protocol. The two antibodies used, which have also been
used by other groups, recognise and bind to two different regions of the antigen.
As described in the methods section (see p.92), the first antibody is the polyclonal anti
C-KIT/ CD117 antibody from DAKO, a rabbit antibody against the 963 to 976 amino
acid residues at the C-terminus of the human C-KIT oncoprotein. The second antibody
is a monoclonal anti C-KIT antibody from Novocastra which recognizes the three C2-
like extracellular domains at the N-terminus of C-KIT and was raised in mice. For
simplicity, the two antibodies are referred in the text as ‘polyclonal’ and ‘monoclonal’.
In the second part, the presence of C-KIT was also investigated in human and rat
neuroendocrine cell lines by immunoblotting, with the intention to analyze the anti-
proliferative effect of imatinib in these cell lines. For immunoblotting, a rabbit
polyclonal C-KIT antibody from Santa Cruz with an epitope mapping to the C-terminus
was used.
7.2 Results
Immunohistochemistry was performed in specimens from 85 NETs patients. Of these
39 patients had foregut NETs including 3 ampullary NETs, 7 bronchial carcinoids, 1
duodenal carcinoid, 6 gastric carcinoids, 1 oesophageal carcinoid, and 21 pancreatic
neuroendocrine tumours. 27 patients were presented with midgut carcinoids including 7
appendiceal carcinoids, 18 ileal carcinoids, 1 caecal carcinoid, and 1 jejunal carcinoid.
The 4 hindgut carcinoid patients included 1 colon carcinoid, 2 rectal carcinoids, and 1
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cervical carcinoid. Finally we analysed 15 more patients with 5 paragangliomas, 5
medullary carcinomas of the thyroid and 5 NETs of unknown primary site. The patients
and their tumour type are shown in table 17.
Staining was repeated twice to three times depending on the availability of tissue.
Staining was scored as strong to weak, diffuse or present in nests of tumour cells rather
than covering the whole tumour area. GIST tumour samples were used as positive
control. In most cases, mast cells found in the arterial vessels of the tumours or in the
surrounding epithelium provided an additional positive control. The differentiation
between mast cells and tumour cells was based on the morphology of the cells as well
as their topology in the tissue.
Table 17: Neuroendocrine tumour types of patients
Neuroendocrine Tumour types (No of patients)
Foregut NETs (39) Ampullary NETs (3)
Bronchial carcinoids (7)
Duodenal carcinoids (1)
Gastric carcinoids (6)
Oesophageal carcinoids (1)
Pancreatic NETs (21)
Midgut NETs (27) Appendiceal carcinoids (7)
Ileal carcinoids (18)
Caecal carcinoids (1)
Jejunal carcinoids (1)
Hindgut NETs (4) Colon carcinoids (1)
Rectal carcinoids (2)
Cervical carcinoids (1)
Medullary Thyroid Carcinomas (5) -
Paragangliomas (5) -
Unknown Primary (5) -
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7.2.1 Polyclonal antibody
Staining with the polyclonal antibody revealed C-KIT expression in 24% (20 out of 85)
of the patients (examples shown in figure 78 (b-f), positive control GIST section in
78a). The detailed results of the staining with the polyclonal antibody are outlined in
table 18, where the intensity of the staining in comparison to the positive control GIST
is also demonstrated.
Positive tumour samples included 5/11upper gastrointestinal NETs, 8/27 midgut NETs,
and 4/21 patients with pancreatic neuroendocrine tumours. The rest of the positive
samples were 1 case of hindgut NET, and 2 cases of NET of unknown primary site.
Staining with the polyclonal anti-C-KIT antibody revealed lack of C-KIT expression in
patients with paragangliomas and medullary thyroid carcinomas as shown in figure
78e-f.
Staining with the polyclonal antibody identified C-KIT primarily in the cytoplasm,
except in 4 cases where the receptor was also identified in the nucleus or the
perinuclear region. Nuclear staining did not correlate with the type of neuroendocrine
tumour. For example, figure 79 shows two patients with ileal carcinoid (a-b) with
cytoplasmic staining in case (a), and cytoplasmic and nuclear staining in case (b).
Paradigms of nuclear staining are also illustrated in figure 79c-d, in nests of tumours
cells of a patient with appendiceal carcinoid. Figure 78 also provides two examples of
perinuclear staining seen in a patient with oesophageal carcinoid (c), and a patient with
ampullary NET (d), in comparison to cytoplasmic staining in a patient with a NET of
unknown primary site (b). In 2 of the patients with a gastric carcinoid and a PNET
respectively, neuronal staining was also observed (data not shown).
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Table 18: Staining with the polyclonal antibody
Specimen (No of +ve patients/total) Intensity Comments
Foregut Ampullary NET (1/3) 2 Perinuclear staining
Bronchial carcinoid (0/7) 0
Duodenal carcinoid (1/1) 0.5
Gastric carcinoid (2/6) 2
1 case with cytoplasmic
and neuronal staining
Oesophageal carcinoid (1/1) 2.5 Perinuclear staining
Pancreatic NET (4/21) 1.5 1 case with cytoplasmic,neuronal and islet staining
Midgut Appendiceal carcinoid (3/7) 1
1 case with cytoplasmic
and nuclear staining
Ileal carcinoid (5/18) 1.5
1 case with cytoplasmic
and nuclear staining
Caecal carcinoid (0/1) 0
Jejunal carcinoid (0/1) 0
Hindgut Colon carcinoid (0/1) 0
Rectal carcinoid (1/2) 0
Cervical carcinoid (0/1) 0
MTC (0/5) - 0
Paraganglioma
(0/5) - 0
Unknown
primary (2/5) - 1.5
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Figure 78: Cases of positive and negative staining with the polyclonal anti-C-KIT
antibody. (a) Gastrointestinal stromal tumour (used as a positive control) with strong
cytoplasmic staining of tumour cells, (b) Retroperitoneal mass NET of unknown
primary site containing partly crushed epithelial cells with moderate to strong
cytoplasmic staining, (c) Oesophageal carcinoid with moderate to strong cytoplasmic
and perinuclear staining of tumour cells, (d) Ampullary NET with staining of the
cytoplasm and nuclear membranes, (e) Paraganglioma where we have no staining of
the tumour but positive staining of mast cells, (f) Medullary carcinoma of thyroid
negative for C-KIT. Magnification a-e: (x20) and f: (x40)
a
dc
b
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Figure 79: Examples of cytoplasmic and nuclear C-KIT staining with the
polyclonal anti-C-KIT antibody. (a) Ileal carcinoid with strong cytoplasmic
staining of tumour cells, (b) Ileal carcinoid with cytoplasmic staining and sporadic
nuclear staining, (c-d) Appendiceal carcinoids (photos from same patient) of
positively stained tumour cells infiltrating the submucosa of the appendix, where
nuclei also stain positive. Magnification a,b,d: (x20) and c: (x10)
7.2.2 Monoclonal antibody
The results for the staining with the monoclonal antibody are outlined in detail in table
19. A significant increase in C-KIT expression was identified in the
immunohistochemical analysis with the monoclonal antibody, with 64% (50 out of 79 –
due to lack of available tissue) of the patients expressing the receptor. C-KIT
expression was predominantly increased in pancreatic NETs and in NETs of unknown
primary site, which were both 80% positive (16/20 PNETs and 4/5 unknown). High
levels of expression were also found in midgut NETs (19/26), and upper G.I NETs
(7/11). Staining with the monoclonal antibody also identified the receptor in one patient
with bronchial carcinoid and one patient with paraganglioma, both of which types of
NETs were negative for the polyclonal antibody.
c
ba
d
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Table 19: Staining with the monoclonal antibody
Specimen (No of +ve patients/total) Intensity Comments
Foregut Ampullary NET (2/3) 1.5 1 case with apical staining
Bronchial carcinoid
(1/4) 1.5
Duodenal carcinoid
(1/1) 1
Gastric carcinoid (3/6) 2 1 case with nuclear staining
Oesophageal carcinoid
(1/1) 1
Pancreatic NET (16/20) 2
7 cases with apical staining and 1
with both cytoplasmic and apical
staining
Midgut
Appendiceal carcinoid
(5/6) 2.5 3 cases with apical staining
Ileal carcinoid (13/18)
3
7 cases with apical staining and 2
with both cytoplasmic and apical
staining
Caecal carcinoid (1/1) 2 Apical staining
Jejunal carcinoid (0/1)
Hindgut Colon carcinoid (1/1) 1
Rectal carcinoid (1/1) 2 Cytoplasmic and apical staining
Cervical carcinoid (0/1) 0
MTC (0/5) 0
Paraganglioma
(1/5) 2
Unknown
primary (4/5) 2.5 1 case with apical staining
With the monoclonal antibody, the expression of the receptor in half of the patients was
markedly increased around the edges of tumour nests, with low concentrations in the
cytoplasm. Examples of this so called apical staining are shown in figure 81a and 81c.
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Nuclear staining was identified in one patient only with gastric carcinoid. Medullary
thyroid carcinoma sections were all negative with the monoclonal antibody as with the
polyclonal one.
7.2.3 Comparison of the two immunohistochemical studies
As the aim was to determine any differences in C-KIT expression between the
polyclonal and monoclonal antibody, we used sequential tissue sections from each
patient (tissue for comparison was available in 79/85 patients). The differences in
staining of neuroendocrine tumour cell types between the two antibodies are outlined in
table 20.
Table 20: Expression C-KIT in NET patients using the monoclonal and the
polyclonal anti C-KIT antibodies
Specimen Specimen Monoclonal Polyclonal
Foregut NETs BronchialNETs 1/4 (25%) 0/7 (0%)
Upper G.I
NETs 7/11 (64%) 5/11 (45%)
Pancreatic
NETs 16/20 (80%) 4/21 (19%)
Midgut NETs 19/26 (73%) 8/27 (30%)
Hindgut NETs 2/3 (66%) 1/4 (25%)
MTCs 0/5 (0%) 0/5 (0%)
Paragangliomas 1/5 (20%) 0/5 (0%)
Unknown
primary 4/5 (80%) 2/5 (40%)
Comparison between the two immunostainings revealed 13 patients showing positivity
with both antibodies (examples shown in figure 80), 37 patients showing expression of
C-KIT with the monoclonal antibody only (examples shown in figure 81), 7 patients
being positive for C-KIT with the polyclonal antibody only, and 27 cases negative for
both antibodies, most notably all cases of medullary thyroid carcinoma (examples
shown in figure 82). The main divergence between the two antibodies is seen in
pancreatic NETs and midgut NETs, where positivity is increased by a factor of 4 and
2.4 respectively with the monoclonal antibody.
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Figure 80: C-KIT expression by both antibodies: (a-b) Ileal carcinoid where strong
cytoplasmic staining is seen in tumour cells, (c-d) pancreatic neuroendocrine tumour
with strong cytoplasmic staining with the monoclonal antibody and medium staining
with the polyclonal antibody, (e-f) pancreatic neuroendocrine tumour where stronger
cytoplasmic staining is seen with the polyclonal antibody. Magnification a-f: (x20)
a
c
b
d
e f
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Figure 81: C-KIT expression with the monoclonal antibody only: (a-b) Ileum
carcinoid where the more common apical staining of tumour cells is seen with the
monoclonal antibody, but no cells stain positive with the polyclonal antibody (C-KIT
positive mast cells are seen that serve as an internal positive control), (c-d) carcinoid
tumour of the pancreas with moderate apical staining of tumour cells with the
monoclonal antibody and again no staining with the polyclonal one. Magnification a-
d: (x20)
a b
c d
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Figure 82: No C-KIT expression of tumour cells with either antibody: (a-b)
medullary thyroid carcinoma, (c-d) carcinoid tumour of the duodenum, (e-f) PNETs
showing normal pancreatic islets expressing C-KIT when stained with the
monoclonal antibody, but no staining of tumour cells with either antibody.
Magnification a-f: (x20)
The expression of C-KIT was also analysed in a panel of neuroendocrine tumour cell
lines including the human bronchial carcinoid NCI-H727 cells, the human small cell
lung cancer SHP-77 cells, and the rat islet CRI-G1and RIN-5F cell lines, as shown in
appendix 4. Following the established expression of C-KIT in our cells, we conducted
preliminary experiments to examine the anti-proliferative effect of imatinib in these
e f
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207
cells. Imatinib showed no effective cytotoxic activity in any of the cell lines used and
experiments were discontinued.
7.3 Discussion
7.3.1 C-KIT prognostic value in cancer
For the past decade C-KIT has been identified in a variety of tumour cells and its
expression could be associated with a poor outcome for patients. C-KIT has therefore
become an attractive target for the use of tyrosine kinase inhibitors such as imatinib that
is used for the treatment of C-KIT positive GISTs.
Although much research has been performed on the expression of C-KIT in tumour
cells, information in the literature about the significance of the receptor’s mutations or
autocrine activation in tumour progression is not comprehensive. In a study by
Scotlandi et al., (2003) C-KIT had no significant prognostic or therapeutic value in
Ewing’s sarcoma, which is characterised by autocrine/paracrine activation of the
receptor. Treatment with STI-571 yielded a low degree of inhibition with small clinical
importance but could be used in patients that overexpress C-KIT. In addition, no
correlation was found between developmental stage of endocrine pancreatic tumours
and expression of C-KIT (Fjallskog et al., 2003). No examination of mutations or
overexpression of the oncoprotein was demonstrated by this group to account for the
role of C-KIT in tumour development. Analysis of C-KIT mutations in tumour
development by Sakurai et al., (1999) showed that the mutated form of the receptor
(activating mutation in exon 11 of the C-KIT gene) was found equally in low- and high-
risk groups of GIST patients, showing no correlation to the Ki-67 labelling index.
Based on these results C-KIT may be considered a target for therapy with tyrosine
kinase inhibitors but its role in tumour growth remains unclear.
In contrast to Sakurai’s results, clinical analysis of 48 patients with GISTs by a
different group (Blanke et al., 2001) proved that the type of C-KIT mutation may
predict the behaviour of the tumour. Deletions/insertions in exon 11 had the lowest
recurrent free survival rate of all other mutations including missense mutations in exon
11 or mutations in exons 9, 13 or 17 or when compared with patients who had no
identified mutations. Also, treatment with imatinib was shown to be more effective in
GIST patients that carry a mutation in C-KIT than in those without a mutation, which
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proves the significance of mutations in the clinical outcome of GISTs (Blanke et al.,
2001). Furthermore, C-KIT mutations appear to be important in tumour progression of
mast cells in dogs (Zemke et al., 2002). In this study mutations in the juxtamembrane
domain of the oncoprotein were found in 12/64 grade II and grade III tumours but none
were found in grade I tumours (grade I being the least aggressive tumour type, grade II
intermediate, and grade III characterises poorly differentiated tumour cells, which grow
rapidly). The mutations were mainly duplications and deletions which lead to
constitutive activation of the receptor. Interestingly, a study in 36 GIST patients, which
were all C-KIT positive, showed co-expression of the C-KIT ligand SCF in 21 cases,
and this was associated with a higher MIB-1 proliferation index, indicating that co-
expression of receptor and ligand could be a marker of tumour proliferation (Hirano et
al., 2008). In addition, a study by Erler et al. showed that C-KIT was overexpressed in
a high percentage (66%, 54/82) of high-grade NETs but was not overexpressed in low
or intermediate-grade NETs. Overexpression of C-KIT did not appear though to affect
the aggressiveness of the tumour growth in terms of affecting survival (Erler et al.,
2004).
Recent studies have demonstrated association of C-KIT expression with
neuroendocrine tumour development. C-KIT expression was related to poor prognosis
in patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma
(LCNEC), as it was associated with advanced disease and poor response to
chemotherapy for SCLC patients or decreased survival and recurrence in LCNEC
patients (Micke et al., 2003; Casali et al., 2004). In addition, C-KIT immunoreactivity
was also identified in 26% of patients with gastrointestinal neuroendocrine carcinoma,
a tumour characterised by aggressive behaviour and poor prognosis (Ishikubo et al.,
2006). Finally, Ferrari et al. evaluated the correlation between C-KIT and the Ki-67
proliferation index in neuroendocrine tumours and showed that 8 out of 11 samples
immunoreactive for C-KIT had poorly differentiated histology, which is associated with
a high proliferation index. No reference was made on mutations present in the C-KIT
oncoprotein (Ferrari et al., 2006). Based on the above results, and the therapeutic
efficacy of imatinib in GISTs expressing C-KIT, we investigated the expression of C-
KIT in a large number of NET patients with the aim to justify the use of imatinib for
therapy.
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As discussed earlier in this chapter, our primary interest was to study the variability in
C-KIT immunoexpression in neuroendocrine tumour cells, which has been previously
demonstrated by other groups (Tsuura et al., 1994; Welin et al., 2006; Fjallskog et al.,
2003; Ishikubo et al., 2006). As these differences have been attributed to different
antibodies or different immunohistochemical protocols used, we decided to use two
commonly used antibodies, one polyclonal and one monoclonal antibody, while
keeping the same protocol for the two staining procedures.
7.3.2 Comparison of monoclonal and polyclonal immunohistochemical studies
Our immunohistochemical analysis identified the C-KIT receptor in 24% of the patients
with the polyclonal antibody and in 64% of the patients with the monoclonal antibody.
This difference was not correlated with the type of tumour carried by the patient or with
the organ affected by the tumour. With the polyclonal antibody from DAKO, C-KIT
immunoreactivity was mostly observed in carcinoids. On the other hand, the
monoclonal antibody from Novocastra identified the expression of C-KIT mostly in
PNETs. By comparing the two immunohistochemical procedures we conclude that the
monoclonal antibody showed a 2-fold increase in C-KIT expression in carcinoid
patients (65% mAb versus 28% pAb) and a 4-fold increase in PNET patients (80%
mAb versus 19% pAb).
The difference could not be accounted for by lack of specificity of the polyclonal
antibody (DAKO). Assessment of the two most common antibodies from DAKO and
Santa Cruz used in research against C-KIT supported the view of the DAKO product
being the more specific antibody (Lucas et al., 2003). The polyclonal antibody by
DAKO is widely used and in a large comparative study of seven C-KIT antibodies in
more than 3000 tumours, the DAKO antibody was found to be the most specific (Went
et al., 2004). Is the variability due to the different epitope being recognised by the two
antibodies? If it is easier for an antibody to bind the extracellular portion of an antigen
(recognised by the monoclonal antibody), heat-induced epitope retrieval should
diminish such a possibility. On the other hand, the tissue sections used in this study
derived from tumour tissue samples which were formalin fixed and embedded in
paraffin, and were up to 5 years old. Prolonged storage has been associated with
epitope fading and this could explain the fewer positive cases observed with the
polyclonal antibody, if its particular epitope was affected. Finally, mutations present in
210
the cytoplasmic part of the receptor, which is recognised by the polyclonal antibody,
could account for the smaller number of positive cases observed. In this case the
difference could only be explained by mutation studies in both extracellular and
intracellular sequences recognised by the two antibodies in all patients tested and this
forms the next step in our research.
For analysis of the two antibody stainings, proper precautions were taken to ensure
accuracy of the results. Firstly, sections of GIST, which is known to overexpress C-
KIT, were used as a primary positive control. In addition, since C-KIT is a
haematopoietic stem cell marker, mast cells present in the tissue served as a
supplementary internal positive control, and have been used as such by other groups
(Lucas et al., 2003; Miettinen & Lasota, 2005). For negative controls, we used
sequential sections for each sample where the primary antibody was omitted. GIST and
mast cells strongly expressed C-KIT with both antibodies used. Analysis of the sections
was carried out by two separate histopathologists at the Royal Free Hospital, with years
of experience in immunohistochemistry. To further prove the accuracy of our results, it
is a well known fact that one characteristic element of true positive staining is the
difference in the intensity of staining among cells, commonly known as ‘cell to cell
heterogeneity’, a feature observed in all of our sections with both antibodies. Finally,
for each antibody appropriate titrations were made to identify the most appropriate
dilution, in order to avoid non-specific binding of the antibody.
It is worth noting that the polyclonal antibody has positioned C-KIT mainly in the
cytoplasm whereas the monoclonal antibody has, in more than half the cases, identified
the receptor mostly in the plasma membrane with low concentrations in the cytoplasm.
C-KIT is a plasma membrane protein which would justify the accuracy of the
monoclonal antibody. On the other hand, although the polyclonal antibody identified
the protein mostly in the cytoplasm, there were cases where C-KIT was also identified
in the plasma membrane with the same antibody. In addition, C-KIT cytoplasmic
staining was also identified with the monoclonal antibody, but in fewer cases. Finally,
the polyclonal antibody also revealed nuclear or perinuclear staining in 4 patients, not
correlating to the type of NET present, while the monoclonal antibody shown nuclear
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C-KIT expression in one patient, a phenomenon which, to our knowledge, has not been
discussed previously.
Nevertheless, diagnosis of NETs is not based solely on a single marker. Patients tested
with both antibodies should combine this with identification of other NETs markers
such as the chromogranins, the NSE or CEA (Lamberts et al., 2001, Eriksson et al.,
2000), the secretion of peptide hormones and amines such as serotonin, insulin, gastrin,
glucagon, or VIP, as well as the presence of clinical syndromes associated with NETs.
7.3.3   Comparison of this study with results from other groups
Our immunohistochemical study demonstrated the presence of C-KIT (CD117) in
gastroenteropancreatic neuroendocrine tumours. Positive immunoreactivity was
established in a range of tumours that included foregut NETs (mainly pancreatic NETs
and gastric carcinoids), midgut NETs (mainly ileal and appendiceal carcinoids),
hindgut NETs, and NETs of unknown primary site. This is in contrast with a study by
Tsuura et al., (1994) where no expression of C-KIT was detected in NETs. The
antibody used by Tsuura and co-workers (1994) was the same polyclonal DAKO
antibody used in our analysis, so any discrepancy observed may be due to the method
employed or other reagents used.
The difference in results obtained by different scientific groups is difficult to examine,
not only due to different immunohistochemical procedures being used but also due to
the biological heterogeneity of NETs. NETs are divided into many different groups
according to the tissue type they arise from and they have different receptor expression
patterns, and this could also depend on whether the tumour is malignant or not. Welin
et al. found no immunoreactivity to C-KIT in malignant midgut carcinoid tumours
(Welin et al., 2006). On the other hand, a group from Sweden showed a 92%
expression of C-KIT in malignant endocrine pancreatic tumours (Fjallskog et al.,
2003).
7.3.4 Imatinib as a therapeutic option for NET patients
In vitro studies have demonstrated positive antitumour activity by imatinib in a variety
of tumours. Imatinib was shown to inhibit the growth of aggressive neuroblastic
tumours (Vitali et al., 2003). Furthermore, Lankat-Buttgereit et al. showed that imatinib
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inhibits the cell growth of insulinomas, gastrinomas, and carcinoids independently of
KIT expression (Lankat-Buttgereit et al., 2005). Preliminary proliferation studies in
neuroendocrine tumour cell lines expressing C-KIT showed no effect on growth of cells
by imatinib (data not shown). As a result, this part of the study was not pursued any
further.
For patients with neuroendocrine tumours, treatment with imatinib as a single agent has
not shown promising response rates. In a phase II trial of imatinib in patients with
advanced carcinoid tumour, only a modest effect on tumour growth was shown (Carr et
al., 2004). C-KIT is overexpressed in up to 70% of cases of small cell lung cancer.
Based on this fact 29 patients with recurrent and refractory small cell lung cancer
immunoreactive to C-KIT were treated with imatinib at 400 mg twice a day for 28
days. Imatinib did not demonstrate an objective response or confirm stable disease (Dy
et al., 2005). Similar results were obtained in a phase II clinical trial by Krug et al.
(Krug et al., 2005). In another phase II trial in patients with advanced metastatic
melanoma imatinib demonstrated lack of efficacy (Ugurel et al., 2005). Finally, in a
phase II multi-center study of 15 patients with disseminated endocrine tumours
including medullary thyroid carcinomas (MTC), adrenocortical carcinomas (ACC),
malignant pheochromocytomas, carcinoids, and neuroendocrine tumours, imatinib was
not found useful for treatment and caused increased toxicity in the group of patients
(Gross et al., 2006).
The above findings might suggest that the use of imatinib as a single agent does not
prove sufficient antitumour activity, but combination with other chemotherapeutic
agents could be of benefit. Gronchi et al. recently showed auxiliary treatment with
imatinib in patients with GISTs can delay the progression of the disease (Gronchi et al.,
2007). In addition, Blackstein et al. demonstrated that the response rate and
progression-free survival in patients with GISTs that are C-KIT negative was not
different from those with C-KIT positive GISTs, implying that a therapeutic trial of
imatinib may be helpful for all patients with GISTs regardless of C-KIT expression
(Blackstein et al., 2006).
Finally, a most recently identified problem with imatinib treatment is that GIST patients
treated with imatinib usually develop resistance to the drug after about 2 years of drug
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administration (Braconi et al., 2008; Jiang et al., 2008). This is mainly due to the
acquisition of secondary mutations in the tyrosine kinase domain of C-KIT, which is
recognized by the drug. This problem has led to the development of new tyrosine
kinase inhibitors with multiple targets, such as sunitinib, which targets C-KIT, PDGFR,
VEGFR, and FMS-related tyrosine kinase 3 receptor, and has shown efficacy in a
number of relapsing patients (Braconi et al., 2008; Jiang et al., 2008). Recent clinical
trials of sunitinib in NETs have shown very promising results (Kulke et al., 2008), and
most recently a study of sunitinib versus placebo in non-functioning NET patients had
to be stopped early after interim analysis demonstrated a significant survival benefit in
the sunitinib treated group (Raymond et al., 2009).
7.3.5 Conclusions
Based on our study C-KIT may play a pivotal role in neuroendocrine tumour growth
and affect the clinical outcome. We have identified C-KIT expression using
immunohistochemical studies with two antibodies against different epitopes in a
significant percentage of patients with NETs. Further exploration of its expression
status as well as sequence analysis is needed in order to investigate its role in the
pathology of NETs. Generally, the lack of clinically relevant anti-proliferative activity
by imatinib in neuroendocrine tumour patients could be because C-KIT is not the
driving force in these tumours. Expression of an oncogene in specific tumour cell types
may not necessarily imply therapeutic potential of drugs against this oncogene, and a
prime example for this is gefitinib, a widely used inhibitor of EGFR that failed to
prolong survival in 90% of patients with non-small cell lung cancer overexpressing
EGFR, in contrast to preclinical studies. Another reason could be the presence of
mutations in the tyrosine kinase domain of the receptor that disable efficacy of the drug
in neuroendocrine tumour cells. This justifies the need for analysis of the C-KIT
receptor for mutations in individual patients to help prognosis and evaluation of the
appropriate therapeutic modes. Finally, it is a well known fact that tyrosine kinase
inhibitors may cross-react with other tyrosine kinases, in the case of imatinib with
PDGFR (both  and ), and this may result in different activity profiles. Therefore
identification of other tyrosine kinases such as PDGFR, which have also shown
response to imatinib, may help unravel the mechanism of drug action in these patients.
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CHAPTER 8
INVESTIGATION OF COMBINATION TREATMENTS
USING OCTREOTIDE WITH CHEMOTHERAPEUTIC
AGENTS IN NET CELLS
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8.1 Introduction
The final receptor target analysed for any anti-proliferative effect in NETs was the
group of somatostatin receptors. Somatostatin (SST) is a gastrointestinal and
hypothalamic peptide hormone found in the gastric mucosa, the pancreatic islets, the
nerves of the gastrointestinal tract, and in the central nervous system. It inhibits
endocrine and exocrine secretions, intestinal motility and cell proliferation (Bousquet et
al., 2004). Somatostatin binds somatostatin receptors (SSTR1-SSTR5), which belong to
the family of G-protein coupled receptors. Somatostatin receptors are expressed in
neuroendocrine tumours, with the SSTR2 subtype being the most frequently expressed.
The presence of SST receptors has greatly aided diagnosis and treatment of
neuroendocrine tumours via binding of SST analogues. These compounds are not only
used for symptomatic relief of patients but also for the localisation and treatment of
primary and metastatic tumours expressing SSTRs via somatostatin receptor
scintigraphy (SRS) and somatostatin receptor-targeted radiotherapy respectively. Of all
existing somatostatin analogues, octreotide has been the most extensively investigated.
Octreotide, binds SSTR2 and SSTR5 with high affinity, SSTR3 with moderate affinity,
but does not bind SSTR1 and SSTR4 subtypes. Somatostatin analogues have
demonstrated anti-neoplastic activity in a variety of experimental models in vitro and in
vivo including mammary, pancreatic, colorectal, and lung cancers (Weckbecker et al.,
1993). Octreotide has also shown anti-proliferative effects in vitro against gastric and
pancreatic adenocarcinoma cells (Hofsli et al., 2002, Wang et al., 2003). In addition,
combinations of octreotide with cytotoxic drugs such as 5-fluorouracil, mitomycin C,
paclitaxel, and doxorubicin resulted in synergistic or additive interactions in AR42J
cells (Weckbecker et al., 1996), and with rofecoxib in gastric cancer SGC-7901 cells
(Tang et al., 2004). In human studies the effects have been variable with tumour growth
stabilisation reported in up to 50% of NET patients. Less than 10% of the patients
demonstrated tumour regression, and in most of these cases octreotide treatment was
combined with chemotherapy, chemoembolisation or alpha-interferon, making it
difficult to assess the anti-proliferative effect of octreotide alone (Leong & Pasieka,
2002).
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Aims
Our aim was to investigate the role of somatostatin receptors in neuroendocrine tumour
cell growth. To this end, we examined the expression of SST receptors in
neuroendocrine tumours cell lines and whether such receptors, when expressed, may
transmit growth inhibitory signals following binding of the somatostatin analogue
octreotide. Treatments included octreotide acting as a single agent or together with
commonly used chemotherapy drugs cisplatin, etoposide, melphalan as well as the non-
covalent DNA binding agent doxorubicin. The SRB proliferation assay was used to
determine survival in octreotide-treated cells with or without the cytotoxic agents. Flow
cytometry was also used to investigate any effect of octreotide on the cell cycle of NET
cells. The presence of SSTR2A and SSTR5, but not SSTR1 or SSTR3 was identified by
immunoblotting.
8.2 Results
8.2.1    SSTR expression in NETs
Initially, the expression of SSTR2A and SSTR5 but not SSTR1 or SSTR3 was
demonstrated by immunoblotting in NCI-H727 human bronchial carcinoid, BON-1
human pancreatic endocrine cells, and the two rat islet tumour cells RIN-5F and CRI-
G1 (figure 83). The expression of SST receptors was also identified in HCT-116 colon
cancer cell line. For this, we used four monoclonal rabbit antibodies against human
SSTR1, SSTR2A, SSTR3 and SSTR5 from Gramsch Laboratories, Germany. This
experiment confirmed the expression of SST receptors with high affinity to octreotide
in neuroendocrine tumours cells, justifying the use of octreotide in our proliferation
studies.
Figure 83: Total cell lysates of CRI-G1, HCT-116, NCI-H727, RIN-5F and BON-1
cells were immunoblotted for A. SSTR2A (80kDa) B: SSTR5 (65kDa). The antibodies
were used at a 1:4000 dilution from a 25l stock in distilled water.
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8.2.2    Proliferation studies using octreotide with chemotherapy
Octreotide, alone or in combination with cisplatin, etoposide, doxorubicin or
melphalan, was tested for its cytotoxic effect in NCI-H727, CRI-G1, BON-1, and RIN-
5F cells. Graphs show results for NCI-H727 cells only, with results for the other cell
lines added in the appendix 5A-5D.
Administered schedules included:
 Simultaneous addition of octreotide (at 10 or 1000nM) and cisplatin, etoposide
doxorubicin or melphalan for a period of 72 hours
 Incubation of cells with octreotide (at 10 or 1000nM) for 24 hours, followed by
48 hour incubation with cisplatin, etoposide doxorubicin or melphalan
o Cytotoxic drugs were added at 0-100M for cisplatin, etoposide and
melphalan, and at 0-10M for doxorubicin
o Drug incubations were followed by 2 days incubation in drug-free media
before analysis
Single treatments
Octreotide was added at 0-1000nM for 24 or 72 hours. Treatment with octreotide as a
single agent had no effect on the proliferation of NCI-H727, CRI-G1, BON-1 and RIN-
5F cells (figure 84, appendix 5A for all other cell lines). All chemotherapy drugs used
had a dose-dependent effect on all four cell lines tested (figures 85-86, appendix 5B-5D
for all other cell lines). The IC50s of cytotoxic drugs for the standard 3-day experiment
are outlined in table 21.
Doxorubicin is the most effective drug with an average IC50 of less than 1M in all 4
cell lines. Cisplatin follows with an average IC50 of less than 10M in 3 out of the 4 cell
lines used, but is less potent in BON-1 cells, where 50% decrease in cell proliferation is
seen at 50M. Etoposide and melphalan are most effective against the rat islet tumour
cells CRI-G1 and RIN-5F, with an average IC50 of less than 10M.  Etoposide is also
effective in NCI-H727 bronchial carcinoid cells where proliferation was inhibited by
50% at 9M. Melphalan is the least cytotoxic drug for NCI-H727 and BON-1 cell
lines.
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Table 21: IC50s of chemotherapy drugs in NET cell lines
BON-1 CRI-G1 NCI-H727 RIN-5F
Cisplatin (M) 53  ± 6.21 8.2 ± 0.75 8.9 ± 0.87 1.7 ± 0.48
Etoposide (M) 55 ± 5.63 3.5 ± 0.39 9.2 ± 0.68 2.3 ± 0.63
Doxorubicin (M) 0.33 ± 0.051 0.37 ± 0.072 0.67 ± 0.084 0.028 ± 0.003
Melphalan (M) 82 ± 7.25 8.1 ± 0.93 51 ± 4.34 3.1 ± 0.64
Note: IC50s of treatments with drugs for a period of 3 days followed by 2 days in
complete media. The values represent means of 3 independent experiments, each
done in triplicate, with standard deviation.
Double treatments
To test whether addition of octreotide to the chemotherapy treatment would increase the
anti-proliferative effect of either single treatment, we decided to treat cells with
octreotide and each chemotherapeutic agent either simultaneously or with one type of
drug treatment following the second as mentioned in the administered schedules above.
In simultaneous combination treatments (figures 85-86) with cisplatin, etoposide,
doxorubicin or melphalan, octreotide -at 10 or 1000nM- did not increase the anti-
proliferative effect of the anti-cancer drugs. Data are shown for NCI-H727 cells while
treatments for all other cell lines are included in the appendix 5B-5D. Cytotoxic drugs
had a dose-dependent effect on cell proliferation in all cell lines. The most cytotoxic
drug was doxorubicin with IC50s below 1M in all cells. Cisplatin and etoposide have
a similar cytotoxic effect in all cell lines, with NCI-H727 bronchial carcinoid cells and
CRI-G1 and RIN-5F rat islet cells being more sensitive to these agents compared to
BON-1 cells. BON-1 pancreatic endocrine cells are more chemo-resistant compared to
all other cell lines used, while CRI-G1 and RIN-5F cells are the most chemo-sensitive.
In sequential combination treatments (figures 87-88, data shown for NCI-H727 cells
only), octreotide or medium alone (control) was added to the cells for 24 hours,
followed by addition of chemotherapy drugs for 48 hours. Again, as in the simultaneous
double treatments, addition of octreotide did not increase the cytotoxic effect of
chemotherapy alone. All chemotherapeutic agents were less cytotoxic in this
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experiment as they were added for 48 hours instead of 72. Pre-treatment with
chemotherapeutic agents before addition of octreotide was also tested with similar
results in all cell lines (data not shown).
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Figure 84: Titration of octreotide in NCI-H727 cells. Cells were treated with octreotide
at 0-1000nM for 24 or 72 hours followed by 2 days incubation in drug free media. In
the graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the logarithmic
scale of the x-axis. Proliferation was calculated as a % of control untreated cells. The
values represent averages of 3 different experiments, each performed in triplicate; bars,
SD.
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Figure 85: NCI-H727 cells were treated with octreotide (at 10 or 1000nM) and
cisplatin or etoposide (both at 0-100M) for 72 hours, followed by 48 hours in drug-
free media. In the graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the
logarithmic scale of the x-axis. Proliferation was calculated as a % of control untreated
cells. The values represent averages of 3 different experiments, each performed in
triplicate; bars, SD.
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NCI-H727 cells with melphalan and octreotide for 3
days
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Figure 86: NCI-H727 cells were treated with octreotide (at 10 or 1000nM) and
melphalan (0-100M) or doxorubicin (0-10M) for 72 hours, followed by 48 hours in
drug-free media. In the graphs, the ‘0’ point of the x-axis is represented as ’0.1’ or
‘0.001’ due to the logarithmic scale of the x-axis. Proliferation was calculated as a % of
control untreated cells. The values represent averages of 3 different experiments, each
performed in triplicate; bars, SD.
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NCI-H727 cells with octreotide (1 day) and then
cisplatin (2 days)
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Figure 87: NCI-H727 cells were treated with octreotide (at 10 or 1000nM) for 24 hours
and then cisplatin or etoposide (both at 0-100M) for 72 hours, followed by 48 hours in
drug-free media. In the graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due
to the logarithmic scale of the x-axis. Proliferation was calculated as a % of control
untreated cells. The values represent averages of 3 different experiments, each
performed in triplicate; bars, SD.
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NCI-H727 cells with octreotide (1 day) and then
melphalan (2 days)
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Figure 88: NCI-H727 cells were treated with octreotide (at 10 or 1000nM) for 24 hours
and then melphalan (0-100M) or doxorubicin (0-10M) for 72 hours, followed by 48
hours in drug-free media. In the graphs, the ‘0’ point of the x-axis is represented as
’0.1’ or ‘0.001’ due to the logarithmic scale of the x-axis. Proliferation was calculated
as a % of control untreated cells. The values represent averages of 3 different
experiments, each performed in triplicate; bars, SD.
224
Many studies analysing the effect of drugs in cellular proliferation use drugs dissolved
in serum-free media to avoid any interaction of the drug with serum proteins, which
might affect the results. To assess whether lack of serum could have any effect in the
cytotoxicity of octreotide, we treated cells with octreotide at 0-10M for 24, 48 or 72
hours in media containing 5, 0.5 or 0% serum. In addition, octreotide in this study was
added fresh daily to enhance effectiveness. An example of this experiment is shown for
NCI-H727 cells in appendix 5E. Any anti-proliferative effect seen was due to the lack
of serum, confirming that octreotide is not cytotoxic to the cell lines used.
8.2.3    Octreotide effect on cell cycle of NET cell lines
Octreotide demonstrated lack of an anti-proliferative effect. As the results of the SRB
proliferation assay depend on the rate of cellular proliferation and not proliferation
itself, the lack of cytotoxicity shown by octreotide could have occurred for the reason
that the effect of octreotide is cytostatic, causing the cells to arrest in a specific phase of
the cell cycle.  To test this hypothesis, cells were treated with octreotide and analysed
by flow cytometry for DNA content, which denotes the cell cycle phase.
As seen in the upper left graph of figure 89, untreated cells in a histogram plot of events
(counts) vs fluorescence intensity (FL2-H) are presented as two peaks. The first peak
(on the left) represents cells in phase G1/S of the cell cycle, while the second peak
represents cells in the G2/M phase of the cell cycle. In any given cell population, more
cells are found in the G1/S phase of the cell cycle than in the G2/M phase. Any drug
causing cell cycle arrest will shift cells from one to the other peak of the histogram.
NCI-H727 cells were treated with octreotide at 0-10M for 72 hours. Even at the
highest dose, octreotide did not induce cell cycle arrest in NCI-H727 cells, as there is
no difference in cell counts between treated and untreated cells. A similar effect was
seen in the rest of the cell lines (appendix 5F-5H). The only difference was that at the
highest dose of octreotide (10M), which is at toxic and clinically irrelevant levels,
BON-1 cells move to the beginning of the x-axis, which indicates cell death by
apoptosis. This did not occur with any of the other cell lines tested which did not
undergo apoptosis at any dose given.
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Figure 89: NCI-H727 cells were treated with octreotide at 0-10,000nM for 24
hours. ‘FL2-H’ denotes DNA content by propidium iodide staining, while ‘counts’
denotes cell number. Bars M1 and M2 indicate populations of cells at phases G1
and G2/M of the cell cycle respectively.
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8.3 Discussion
8.3.1 Proliferation studies
In the second part of this study, the somatostatin analogue octreotide was assessed for
its effect on the cell growth of two rat islet tumour cell lines CRI-G1 and RIN-5F, the
NCI-H727 human lung carcinoid cell line and the BON-1 human pancreatic endocrine
cell line. Although, the receptors selective for octreotide were expressed in all cell lines,
octreotide treatment did not demonstrate any anti-proliferative or cytostatic activity
under the conditions used. All cell lines displayed resistance to octreotide even at toxic
doses.
Somatostatin analogues and in particular octreotide have been widely tested for their
effect on growth of cells in vitro and in xenograft models. The proliferation of AR42J
pancreatic cells was abolished by octreotide at concentrations as low as 0.1nM. The
growth of AR42J cells was either induced by EGF or gastrin, all of which promote the
growth of pancreatic cells (Charland et al., 2001; Hofsli et al., 2002). A similar effect
was seen in pancreatic growth in rats induced by caerulein (Charland et al., 2001).
Octreotide also inhibited the serum and bFGF stimulated growth of NIH3T3 cells
transfected with human SSTR2 receptor at doses up to 1nM via activation of tyrosine
phosphatases (Buscail et al., 1994). In our study the effect of the drugs was investigated
on the basal proliferation of neuroendocrine tumour cells, without induction by external
growth factors. The presence of exogenous factors may justify cytotoxicity observed by
the other groups.
8.3.2 Drug treatments in serum-free media
The cells in our study were also treated with drugs dissolved in complete media
containing 10% foetal calf serum. In both studies mentioned above using AR42J cells,
octreotide decreased proliferation of cells deprived of serum (Charland et al., 2001;
Hofsli et al., 2002). Cholangiocarcinoma cells also grown in serum-free conditions or
transplanted in nude mice showed reduction in tumour growth when octreotide was
added for 48 hours at 1-104 ng/ml (Zhao, 2002). A similar effect was seen in serum
deprived gastric adenocarcinoma SGC-7901 cells and in xenograft models with
octreotide added at concentrations up to 104 nM (Wang, 2003). Based on these facts,
we also treated cells with octreotide in 5, 0.5 or 0% serum-containing media. In this
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case, cell proliferation was inhibited by the lack of serum and not by octreotide,
confirming our previous results.
On the other hand, studies exist which, in concordance with our results have shown no
effect of octreotide on cell proliferation. Liebow and co-workers showed inhibition of
growth of the pancreatic cells Mia PaCa-2 by another somatostatin analogue, the RC-
160, but not by octreotide which was also tested (Liebow et al., 1989). Octreotide also
inhibited the GLP-1 induced insulin secretion in RIN-5F cells, but showed no effect on
basal or GLP-1 induced proliferation even in 1% serum, which agrees with our results
(Stark & Mentlein, 2002). Most recently, Ono et al. showed that the somatostatin
analogue SOM230 inhibited proliferation of NCI-H727 cells but octreotide did not
which confirms our results (Ono et al., 2007).
8.3.3 Apoptosis and cell cycle analysis
Other groups have shown an apoptotic or a cytostatic effect of octreotide. Oberg
showed that a high-dose octreotide treatment in a xenograft model resulted in an
increase of apoptotic cells, but tumour growth inhibition was related to cell cycle arrest
and not induction of apoptosis by octreotide (Imam et al., 1997). Octreotide treatment
in IL-6 dependent and independent multiple myeloma cells at 0-1000nM resulted in
inhibition of growth by blocking the cell cycle rather than decreasing the cell viability
(Georgii-Hemming, 1999). Finally, apoptosis and inhibition of angiogenesis was
induced in human rectal neuroendocrine carcinoma cells in vitro and in vivo by
octreotide, which resulted in tumour necrosis (Koizumi et al., 2002). In contrast to the
above groups, our results showed no blocking of the cell cycle or induction of apoptosis
by octreotide in four neuroendocrine cell lines.
8.3.4 Conclusions
Octreotide is a somatostatin analogue that is widely used for the detection of
neuroendocrine tumours due to its high affinity binding to somatostatin receptor 2A. As
part of the therapeutic treatment of gastrointestinal endocrine tumours it is mainly used
for the control of symptoms resulting from excessive hormone release in patients with
carcinoid, Verner-Morrison and glucagonoma syndromes. Despite the promising results
in in vitro models (Hofsli et al. 2002, Wang Chun-Hui et al., 2003), and the
stabilisation of tumour growth in 30 – 70% of neuroendocrine tumour patients (Behr et
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al., 2002), in our study, octreotide showed no cytotoxic or cytostatic activity. As
previously mentioned, the doses chosen were based on preclinical studies. Combined
treatment with chemotherapy had no added value in inhibition of proliferation of
neuroendocrine cells. As a result, a further examination of the conditions used will be
needed to examine the role of somatostatin receptors in the molecular biology of
neuroendocrine tumours.
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CHAPTER 9
CONCLUSIONS AND FUTUREWORK
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Three therapeutic targets in neuroendocrine tumours have been analysed in this study.
In chapters 4-6 we analysed the therapeutic potency of a well-known receptor tyrosine
kinase; EGFR. EGFR is expressed in many cancers and is associated with poor
prognosis. EGFR is frequently expressed in neuroendocrine tumours and has been
implicated with tumour growth and progression in gastrointestinal carcinoids and
PNETs (Wang et al., 1997; Nilsson et al., 1995; Rusch et al., 1996; Papouchado et al.,
2005; Wulbrand et al., 1998; Peghini et al., 2002). Blockade therefore of EGFR
signalling pathways represents a promising strategy for anti-cancer therapy.  Gefitinib
(Iressa or ZD1839) is a specific tyrosine kinase inhibitor of EGFR used for the
treatment of non-small cell lung cancer as well as for other solid tumours.
Antineoplastic activity has been shown in a variety of human cancers including
prostate, breast, ovarian, colon and lung cancer cells (Schiller, 2003; Herbst, 2002;
Blackledge & Averbuch, 2004).
Gefitinib alone or in combination with other anti-cancer therapies, such as
chemotherapy drugs and radiation therapy has demonstrated efficacy against tumour
growth in a variety of cancer cell lines and in xenograft models (Ciardiello et al., 2000;
Ciardiello et al., 2001b; Huang, 2002; Magne, et al., 2002; Sirotnak, et al., 2000). In
our study, gefitinib displayed a dose-response cytotoxic effect in four neuroendocrine
tumour cell lines, though in very high and clinically irrelevant doses. Gefitinib is known
to inhibit EGFR homodimers but not EGFR heterodimers, therefore the presence of
EGFR heterodimers could explain the relative resistance of the neuroendocrine tumour
cell lines to gefitinib. This is a theory worth further exploration. Gefitinib anti-
proliferative effect was associated with induction of apoptosis but no cell cycle arrest.
Gefitinib was also used in combination with anticancer drugs with a variety of
mechanisms of action, including the DNA cross-linking compound cisplatin, the
topoisomerase II poison etoposide, the mitotic inhibitor paclitaxel, and the
antimetabolite methotrexate. Gefitinib demonstrated synergy with etoposide in ¾ NET
cell lines and with cisplatin in NCI-H727 cell line. Gefitinib-induced apoptosis did not
result in synergy with all cytotoxic drugs used, therefore apoptosis alone cannot account
for the presence of absence of synergy.
The reason why gefitinib co-treatment led to synergistic anti-tumour effect with
etoposide but not methotrexate or paclitaxel, or why cisplatin increased the anti-
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proliferative effect of gefitinib in one cell line but not in the rest is unclear. It would be
interesting to see whether synergy shown with etoposide is also seen with other
topoisomerase II inhibitors such as teniposide or even doxorubicin, which intercalates
DNA resulting in impediment of topoisomerase II and DNA biosynthesis. In the same
mode, do other alkylating-like agents such as carboplatin or oxaliplatin have the same
effect as cisplatin, and is it cell type specific? This investigation would help understand
whether synergy occurs with anti-cancer agents according to their mechanism of action
and their direct or indirect effect on DNA, and lead to better combinations that can be
exploited in the clinic.
Analysis of the effect of chemotherapeutic drugs on EGFR activity showed transient
activation of EGFR after 3 hours of cisplatin treatment in all the NET cell lines, after 3
hours of incubation with etoposide in CRI-G1 and NCI-H727 cell lines, and after 6
hours of incubation with paclitaxel in RIN-5F cell line. Activation of EGFR by cisplatin
was mediated through the Ras/MAPK and PI-3K/Akt signalling cascades that promote
cell proliferation and survival. Therefore cisplatin may induce EGFR-dependent
survival pathways in neuroendocrine tumour cells. The etoposide-induced activation of
EGFR has not been assessed for downstream signalling and this could form a future
step in our research to see whether activation of EGFR-dependent survival pathways
applies to other anti-cancer drugs as well.  Again the question why cisplatin, which
synergised with gefitinib in one cell line only, led to EGFR activation but not paclitaxel
or methotrexate remains unanswered. The reason behind this may be associated with the
mode of action of each drug, and more agents of the same class with cisplatin should be
tested to delineate this effect. On the other hand, small molecule inhibitors of Akt and
MAPK are also currently under development. The demonstration of activated Akt and
MAPK after exposure to cisplatin identifies therapeutic potential in combination of
chemotherapy with Akt/MAPK inhibitors in neuroendocrine tumours.
This study has shown that sensitivity to chemotherapeutic agents can be enhanced
significantly by inhibition of growth factor pathways such as the EGFR signalling
pathway. In contrast to the preclinical data from other groups and ours, four large phase
III clinical trials in patients with either locally advanced stage III disease or stage IV
NSCLC failed to show any benefit for combined treatment of gefitinib with cisplatin,
carboplatin, gemcitabine or paclitaxel (Giaccone et al., 2004; Herbst et al., 2004;
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Gatzemeier et al., 2004; Moore et al., 2005). The upregulation of phosphorylated
receptor following treatment with chemotherapeutic agents shown by us and other
groups (Benhar et al., 2002) could explain the failure of combination treatments in
clinical trials, and further analysis of combined treatment scheduling as well as dosage
is needed for optimal results. In addition, recent studies have indicated that EGFR
mutations, including the commonly occurring EGFRvIII deletion mutation, can
determine tumour behaviour and response to anti-EGFR therapy. In particular, a
number of mutations have been discovered, occurring at the region encoding for the
ATP binding site of EGFR, which result in enhanced EGFR activation as well as a
higher susceptibility to TKIs (Lynch et al., 2004; Paez et al., 2004). These mutations
however, have been shown not to occur in neuroendocrine tumours (Gilbert et al.,
2005), whereas the role of EGFRvIII in neuroendocrine tumours has not yet been
determined. Whether specific mutations affect response to a chemotherapeutic agent is
still unclear and should be investigated.
To understand modulation of EGFR by cisplatin we analysed the effect of this agent on
EGFR localisation based on previous reports showing cisplatin-induced EGFR
translocation to the nucleus (Dittmann et al., 2005a). Also based on the clinical failure
of gefitinib with chemotherapy, but the success of cetuximab in radiosensitising
patients with head and neck squamous cell carcinoma (Bonner et al., 2006), we
investigated whether any interaction exists between radiation treatment and EGFR
inhibition. Cisplatin induced translocation in ¾ NET cell lines within 5 minutes after
drug exposure. X-ray irradiation at 4Gy induced EGFR nuclear entry in the same cell
lines as cisplatin also within 5 minutes after irradiation. This event was completely
abrogated by EGFR inhibitors gefitinib and cetuximab. Abortion of EGFR nuclear
entry was associated with a delay in the repair of radiation-induced double DNA strand
breaks. Inhibition of EGFR has previously been correlated to a decrease in DNA-PKCS
activity along with redistribution of this non-homologous end joining (NHEJ)-DNA
repair enzyme to the cytosol (Huang & Harari, 2000; Dittmann et al., 2005b;
Friedmann et al., 2006). Gefitinib treatment in neuroendocrine cells led to a small
increase in cytosolic amounts of DNA-PK but no direct association between EGFR
inhibition and DNAPK have been proved so far. Since there is a definite effect of anti-
EGFR therapy on DNA repair, the effect of nuclear EGFR and its inhibitors on
DNAPK will be studied further. Any physical association of the EGFR and DNA-PK
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can be analysed by immunoprecipitation experiments after irradiation and gefitinib
treatment. To further examine the relation between EGFR and DNA-PKcs activity after
exposure to ionising radiation, DNA repair can be examined by the comet assay using
two glioma cell lines: M059K and M059J. M059J cells are deficient in DNA-PKcs and
are more sensitive to radiation than the M059K cells, therefore any effect by EGFR
inhibitors should be identified in M059K cells only.
Further studies should also be carried out to determine whether cisplatin-induced
EGFR nuclear translocation is inhibited by co-treatment with gefitinib or cetuximab,
and whether anti-EGFR agents have any effect on DNA repair of interstrand cross-
links (ICL) produced by exposure to cisplatin. Although pathways of ICL repair have
been reported to involve excision repair (Sarkar et al., 2006), inhibition of the DNA-
PK was shown to modulate resistance to cisplatin (Durant & Karran, 2003). DNA-PK
involvement in ICL repair can be analysed as before by co-immunoprecipitations with
EGFR after cisplatin as well as quantitation of ICL repair by the comet assay. Apart
form DNA-PK, other DNA repair enzymes can also be analysed including ERCC1 and
XRCC1 (both involved in excision repair) to investigate whether other DNA repair
pathways can be modulated by nuclear EGFR.
Nuclear translocation of EGFR in response to irradiation or cisplatin is a novel function
of EGFR even though nuclear EGFR has been identified in breast cancer cells and its
locality has been associated with increased expression of Ki-67 proliferation index (Lo
et al., 2005a). Another mode of EGFR nuclear translocation is by ligand binding. EGF-
dependent translocation of EGFR was shown to lead to transcriptional activation of
genes involved in increased proliferation of tumours, including cyclin D1, B-Myb, and
inducible nitric oxide synthase (iNOS) (Lo & Hung, 2006). The last protein was shown
to induce activation of DNA-PK, thus connecting proliferation with increased DNA
repair (Xu et al., 2000). This mode of EGFR nuclear transfer has not been investigated
in neuroendocrine tumour cells, although activation of EGFR by EGF was shown not
to induce alterations in iNOS expression. It would be interesting to see whether EGF
can induce EGFR translocation and if this is associated with activation of proliferation
genes or with DNA repair.
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RIN-5F rat islet tumour cells was the only cell line not demonstrating EGFR nuclear
transfer by radiation or cisplatin, and treatment with EGFR inhibitors had no effect on
EGFR localisation or the kinetics of DNA repair of radiation-induced strand breaks.
Activation though of EGFR by cisplatin (but not radiation) was shown, even though it
had no effect on EGFR localisation, but it led to activation of Akt and MAPK survival
pathways. Taken together, the results in RIN-5F cells indicate a non-significant role of
EGFR in the growth of RIN-5F cells, or even an impairment of their nuclear transport
mechanism and this should be further investigated. It would be interesting to see
whether EGF leads to EGFR import in RIN-5F cells, which would prove that the
mechanisms of ligand dependent or independent transport are distinct as previously
postulated (Szumiel, 2006).
Chapter 6 analysed the possible mechanisms for EGFR nuclear transport using RIN-5F
cells as a negative control. Nuclear transport of EGFR is mediated through the nuclear
pore complex via association with karypherins (nuclear importins and exportins). The
inhibitor of nuclear import wheat germ agglutinin (WGA) blocked EGFR import in
CRI-G1 but not in RIN-5F cells and caused a delay in repair of radiation-induced DNA
strand breaks, while nuclear export inhibitor leptomycin B had no effect as a single
agent, but abrogated the gefitinib-induced delay in the repair of strand breaks.
Association with nuclear importins requires a nuclear localisation signal (NLS)
sequence. Transfection with mutant EGFR in the putative NLS identified by Hsu &
Hung (2007), inhibited EGFR nuclear transit, confirming the involvement of the NLS
sequence in EGFR nuclear transport. Furthermore, similar studies on the mutant EGFR
cell lines and other specific EGFR deletion constructs will enable the mapping of the
EGFR regions that may be involved in transcriptional activation of genes by EGFR.
Further investigation is needed to understand where the EGFR nuclear transport is
initiated and what mechanisms are involved, for example if internalisation of EGFR
takes place in clathrin-coated pits or caveosomes (see section 6.1.2 for details). For
this, the inhibitor of clathrin-coated pit formation -methyl cyclodextrin can be used. In
addition, we don’t know whether radiation-induced EGFR nuclear transport involves
activation of downstream EGFR signalling pathways. Thus, the effect of SR13668
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inhibitor of Akt, or of PD98059 specific inhibitor of MEK1/2 kinases can be analysed
to identify connection between EGFR signalling and nuclear entry.
It must be noted that this study has been qualitative rather than quantitative as time was
a limiting factor. Statistical analysis of the results obtained would involve the use of
comparative tests such as the ANOVA (analysis of variance) and the t-test.
A. The three-way ANOVA test would be used for statistical analysis of dose response
curves shown in proliferation studies of:
1. Gefitinib alone or in combination with chemotherapeutic agents
2. Radiation alone or in combination with gefitinib or cetuximab
The three-way ANOVA is based on the equation y=x1+x2+x3+where the dependent
variable y denotes the % proliferation, x1 is the concentration of the single or double
treatments (values of the x-axis), x2 denotes the presence or absence of treatment A
(1=gefitinib, 2=radiation) with values of 1 or 0 respectively, x3 denotes the presence or
absence of treatment B (1=chemotherapeutic agent, 2=gefitinib) with values of 1 or 0
respectively, and is the error.
The reason for using the three way ANOVA is because the y value can predicted when
the values of the x factors called independent variables or fixed factors is known. The
level of significance, which is the probability to reject the null hypothesis (the null
hypothesis always states that there is no difference between two sets of data) is 0.05. P
values are calculated for x1, x2, and x3. If for any of the fixed factors p> 0.05 then the
fixed factor is not statistically significant.
B. For comet analysis data of double treatments using radiation alone, or radiation in
combination with gefitinib, or of triple treatments (chapter 6) using radiation with
gefitinib and WGA/leptomycin, the three-way ANOVA and the five-way ANOVA
tests would be used. The equations would be in the form of y= x1+x2+x3+y=
x1+x2+x3+x4+ x5+where the dependent variable y denotes the % tail moment, the
independent variable x1 denotes the time (values of the x-axis), x2 denotes the
presence or absence of treatment A (radiation) with values of 1 or 0 respectively, x3
denotes the presence or absence of treatment B (gefitinib) with values of 1 or 0
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respectively, x4 denotes the presence or absence of treatment C (WGA) with values
of 1 or 0 respectively, x5 denotes the presence or absence of treatment D
(leptomycin) with values of 1 or 0 respectively, and is the error. The level of
significance is 0.05 and p values are calculated for each of the x factors. Statistical
significant factors have p<0.05.
C. For comet analysis in cells transfected with wild type or mutant EGFR the four-
way ANOVA test would be used. In the equation y= x1+x2+x3+x4+, y denotes the
% tail moment, x1-x4 factors denote the time,  presence or absence or radiation,
presence or absence of gefitinib, and presence of wild type or mutant EGFR, and
is the error. The calculation of p values is same as above.
D. For western blots, the amounts of P-EGFR, P=MAPK, and P-Akt would be
quantified in relation to alpha tubulin control and total unphosphorylated protein
level in each case. In this study the densitometry analysis amounts where quantified
only in relation to the untreated control band and this quantification may be
different to the results that would be obtained with the new quantification. To
assess the statistical significance of treatments with chemotherapeutic agents at
different doses or for different time intervals the two-way ANOVA test would be
employed, as only two factors (concentration and time) affect the y value (level of
protein). The equation would be y= x1+x2+, where x1 denotes the concentration, x2
denotes the time, and is the error. The calculation of p values is same as above.
E. For western blots of EGFR in cells treated with radiation alone or in combination
with WGA or leptomycin, the level of the protein would be compared with each
one of the factors (radiation, WGA, or leptomycin or combinations of two)
separately. As the amount of each band separately (three sets of experiments for
each sample), which is called the test variable, follows a normal distribution, the t-
test can be employed. The equation would be y=x1+wherex would denote the
appropriate factor and is the error. The calculation of p values is same as above.
NOTE: The equations presented above represent the relation between the dependent (y)
and independent (x) variables and are not the actual equations used in the statistical
analysis, which are much more complex and are not dealt with in this study.
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In chapter 7, we examined C-KIT, a tyrosine kinase inhibitor that has also been
identified in a variety of tumour cells including gastrointestinal stromal tumours
(GISTs) (Fletcher et al., 2002), and its expression has been associated with a poor
outcome for patients (Ferrari et al., 2006). Based on the clinical efficacy of imatinib
mesylate tyrosine kinase inhibitor (TKI) against C-KIT in GISTs (Cohen et al., 2005)
we investigated the presence of C-KIT in neuroendocrine tumour patients by
immunohistochemistry.
Expression of C-KIT was established in a range of tumours that included foregut NETs
(mainly pancreatic NETs and gastric carcinoids), midgut NETs (mainly ileal and
appendiceal carcinoids), hindgut NETs, and NETs of unknown primary site. Therefore,
C-KIT has been identified as a receptor tyrosine kinase with therapeutic potential.
Unfortunately, clinical trials for imatinib mesylate as a single agent have not
demonstrated objective responses or stability of disease in patients with neuroendocrine
tumours (Carr et al., 2004; Dy et al., 2005; Krug et al., 2005; Gross et al., 2006). The
efficacy of imatinib mesylate being used as an adjuvant therapy is still not clear. Some
investigators have suggested using C-KIT expression as a prognostic marker (Erler et
al., 2004; Ferrari et al. 2006), but whether this is true for neuroendocrine tumours
remains to be shown.
Nevertheless, new tyrosine kinase inhibitors with multiple targets including C-KIT
have been synthesised, proving that therapies interacting with C-KIT-signalling
pathway should be taken into account for possible future clinical trials. A recently
developed drug named sunitinib (SU011248; Sutent) is a multi-targeted tyrosine kinase
inhibitor with selectivity for PDGF receptors, VEGF receptors, FMS-like tyrosine
kinase 3 (FLT3), and C-KIT, that was known to inhibit angiogenesis (Chow &
Eckhardt, 2007). Sunitinib has demonstrated in vitro inhibition of C-KIT
phosphorylation and cell proliferation at nanomolar concentrations, and is therefore 10
times more potent that imatinib (Abrams et al., 2003). Compared with imatinib,
sunitinib is also more effective against PDGFR and inhibits additional receptors
including VEGFR2, and this may account for its efficacy in imatinib-resistant GISTs
(Demetri et al., 2009). Recently completed phase II and III trials in renal cell carcinoma
(RCC) and imatinib-refractory GISTs, respectively, have led to approval of sunitinib by
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the US FDA for these diseases in 2006. Additionally, phase II clinical trials with
sunitinib have shown anti-tumour activity in patients with advanced malignancies,
including neuroendocrine tumours, breast cancer, and colorectal cancer (Chow &
Eckhardt, 2007). Clinical trials of sunitinib in NETs have shown very promising results
(Kulke et al., 2008) The most successful outcome was recently released in a clinical
trial of sunitinib in patients with non-functioning NET, which had to be stopped early
after interim analysis demonstrated a significant survival benefit in the sunitinib treated
group (Raymond et al., 2009). Therefore, targeting C-KIT in combination with other
biomarkers may prove useful for the treatment of neuroendocrine tumour patients.
Chapter 8 included assessment of somatostatin analogue octreotide for any effect on
growth of neuroendocrine tumour cells. Somatostatin binds somatostatin receptors
(SSTR1-SSTR5), all of which are overexpressed in NET patients with the SSTR2
subtype being the most frequently expressed. The molecular cloning of five distinct
subtypes of somatostatin receptors in the 1980s significantly increased our insight into
the biology of somatostatin and its receptor subtypes and led to the development of
subtype-selective peptides and nonpeptide agonists and antagonists (Öberg, 2004).
Somatostatin analogues octreotide and lanreotide are widely accepted as the main
treatment for symptomatic relief of NET patients, especially those tumours
characterised by hypersecretion of hormones such as VIPoma, glucagonoma and
carcinoid syndrome. Somatostatin receptor scintigraphy is the main imaging technique
for the localization and staging procedure in these tumours (Melen-Mucha et al., 2006).
Clinical trials with long-term somatostatin analogues have not demonstrated significant
anti-tumour activity with less than 5% of patients showing objective tumour regression,
although about 50% of patients showed stabilisation of tumour size (Modlin et al.,
2008).  In agreement with this, our results showed no effect on tumour growth of
neuroendocrine tumour cells by octreotide. Octreotide was used at high concentrations
and added to cells in both serum-free and serum-containing media. No effect on cell
proliferation or cell cycle was observed in any of the cells tested. However,
somatostatin receptors are biologically specific receptor-targets to NETs and new
strategies are being developed for their utilisation. Somatostatin receptors targeted with
somatostatin analogues conjugated to cytotoxic drugs have shown promising results
and are being further developed in clinical trials (Melen-Mucha et al., 2006; Modlin et
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al., 2008). New biological agents and somatostatin-tagged radionuclides are under
investigation. Furthermore, treatment of neuroendocrine gut tumours with ultra-high
doses of somatostatin analogues has demonstrated significant clinical effects in patients
resistant to standard-dose treatment with the same somatostatin analogue. Finally, new
somatostatin analogues are being designed with specificity to one somatostatin receptor
subtype or all subtypes (pan-receptor analogues) that can bind the receptor(s) with
higher affinity but causing less toxic effects (Öberg, 2004; Modlin et al., 2008).
Somatostatin receptors are molecular targets closely associated to NETs and novel
treatment regimens for NET patients should take advantage of this distinctive
relationship.
Finally, apart from the three receptors analysed in this study, other protein targets have
been identified in neuroendocrine tumours including the proangiogenic VEGFR and its
ligand, PI-3K and Akt, and the mammalian target of rapamycin (mTOR). Drugs against
these proteins have been developed and some have been tested in clinical trials, and
these could be analysed for efficacy in combination with chemotherapy or radiotherapy
as with EGFR.
Taken together, our results may explain why EGFR has been associated with chemo- or
radioresistance of tumour cells, and it may also explain the lack of efficacy of
chemotherapy or radiotherapy in neuroendocrine tumour patients. We conclude by
suggesting a combination modality using radiotherapy and anti-EGFR therapy for the
treatment of neuroendocrine tumours. Indeed, based on our study, a clinical trial will
take place at the Royal Free Hospital to evaluate the effect of radiotherapy combined
with cetuximab in selected neuroendocrine tumour patients.
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Appendix 1A: Gefitinib and chemotherapeutic agents in SHP-77 cells
SHP-77 cells with gefitinib and etoposide
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Cells were treated with chemotherapeutic agents at the indicated concentrations alone,
simultaneously with gefitinib (10M) for 72 hours, or with drug A for 1 day followed
by drug B for 2 days and vice versa, followed by 48 hours in drug free medium.
Proliferation was calculated as a % of control untreated cells. Data represents the
averages of three different experiments, each performed in triplicate; bars, SD.
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Appendix 1B: Gefitinib and chemotherapeutic agents in CRI-G1 cells
CRI-G1 cells w ith gefitinib and cisplatin
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Cells were treated with chemotherapeutic agents at the indicated concentrations alone,
simultaneously with gefitinib (10M) for 72 hours, or with drug A for 1 day followed
by drug B for 2 days and vice versa, followed by 48 hours in drug free medium.
Proliferation was calculated as a % of control untreated cells. Data represents the
averages of three different experiments, each performed in triplicate; bars, SD.
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Appendix 1C: Gefitinib and chemotherapeutic agents in NCI-H727 cells
NCI-H727 cells w ith gefitinib and cisplatin
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Cells were treated with chemotherapeutic agents at the indicated concentrations alone,
simultaneously with gefitinib (10M) for 72 hours, or with drug A for 1 day followed
by drug B for 2 days and vice versa, followed by 48 hours in drug free medium.
Proliferation was calculated as a % of control untreated cells. Data represents the
averages of three different experiments, each performed in triplicate; bars, SD.
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Appendix 1D: Gefitinib and chemotherapeutic agents in RIN-5F cells
RIN-5F cells w ith gefitinib and cisplatin
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Cells were treated with chemotherapeutic agents at the indicated concentrations alone,
simultaneously with gefitinib (10M) for 72 hours, or with drug A for 1 day followed
by drug B for 2 days and vice versa, followed by 48 hours in drug free medium.
Proliferation was calculated as a % of control untreated cells. Data represents the
averages of three different experiments, each performed in triplicate; bars, SD.
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Appendix 1E: Gefitinib and chemotherapeutic agents in HCT-116 cells
HCT-116 cells with gefitinib and cisplatin
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Cells were treated with chemotherapeutic agents at the indicated concentrations alone,
simultaneously with gefitinib (10M) for 72 hours, or with drug A for 1 day followed
by drug B for 2 days and vice versa, followed by 48 hours in drug free medium.
Proliferation was calculated as a % of control untreated cells. Data represents the
averages of three different experiments, each performed in triplicate; bars, SD.
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Appendix 1F: Time course analysis of the effect of methotrexate on EGFR
activity
Methotrexate at 100M
Tyrosine phosphorylation of EGFR in NET cell lines determined by immunoblotting
for PY20 (170kDa). Cells were treated with methotrexate at 100M for 3, 6 or 12
hours. Bottom panel shows -tubulin bands (50kDa) as loading control. Amounts of P-
EGFR in percentages were determined by densitometry analysis.
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Appendix 1G: Time course analysis of the effect of paclitaxel on EGFR
activity
Paclitaxel at 10M
Tyrosine phosphorylation of EGFR in NET cell lines determined by immunoblotting
for PY20 (170kDa). Cells were treated with paclitaxel at 10M for 3, 6 or 12 hours.
Bottom panel shows -tubulin bands (50kDa) as loading control. Amounts of P-EGFR
in percentages were determined by densitometry analysis.
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Appendix 1H: Dose response analysis of the effect of methotrexate on
EGFR activity
Methotrexate for 24 hours
Tyrosine phosphorylation of EGFR in NET cell lines determined by immunoblotting
for PY20 (170kDa). Cells were treated with methotrexate at 0, 10, 25, 50 or 100M for
24 hours. Bottom panel shows -tubulin bands (50kDa) as loading control. Amounts of
P-EGFR in percentages were determined by densitometry analysis.
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Appendix 1I: Dose response analysis of the effect of paclitaxel on EGFR
activity
Paclitaxel for 24 hours
Figure 67: Tyrosine phosphorylation of EGFR in NET cell lines determined by
immunoblotting for PY20 (170kDa). Cells were treated with paclitaxel at 0, 1, 2.5, 5 or
10M for 24 hours. Bottom panel shows -tubulin bands (50kDa) as loading control.
Amounts of P-EGFR in percentages were determined by densitometry analysis.
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Appendix 2A: Radiation and EGFR inhibitors in proliferation study using
NCI-H727 cells
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Cells were treated with radiation at 30Gy on day 1 and gefitinib or cetuximab at the
indicated concentrations on day 2, or in reverse order, followed by 48 hours in drug
free medium. Proliferation was calculated as a % of control untreated cells. Data
represents the averages of three different experiments, each performed in triplicate;
bars, SD.
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Appendix 2B: Radiation and EGFR inhibitors in proliferation study using
SHP-77 cells
SHP-77 cells
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Cells were treated with radiation at 4Gy on day 1 and gefitinib or cetuximab at the
indicated concentrations on day 2, or in reverse order, followed by 48 hours in drug
free medium. Proliferation was calculated as a % of control untreated cells. Data
represents the averages of three different experiments, each performed in triplicate;
bars, SD.
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Appendix 2C: Radiation and EGFR inhibitors in DNA repair analysis
using NCI-H727 cells
Radiation and gefitinib in NCI-H727 cells
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Measurement of irradiation-induced DNA strand breaks and their repair in NCI-H727
cells. Strand break formation quantitated as tail moment, plotted against time after
irradiation. Cells were treated with gefitinib at 10M or cetuximab at 30nM for 3
hours, drug was removed, and then cells were irradiated at 30 Gy and incubated for up
to 120 minutes at 37oC. Data represents the averages of three different experiments,
each performed in triplicate; bars, SD.
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Appendix 2D: Radiation and EGFR inhibitors in DNA repair analysis
using SHP-77 cells
Radiation and gefitinib in SHP-77 cells
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Measurement of irradiation-induced DNA strand breaks and their repair in SHP-77
cells. Strand break formation quantitated as tail moment, plotted against time after
irradiation. Cells were treated with gefitinib at 10M or cetuximab at 30nM for 3
hours, drug was removed, and then cells were irradiated at 15 Gy and incubated for up
to 120 minutes at 37oC. Data represents the averages of three different experiments,
each performed in triplicate; bars, SD.
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Appendix 3A: Radiation with gefitinib and EGFR nuclear transport
inhibitors in DNA repair analysis using NCI-H727 cells
Measurement of irradiation-induced DNA strand breaks and their repair in NCI-H727
cells. Strand break formation quantitated as percentage of control cell (irradiated cell at
t=0) tail moment, plotted against time after irradiation. Cells were treated with gefitinib
at 10M for 3 hours, and/or WGA (0.05mg/ml) or leptomycin B (2nM) for 30 minutes.
Drug was removed, and then cells were irradiated at 15Gy and incubated for up to 120
minutes at 37oC. Data represents the averages of three different experiments, each
performed in triplicate; bars, SD
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Appendix 3B: Radiation with gefitinib and EGFR nuclear transport
inhibitors in DNA repair analysis using SHP-77 cells
Measurement of irradiation-induced DNA strand breaks and their repair in SHP-77
cells. Strand break formation quantitated as percentage of control cell (irradiated cell at
t=0) tail moment, plotted against time after irradiation. Cells were treated with gefitinib
at 10M for 3 hours, and/or WGA (0.05mg/ml) or leptomycin B (2nM) for 30 minutes.
Drug was removed, and then cells were irradiated at 15Gy and incubated for up to 120
minutes at 37oC. Data represents the averages of three different experiments, each
performed in triplicate; bars, SD
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Appendix 3C: Radiation with gefitinib and EGFR nuclear transport
inhibitors in immunofluorescent analysis using NCI-H727 cells
NCI-H727 cells were treated with gefitinib at 10M for 3 hours and/or WGA
(0.05mg/ml) or leptomycin B (2nM) added in the last 30 minutes. Cells were then
irradiated at 30Gy and incubated for 5 minutes at 37oC. Cells were then fixed and
stained for EGFR (green) and nucleus was stained with propidium iodide (red).
NCI-H727 untreated irradiated
WGA Leptomycin
B
Leptomycin B / X-rayWGA / X-ray
Gefitinib +WGA /  X-ray Gefitinib + Leptom / X-ray
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Appendix 3D: Radiation with gefitinib and EGFR nuclear transport
inhibitors in immunofluorescent analysis using SHP-77 cells
SHP-77 cells were treated with gefitinib at 10M for 3 hours and/or WGA
(0.05mg/ml) or leptomycin B (2nM) added in the last 30 minutes. Cells were then
irradiated at 4Gy and incubated for 5 minutes at 37oC. Cells were then fixed and
stained for EGFR (green) and nucleus was stained with propidium iodide (red).
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Appendix 4: Titration of anti-gastrin pathway drugs in SW1222 and
HCT-116 colon cancer cells
Immunoblot of lysates from CRI-G1, NCI-H727, SHP-77 and RIN-5F cell lines using
1µg/ml anti-c-KIT antibody for 2 hours. The bands of 145kDa were revealed using an
HRP-conjugated goat anti-rabbit antibody.
NCI-H727    SHP-77    CRI-G1    RIN-5F
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Appendix 5A: Titration of octreotide in CRI-G1, RIN-5F and BON-1 cells
Titration of octreotide in CRI-G1, RIN-5F and BON-1 cells. Cells were treated with
octreotide at 0-1000nM for 72 hours followed by 2 days incubation in drug free media.
In the graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the logarithmic
scale of the x-axis. Proliferation was calculated as a % of control untreated cells. The
values represent averages of 3 different experiments, each performed in triplicate; bars,
SD.
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Appendix 5B (part I): Chemotherapeutic agents with octreotide in
CRI-G1 cells
CRI-G1 cells were treated with octreotide (at 10 or 1000nM) and cisplatin or etoposide
(both at 0-100M) for 72 hours, followed by 48 hours in drug-free media. In the
graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the logarithmic scale
of the x-axis. Proliferation was calculated as a % of control untreated cells. The values
represent averages of 3 different experiments, each performed in triplicate; bars, SD.
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Appendix 5B (part II): Chemotherapeutic agents with octreotide in
CRI-G1 cells
CRI-G1 cells were treated with octreotide (at 10 or 1000nM) and melphalan (0-
100M) or doxorubicin (0-10M) for 72 hours, followed by 48 hours in drug-free
media. In the graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the
logarithmic scale of the x-axis. Proliferation was calculated as a % of control untreated
cells. The values represent averages of 3 different experiments, each performed in
triplicate; bars, SD.
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Appendix 5C (part I): Chemotherapeutic agents with octreotide in
RIN-5F cells
RIN-5F cells were treated with octreotide (at 10 or 1000nM) and cisplatin or etoposide
(both at 0-100M) for 72 hours, followed by 48 hours in drug-free media. In the
graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the logarithmic scale
of the x-axis. Proliferation was calculated as a % of control untreated cells. The values
represent averages of 3 different experiments, each performed in triplicate; bars, SD.
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Appendix 5C (part II): Chemotherapeutic agents with octreotide in
RIN-5F cells
RIN-5F cells were treated with octreotide (at 10 or 1000nM) and melphalan (0-100M)
or doxorubicin (0-10M) for 72 hours, followed by 48 hours in drug-free media. In the
graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the logarithmic scale
of the x-axis. Proliferation was calculated as a % of control untreated cells. The values
represent averages of 3 different experiments, each performed in triplicate; bars, SD.
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Appendix 5D (part I): Chemotherapeutic agents with octreotide in
BON-1 cells
BON-1 cells were treated with octreotide (at 10 or 1000nM) and cisplatin or etoposide
(both at 0-100M) for 72 hours, followed by 48 hours in drug-free media. In the
graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the logarithmic scale
of the x-axis. Proliferation was calculated as a % of control untreated cells. The values
represent averages of 3 different experiments, each performed in triplicate; bars, SD.
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Appendix 5D (part II): Chemotherapeutic agents with octreotide in
BON-1 cells
BON-1 cells were treated with octreotide (at 10 or 1000nM) and melphalan (0-100M)
or doxorubicin (0-10M) for 72 hours, followed by 48 hours in drug-free media. In the
graphs, the ‘0’ point of the x-axis is represented as ‘0.001’ due to the logarithmic scale
of the x-axis. Proliferation was calculated as a % of control untreated cells. The values
represent averages of 3 different experiments, each performed in triplicate; bars, SD.
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Appendix 5E: Octreotide effect in cell proliferation in media containing
5%, 0.5% or 0% serum
NCI-H727 cells with octreotide for 72 hours (changed daily)
in 5, 0.5 and 0% serum-containing media
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Octreotide at 0-10M added for 72 hours (changed daily) in media containing 5, 0.5 or
0% serum. Proliferation was calculated as a % of control untreated cells. The values
represent averages of 2 different experiments, each performed in triplicate; bars, SD.
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Appendix 5F: Octreotide effect on the cell cycle in BON-1 cells
BON-1 cells were treated with octreotide at 0-10,000nM for 24 hours. ‘FL2-H’
denotes DNA content by propidium iodide staining, while ‘counts’ denotes cell
number. Bars M1 and M2 indicate populations of cells at phases G1 and G2/M
of the cell cycle respectively.
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Appendix 5G: Octreotide effect on the cell cycle in CRI-G1 cells
CRI-G1 cells were treated with octreotide at 0-10,000nM for 24 hours. ‘FL2-
H’ denotes DNA content by propidium iodide staining, while ‘counts’ denotes
cell number. Bars M1 and M2 indicate populations of cells at phases G1 and
G2/M of the cell cycle respectively.
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Appendix 5H: Octreotide effect on the cell cycle in RIN-5F cells
RIN-5F cells were treated with octreotide at 0-10,000nM for 24 hours. ‘FL2-
H’ denotes DNA content by propidium iodide staining, while ‘counts’ denotes
cell number. Bars M1 and M2 indicate populations of cells at phases G1 and
G2/M of the cell cycle respectively.
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